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Abstract 
 
The first part of this thesis investigated the growth-inhibitory and immunomodulatory 
potential of six wild Canadian mushrooms. Out of 24 crude extracts, six showed strong growth-
inhibitory activity, two exhibited strong immuno-stimulatory activity and nine demonstrated 
potent anti-inflammatory activity. 
The second part of this thesis involved purification and characterization of growth-
inhibitory compounds from Albatrellus flettii. Liquid-liquid extraction, Sephadex LH-20 and 
HPLC-Mass Spectrometry (HPLC-MS) were used to purify the three compounds of interest. 
NMR analyses confirmed their identity as grifolin, neogrifolin and confluentin. Grifolin and 
neogrifolin inhibited IMP1-KRas RNA interaction as demonstrated using an in-vitro fluorescent 
polarization assay. The three compounds suppressed KRas expression in SW480 and HT-29 
human colon cancer cells. Confluentin, shown for the first time, to induce apoptosis and arrest 
cell cycle in SW480 cells.  
The third part of this thesis involved the development of methods to purify growth-inhibitory 
compounds from Sarcodon scabripes. HPLC-MS detected some potential novel compounds. 
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Chapter 1: Introduction and literature review 
1.1 Mushrooms are not just food 
Fungi comprise the second largest kingdom of eukaryotic life on this planet (Schoch et 
al., 2012). Mushrooms are macro-fungi with a distinctive fruiting body, which can be either 
epigeous or hypogeous; they are large enough to be visible with the naked eye (Chang & Miles, 
1992). Hypogeous mushrooms have their fruiting bodies below ground, while epigeous 
mushrooms have their fruiting bodies above ground. There is estimated to be about 1.5 million 
mushroom species but only about 10% are currently described (Hawksworth, 2012). Canada, 
specifically British Columbia (BC), has not been explored greatly for these valuable and 
interesting fungi. These facts and figures indicate the need to explore wild mushrooms from the 
vast and untapped regions of the world such as BC where novel mushrooms can be discovered, 
and their medicinal value can be determined. 
Mushrooms are nutritionally important because they are low in calories, carbohydrates, 
fat, sodium, and cholesterol; they provide important nutrients including selenium, potassium, 
riboflavin, niacin, vitamin D, proteins, and fibers (Valverde et al., 2015). Both wild and 
commercial mushrooms are used as sources of nutrients and nutraceuticals. Most of the edible 
mushrooms have an added benefit of being anti-microbial and provide resistance to various 
diseases (Barros et al., 2015).  
Aside from the oriental folk medicines, mushrooms have become more important in the 
last decade because of their promising medicinal properties (Lindequist et al., 2005). Medicinal 
Mushrooms are now proven to have anti-oxidant, anti-fungal, anti-bacterial, anti-viral, anti-
allergic, antidiabetic, anti-parasitic, anti-atherogenic, hepato-protective, anti-cancer and immuno-
modulatory activities among others (Lindequist et al., 2015). Mushrooms can also be used as 
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prophylactic agents against inflammation and tumorigenesis (Finimundy et al., 2013). For 
instance, anti-cancer agents from Albatrellus confluens have been reported to have effects 
against gastric cancer cells, nasopharyngeal carcinoma and osteosarcoma (Wu & Li, 2017). 
Thus, these mushrooms are not just part of our diet but rather encapsulate medicinal properties 
that can potentially be exploited by humans. 
1.2 Mushrooms as ancient remedy 
Mushrooms have been used as medicine for thousands of years by our ancestors. In the 
5th century, the alchemist Tao Hongjing first described Ganoderma lucidum and 
Dendropolyporus umbellatus (Stamets & Zwickey, 2014). The use of Ganoderma and related 
species as a medicinal constituent in traditional medicines dates back thousands of years 
(Stamets & Zwickey, 2014). Ganoderma lucidum (Ling zhi) is commonly referred to as the 
mushroom of immortality in China, Japan and Korea (Pegler, 2002). In China and Japan 
particularly, hot water extracts of mushrooms are used for the treatment of several diseases (Dias 
et al., 2004). The medicinal use of mushrooms has a very long tradition in Asian countries, 
whereas their use in the Western culture is only slowly gaining attention. Moreover, the dried 
powder of G. lucidum is also used in eastern countries as a preventive household medicine or 
cure against various cancers like prostate and human breast cancer (Daniel et al., 2003). 
Today, Ganoderma lucidum has been shown to contain 16,000 genes that code for many 
active compounds (Stamets & Zwickey, 2014). Although mushrooms have long been used by 
various ancient cultures, only from research done in the last decade has modern science been 
able to rediscover what the ancients knew long ago, that mushrooms can be a tremendous 
resource of powerful medicines (Stamets & Zwickey, 2014). Pharmacological activity includes 
hepatic and renal protection from oxidation through its prominent superoxide scavenging effects 
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(Shieh et al., 2011), enhancing innate immunity by activating NF-kappa-B (Kuo et al., 2006), 
and proven anti-cancer benefit by inducing apoptosis and causing mitochondrial damage (Kim et 
al., 2007). Among these therapeutic potentials, the immuno-modulating effects of 
Ganoderma lucidum gained special interest; the immuno-modulatory mechanism of action 
includes promoting the function of antigen-presenting cells, as well as encouraging the 
mononuclear phagocyte system, humoral immunity, and cellular immunity (Lin, 2005). 
Therefore, this strong history of traditional use of medicinal mushrooms supported by scientific 
research can be a hope for the eradication of chronic diseases including cancer.  
1.3 Medicinal mushrooms and their compounds as a source of anti-proliferative 
activity 
1.3.1 Anti-proliferative mushrooms 
The feasibility of using mushroom-derived compounds exhibiting anti-cancer effects is 
becoming increasingly evident. The anti-cancer properties of compounds extracted and purified 
from mushrooms impart anti-tumor effects using one or a combination of the following 
mechanism(s): reactive oxygen species inducer, mitotic kinase inhibitor, signal transduction 
cascade modifier, angiogenesis inhibitor, and topoisomerase inhibitor. These mechanisms 
ultimately lead to apoptosis and an anti-proliferative response (Patel & Goyal, 2012). One of the 
prominent anti-cancer compounds from the mushroom Trametes versicolor is Polysaccharide K 
(PSK), imparting anti-cancer effects by selectively activating the Toll like receptor 2 (TLR-2) in 
tumor-bearing neu transgenic mice after oral administration (Lu et al., 2011). Inocybe 
umbrinella, a toxic mushroom, is also reported to have a novel lectin that has shown anti-
proliferative activity against hepatoma HepG2 cells and breast cancer MCF7 cells (Zhao et al., 
2009). Similarly, studies on the anti-proliferative activity of mushroom extracts from Auricularia 
auricula-judae, Pleurotus abalonus and Pleurotus sajor-caju against U937 leukemia cells 
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showed that fungi do exhibit promising results (Friedman, 2016). Friedman (2016) also studied 
several mushroom extracts that have demonstrated the anti-tumor effect via anti-angiogenic 
pathways. The findings suggested that Phellinus linteus significantly inhibit proliferation, 
migration, tube formation and vascular endothelial growth factor receptor phosphorylation of 
human vein endothelial cells (Lee et al., 2010). The polysaccharide isolated from Antrodia 
cinnamomea also exhibit anti-angiogenic activity by down-regulating cyclin D1 expression via 
antagonizing vascular endothelial growth factor receptor signaling (Cheng et al., 2005). 
Anti-proliferative activity can be due to changes in cell morphology, activation of 
caspase-like activities, release of cytochrome C into cytosol, or DNA fragmentation. Clitocine, a 
bioactive compound from Leucopaxillus giganteus, has shown apoptotic activity in human 
cervical cancer cells (HeLa), demonstrating the anti-proliferative potential of this purified moiety 
(Ren et al., 2008). Similarly, various terpenes also exhibit tumor growth-inhibitory properties. 
For example, terpenes isolated from the ethyl acetate-extract of Hypsizigus marmoreus exhibited 
strong tumor growth-inhibitory activity against murine sarcoma cells and against human tumor 
cell lines including U937 and HL-60 (Mizutani et al., 2006). 
1.3.2 Cytotoxic Extracts 
Mushroom extracts are also reputed to possess cytotoxic activity. Mushrooms extracts are 
not only used alone but also in combinational therapy to impart synergistic effects on tumor 
growth inhibition. Some of the prominent cytotoxic compounds and extracts will be described 
briefly here to highlight the potency of these mushrooms against cancer cell lines. A cytotoxic 
component, called suillin, isolated from the extract of the mushroom Suillus placidus, 
demonstrated a significant cytotoxic activity against human liver cancer cells (HepG2 cells, 
Hep3B cells, and SK-Hep-1) (Liu et al., 2009). The fungal extract of Agaricus blazei is also in 
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use by gynecological cancer patients undergoing cancer chemotherapy (Ahn et al., 2004). 
Similarly, hot water extracts of some common dietary mushrooms, including maitake, crimini, 
portabella, king oyster, and white button, have shown ability to reduce mitogenesis and induce 
apoptosis and cytotoxic activity in MCF7 human breast cancer cells (Martin et al., 2009). Among 
these mushrooms, maitake is well-known to have both immunomodulatory and antitumor 
properties; its 5% NaOH extract has previously been reported with potent cytotoxic effects and 
has shown promising results in reducing tumor cell viability due to apoptosis (Soares et al., 
2011). 
1.4 Overall Medicinal Prospects of Mushrooms 
The spectrum of medicinal properties of mushrooms is not confined to anti-cancer 
activity, but rather they have also been documented to have other promising healing properties. 
These include antimicrobial (antiviral, antibacterial and anti-fungal), antiallergic, 
immunomodulating (both immuno-stimulating and anti-inflammatory), antiatherogenic, anti-
diabetic (hypoglycemic), anti-oxidative (hepatoprotective) (Lindequist et al., 2015). 
1.4.1 Anti-Bacterial Mushrooms 
Many parts of the world are facing problems related to prevalence of infectious diseases 
and complications related to resistance to antibiotics. Prophylactically and therapeutically, 
antimicrobial drugs have been over-used, which has caused the bacterial strains to become 
resistant towards antibiotics (Klein et al., 2007). Compounds from mushroom extracts have 
shown both bactericidal and bacteriostatic potential. The type of activity exhibited by extracts 
can be related to the nature of bioactive compounds (Alves et al., 2012). For example, Lentinus 
edodes extracts have shown strong bactericidal activity against Streptococcus pyogenes (Hatvani, 
2001). These extracts are helpful in killing bacteria responsible for oral infections and tooth 
6 
 
decay (Signoretto et al., 2011). Mushroom extracts have also proven their anti-microbial activity 
against very resistant strains of bacteria. For example, extracts from Phellinus linteus have 
shown antibacterial activity against methicillin resistant Staphylococcus aureus (Hur et al., 
2004). 
1.4.2 Cardiovascular diseases 
The western world is suffering from a high level of mortality and morbidity related to 
cardiovascular diseases. Cardiovascular diseases can be linked with different metabolic markers 
including high density lipoproteins, low density lipoproteins, cholesterol and triglycerides. 
Metabolic markers for cardiovascular diseases are impacted positively (a decrease is noted), by 
several compounds present in mushrooms, such as low trans-isomers of unsaturated fatty acids, a 
low concentration of sodium, eritadenine, phenolic compounds, sterols (such as ergosterol), 
chitosan and triterpenes (Guillamón et al., 2010). 
1.4.3 Anti-inflammatory 
Overproduction of inflammatory mediators is a biological response of the immune 
system in response to pathogens. Inflammatory biomarkers include interleukins, tumor necrosis 
factor, nuclear factor-κB, intercellular adhesion molecule, cyclooxygenases, and prostaglandins 
(Elsayed et al., 2014). Mushrooms contain polysaccharides, terpenoids, phenolic compounds, 
and low molecular weight molecules, which have all shown strong anti-inflammatory properties 
(Elsayed et al., 2014). Inonotus obliquus, known as Chaga, is a well-known anti-inflammatory 
mushroom (Park et al., 2005). Various triterpenoids and steroids from I. obliquus were purified 
and found responsible for this anti-inflammatory potential in various in-vitro and in-vivo models 
(Park et al., 2005). Similarly, proteoglycan derived from the medicinal mushroom Phellinus 
linteus can prevent and treat collagen-induced arthritis (CIA) in mice (Kim et al., 2003). 
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1.4.4 Anti-oxidative 
An antioxidant is a molecule capable of inhibiting the oxidation of other molecules 
(Kozarski et al., 2015). Imbalanced metabolism or an excess of reactive oxygen species can lead 
to oxidative stress in human systems. Dietary intake of antioxidant supplements can regulate 
oxidative homeostasis. Mushrooms have  shown significant antioxidant properties due to their 
bioactive compounds, such as polyphenols, polysaccharides, vitamins, carotenoids and minerals. 
Their anti-oxidant mechanism can be primary (chain breaking, free radical scavengers) or 
secondary or preventive (Kozarski et al., 2015). 
Kozarki et al. (2012) studied the anti-oxidative potential of four reputed mushrooms 
(Ganoderma applanatum, G. lucidum, L. edodes and T. versicolor) and, among these, four 
different extracts of G. applanatum and L. edodes, were the most potent. All four extracts 
demonstrated strong correlation between phenol and α-glucan levels and bioactivity, suggesting 
the possibility of the active molecule(s) to be phenolic and α-glucan derivatives (Kozarki et al. 
2012). 
1.5 Wild mushrooms in Canada: a source to discover new anti-cancer compounds 
Canadian ecosystems, especially the habitats of British Columbia, provide favorable 
conditions for growth of many species of mushrooms. Classification of these mushrooms is 
complex, and it used to be based on their reproductive structures; these may be bracket, crust, 
truffle, morel, gilled, coral, jelly, toothed, bird’s nest, pore, club, puffball, earthstar, stinkhorn cup, 
earth tongue mushrooms, along with many others (Arora 1986). 
Wild mushrooms, especially from North America, are still mostly un-explored for their 
medicinal properties. Commercially available and wild edible mushrooms have long been 
consumed in Canada for their nutritional value, but prior to research at UNBC, there had been 
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only two studies on the bioactivity of wild mushrooms native to Canada. A new compound in 
Ganoderma applanatum collected from BC forests was reported (Ming et al., 2002), but there 
was no insight into its biological activity. A second study shows anti-inflammatory effects of 
Inonotus obliquus collected from northern Manitoba, but no compound characterization was 
provided (Van et al., 2009).  
Three recent studies in Dr. Lee’s lab have provided insights to the medicinal properties of 
several Canadian wild mushrooms; these were found to have immunomodulatory and growth-
inhibitory activities. The first report on growth-inhibitory and immunomodulatory potential of 
BC wild mushrooms has provided a direction for further exploration (Smith et al., 2017). The 
second report was on a growth-inhibitory heteroglycan (GIPinv) polysaccharide isolated 
from Paxillus involutus. GIPinv (229KDa) has ability to induce apoptosis in HeLa cancer cells 
(Barad et al., 2018). The third study focused on a small molecular weight carbohydrate (5-
25KDa) purified from E. tinctorium (Javed et al., 2017). The anti-inflammatory polysaccharide 
can inhibit the TNF-α production in LPS activated RAW 264.7 cells as well as ameliorate 
histamine-induced vasodilation in the 2A arterioles (gluteus maximus muscle) in mice (Javed et 
al., 2017). Based on these studies, it is clear that Canadian wild mushrooms are beneficial and a 
possible economical source of small and large molecules with potential for the treatment or 
prevention of many acute and chronic diseases.  
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1.6 Compounds with anti-proliferative activity 
There are great variety of growth-inhibitory compounds when it comes to the size of 
molecules. The growth-inhibitory compounds are classified based on their size and chemical 
nature. Figure 1.1 provides a general classification of high molecular weight and small molecular 
compounds that have been isolated from mushrooms. A brief description of some of these 
compounds is provided below. 
 
 
Figure 1.1 Classification of compounds with anti-tumor potential based on their molecular 
weight (Ferreira et al., 2010). 
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1.6.1 Large molecules (High Molecular weight compounds) 
High-molecular-weight bioactive compounds isolated from mushrooms include 
homoglucan, heteroglucans, glycan, glycoproteins, glycopeptides, proteoglycans, proteins and 
RNA-protein complexes (Figure 1.1). Mushrooms contain high amounts of proteins, ranging 
from 10-40% of dry weight. These proteins should be cytotoxic in their nature for instance a 
cytotoxic high molecular weight protease purified from the dried fruiting bodies of Cordyceps 
militaris showed remarkable effects against different human cancer cell lines (Park et al., 2009). 
Alkaline protease, having the molecular weight of 15 kDa, isolated from fruiting bodies of 
Amanita farinosa was shown to dose-dependently inhibit proliferation of HepG2 cells (Sun et al., 
2011). Similarly, a sulfated polysaccharide isolated from Grifola frondosa showed a 
concentration-dependent inhibition of proliferation in HepG2 cells by inducing apoptosis and 
causing cell cycle arrest at S phase (Wang et al., 2013). Likewise, the polysaccharide from G. 
frondosa and vitamin C, when tested in combination, showed the synergistic effects on 
hepatocellular carcinoma cells (SMMC-7721) by reducing the viability by 70%. This effect was 
observed because of cell cycle arrest at the G2/M phase (Zhao et al., 2016). Table 1.1 provides 
insights from the literature to some of the purified large molecules from fruiting bodies of the 
mushrooms. 
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Table 1. 1 Large compounds from mushroom and their biological properties 
Mushroom species Compounds Biological activity Reference 
Polysaccharides:     
Paxillus involutus GIP-inv 
polysaccharide  
Anti-proliferative (apoptosis 
induction) 
Barad et al., 
2018. 
Agaricus bisporus RK2-Ab manno-
galacto-glucan  
Anti-proliferative (apoptosis 
induction) 
Pires et al., 
2017. 
Flammulina velutipes 
 
FVP2A, FVP2B 
and FVP2C 
↑cellular NO formation, iL-1 
production and TNF-α secretion in 
macrophages 
Yin et al., 
2010. 
Sarcodon aspratus 
 
Water-soluble 
polysaccharide 
(HCP) 
Stimulate the proliferation of the 
cultured mice spleen lymphocyte 
Han et al., 
2011. 
Lentinus edodes 
 
Branched β-(1, 
3)-glucan (LNT) 
Induction of apoptosis, inhibition of 
proliferation 
Xu et al., 
2016. 
Proteins/Enzymes:    
Ganoderma lucidum Laccase Inhibition of the activity of HIV-1 
reverse transcriptase 
Wang et al., 
2006 
 (FIP) fungal 
immunomodulat
ory protein 
Enhanced the transcription of (IL)-
2, IL-3, IL-4, interferon (IFN)-γ, 
(TNF)-α 
Li et al., 
2010. 
Hypsizigus marmoreus (RIP) Ribosome 
inactivating 
protein  
↓ Proliferation of Hep G2 cells 
MCF-7 cells 
Wong et al., 
2008 
Stachybotrys 
chlorohalonata 
(FIP) Fungal 
immunomodulat
ory protein 
Induced apoptosis and interrupt 
migration in A549 cells 
Jiang et al., 
2017 
Ganoderma 
microsporum 
 
(GIP) 
Ganoderma 
immunomodulat
ory protein  
Down-regulation of TNF-a Induced 
Expression of Matrix 
Metalloproteinase 9 
Lin et al., 
2010. 
Trametes versicolor 
 
FIP-TVC Enhanced the proliferation of 
splenocytes and human peripheral 
blood lymphocytes.  
Li et al., 
2011. 
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1.6.2 Small molecules (Low Molecular weight compounds) 
Smaller compounds with anti-proliferative potential identified so far in mushrooms, 
include quinones, cerebrosides, isoflavones, catechol, amines, triacylglycerols, sesquiterpenes, 
steroids, organic germanium and selenium (Figure 1.1). Terpenoids can be phenolic in nature, such 
as Isopropyl 2,6-bis(1-phenylethyl)phenol isolated from the butanol extract of Cordyceps 
bassiana. This terpenoid has shown anti-proliferative and apoptotic activity on several cancer cell 
lines such as C6 glioma, MDA-MB-231, and A549 cells (Kim et al., 2015). 
Terpenes also play a major role in inhibiting cancer cells growth. Ergosterol peroxide from 
Chaga exhibited anti-proliferative activity by down-regulating the β-catenin pathway in different 
colorectal cancer cell lines (Kang et al., 2015). Methanolic extracts contain the cytotoxic sterols, 
sterols with peroxide ring or an epoxide ring . Sterols extracted from the dried powder of cultured 
mycelium of C. sinensis showed significant cytotoxic activity on human cancer cell line HL60 
(Matsuda et al., 2009). 
Low molecular weight (LMW) polyphenolic compounds having polyhydroxylated benzyl, 
moiety in their structure are abundant in Inonotus obliquus. These low molecular weight 
polyphenolic compounds include caffeic acid, 3,4-dihydroxybenzalacetone, gallic acid, syringic 
acid, protocatechuic acid, 3,4-dihydroxybenzaldehyde and 2,5-dihydroxyterephthalic acid. These 
low molecular weight polyphenolic compounds were able to inhibit human topoisomerase II 
(Kuriyama et al., 2013).  Some potent anti-cancer small molecules purified from the fruiting bodies 
of the mushrooms are shown in Table 1.2. 
 
13 
 
Table 1. 2 Small compounds from fruiting bodies of mushrooms and their biological 
properties 
Mushroom species Compounds Biological activity Reference 
Terpenoids:    
Albatrellus 
confluens 
Grifolin Inducing apoptosis Ye et al., 2005. 
 Confluentin Weak antagonist for human 
vanilloid receptor VR1 
Hellwig et al., 
2003. 
Albatrellus flettii Grifolin, Neogrifolin 
and Confluentin. 
Anti-bacterial activity Liu et al., 2010. 
Albatrellus ovinus 
 
3-
hydroxyneogrifolin, 
1-formylneogrifolin 
and 1-formyl-3-
hydroxyneogrifolin 
Grifolin, Neogrifolin 
Antioxidative activity Nukata et al., 
2002. 
Sarcodon scabrosus Sarcodonin G ↓ Proliferation by inducing HeLa 
cell apoptosis 
Mei et al., 2010. 
 Scabronine A Potent inductive activity of the 
nerve growth factor synthesis 
Ohta et al., 1998. 
 Scabronine G and H Antibacterial and antifungal activity Ma et al., 2010. 
Pleurotus eryngii Eryngiolide A Moderate cytotoxicity against two 
human cancer lines in vitro 
Wang et al., 2012. 
Cyathus africanus 
 
Cyathane diterpenes Inhibition of nitric oxide production 
in LPS-activated macrophages 
Han t al., 2013. 
Ganoderma 
lucidum 
Ganoderic acid A 
 
Suppress growth and invasion of 
breast cancer cells by modulating 
AP-1 and NF-κB signaling 
Jiang et al., 2008. 
 Ganoderic acid T 
 
Mitochondria mediated apoptosis in 
lung cancer cells 
Tang et al., 2006. 
Fomitopsis nigra Fomitoside-K Induce apoptosis via ROS-
dependent mitochondrial 
dysfunction 
Bhattarai et al. 
2012.  Lee et al. 
2012. 
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1.7 Research Goals 
 Canada and particularly British Columbia is fortunate with a wide range of 
basidiomycetes fungi that should be explored for their biological activity. The probability of 
finding novel immunomodulatory or growth-inhibitory compounds from Canadian wild 
mushrooms is very high. Mushrooms contain a wide range of small to large compounds, but the 
purification technique and strategy are to be used to isolate compounds will depend on its 
characteristic and chemical nature. 
Following are the specific research goals of my MSc thesis: 
(i) Genetic identification, chemical extraction and biological assessment (immuno-
modulatory and growth-inhibitory activities) of six Canadian mushroom 
specimens. 
(ii) Purification and characterization of small molecule growth-inhibitors from 
Albatrellus flettii 
(iii) Purification and identification of small molecules from Sarcodon scabripes 
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Chapter 2: Evaluation of Canadian wild mushrooms for growth-
inhibitory and immuno-modulatory activities  
The immune system is known as body’s defense system against pathogens. The exposure 
to the pathogens results in the activation of different immune-system markers: which could be 
either anti-inflammatory or immunostimulatory. Mushroom extracts could possess the potential 
to either stimulate TNF-α (immunostimulatory) or inhibit TNF-α (anti-inflammatory). 
Mushroom extracts could also be growth-inhibitory or cytotoxic in nature. 
This chapter concerns the analysis of five mushroom species collected from British 
Columbia (BC) and one mushroom species collected from Quebec. The mushrooms were first 
genetically identified followed by chemical extractions to generate crude extracts. The crude 
extracts were then screened for growth-inhibitory and immuno-modulatory activities. 
2.1 Materials and Methods 
2.1.1 Mushroom Collection & Identification 
The mushrooms used in this study were collected by the UNBC research team (Drs. 
Hugues Massicotte, Keith Egger, Chow Lee, Maggie Li and Ms. Linda Tackaberry) at different 
locations across north-central BC and Ste-Geneviève of Batiscan, in Quebec. The collected fungi 
were dried overnight in the hot air oven at 60 °C. The species were identified using 
morphological and genetical approaches. Morphological identification was based on different 
morphological parameters identified using the software “Matchmaker” (Gibson et al., 2010) and 
the reference guide Mushrooms Demystified (Arora, 1986). 
To genetically identify mushroom samples, tissue sample from the cap flesh was 
collected and further processed for DNA extraction. After genomic DNA extraction, samples 
were sent for sequencing using the forward primer ITS3 (5’-GCATCGATGAAGAACGCAGC-
3’) and the reverse primer NLB4 (5’-GGATTCTCACCCTCTATGAC-3’). The minimum 
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concentration required to send for sequencing was 10.0 ng/µL. The sequences obtained from 
Macrogen Corporation were compared with sequences available in the National Center for 
Biotechnology Information (NCBI) internet database, GenBank, using the Basic Local 
Alignment Search Tool (BLAST) program. Specimens were considered to be tentatively 
identified if BLAST results indicated at least 97% similarity. 
 Table 2.1: Photographs of the mushroom specimens collected from different locations 
across Canada 
 
 
 
Fomitopsis officinalis (115) 
(also called Laricifomes officinalis) 
 
Collected on October 1st, 2015 
 
Location: Douglas-fir, Prince George, BC 
 
 
 
 
 
 
Sarcodon scabripes (124) 
 
 
Collected on August 21, 2016 
 
Location: Twin Falls, Smithers, BC 
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Tricholoma vaccinum (125) 
 
Collected on August 21, 2016 
 
Location: Twin Falls, Smithers, BC 
 
 
 
 
 
 
 
 
Cerrena unicolor (127) 
 
 
Collected on August 21, 2016 
 
Location: Seeley Lake Provincial Park, BC 
 
 
 
 
 
 
 
Albatrellus flettii (128) 
 
 
Collected on September 3, 2016 
 
Location: Twin Falls, Smithers, BC 
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Trametes versicolor (143) 
 
 
Collected on October 29, 2016 
 
Location: Rang des Forges, Ste-Geneviève de 
Batiscan, QC. 
 
 
 
 
 
 
Albatrellus flettii (151) 
 
 
Collected on September 20, 2017 
 
Location: Twin Falls, Smithers, BC 
 
2.1.2 Genetic identification of the mushroom samples using ITS3 and NLB4 primers 
Before determining the medicinal properties of collected mushrooms, their identity  needs 
to be determined. In the past, mushrooms were primarily identified based on morphological 
characteristics of the fruiting body such as whether it was gilled or toothed, and then classified 
according to the system developed by Elias Fries (Binder & Hibbett, 2002), but often there was 
difficulty separating closely-related species due to similar morphological characteristics. One of 
the major advances in the past few decades in the field of taxonomy is the application of 
molecular genetic techniques to species identification.  
The ITS regions have been found to have the greatest probability of correct identification 
for the greatest range of fungi as compared to other possible identification sequences. 
Researchers from previous literature have used either the ITS1, ITS2 or both regions to 
genetically identify unknown mushrooms samples (Martin & Rygiewicz, 2005). However, we 
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focused on the ITS2 region because the primer sets ITS3 and NLB4 extends into the 28S large 
subunit gene (Kowalczyk et al., 2015). The ITS2 region of the genomic DNA (gDNA) could be 
amplified using the forward primer ITS3 and the reverse primer NLB4. Thus, using these set of 
primers can aid in the identification of unknown mushroom samples. 
2.1.3 DNA extraction procedures 
The MoBio DNA PowerSoil Kit was used to extract genomic DNA from mushroom 
samples. The mushroom samples were emulsified using PowerBeadTM tubes and then subjected 
to DNA extraction. Modifications made to the manufacturer’s protocol include heating the 
mushroom samples to 95°C for 15 min in PowerBead tube solution as well as increasing the time 
vortexing the PowerBead tubes increased to 15-20 min. The process of gDNA extraction was 
performed for two samples only (143 and 151). The gDNA from other samples was extracted by 
Dr. Maggie Li. The extracted DNA was then quantified spectrophotometrically using a 
NanodropTM spectrophotometer (Table 2.2).  
Table 2.2: Concentration of the genomic DNA and of the purified PCR product/Gel 
Extraction, using Nanodrop. 
Sample Concentration of gDNA 
(ng/μL) 
Concentration after PCR purification 
(ng/μL) / gel Extraction 
Mushroom 143 13.4 30.3 
Mushroom 151 12.4 38.1 
 
2.1.4 PCR amplification and purification procedure 
The genomic DNA (gDNA) of mushroom samples (Table 2.2) were subjected to PCR 
using the conditions listed in Tables 2.3 and 2.4. The ITS2 region of the gDNA was amplified 
using the forward primer ITS3 (5’-GCATCGATGAAGAACGCAGC-3’) and the reverse primer 
NLB4 (5’-GGATTCTCACCCTCTATGAC-3’). The efficiency of the PCR samples was 
assessed by agarose gel electrophoresis. Gel electrophoresis was performed at 140 V using a 1% 
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agarose gel, ethidium bromide and 0.5 x TBE Buffer. The gel ran for approximately 40 min at 
140 V and was subsequently visualized under a UV transilluminator. In the case that no band 
was visualized, the amplification procedure was repeated except that a larger volume of gDNA 
was used (2-4 µL) and the source of TAQ polymerase and 10x thermopol buffer was changed. In 
the case where a faint band was observed, multiple PCR amplifications were done using higher 
amount of gDNA (2 µL) and after combining all amplified PCR products, PCR cleanup was 
performed using the QIAquick PCR kit. After purification, samples were sent to Macrogen 
Corporation for DNA sequencing using the forward primer ITS3 (5’-
GCATCGATGAAGAACGCAGC-3’) and the reverse primer NLB4 (5’-
GGATTCTCACCCTCTATGAC-3’). The minimum concentration required to send for 
sequencing was 10.0 ng/µL. 
Table 2.3: PCR reaction protocols required to amplify the extracted DNA from the 
mushroom species using both the forward (NLB4) and reverse (ITS3) primers.  
Component Volume used (µL) 
H2O 16 
10x Thermo Pol Buffer 2.5 
dNTPs (2.5 mM) 2.5 
ITS3 (10 µM) 1 
NLB4 (10 µM) 1 
DNA template 1.5 
TAQ polymerase  0.5 
 
Table 2.4: PCR program, steps 2, 3, 4 are repeated 29 times in the cycle. 
 
 
 
 
 
 
PCR Program 
Step Temp Time 
1 95 °C 5min 
2 95 °C 30sec 
3 52 °C 30sec 
4 72 °C 30sec 
5 72 °C 10min 
6 4 °C 10min 
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2.2 Chemical extraction of mushrooms 
The choice of appropriate extraction technique solely depends on the compounds of 
interest and their chemical nature. Use of high temperature extraction technique becomes 
impossible if the bio-active compounds are thermolabile. To get the maximum quantity of 
desired bio-active compounds, the extraction must be based on the appropriative technique and 
pattern. Dr. Lee’s lab recently adopted the use of Dionex speed extractor (ASE 350) in preparing 
extracts from mushrooms. Dionex Accelerated Solvent Extractor ASE 350 is an automated, safe 
and easy way for sequential extraction (80% ethanol, 50% methanol, and water) of bioactive 
compounds from solid and semisolid samples.  
 
Figure 2. 1 Flowchart summarizing the chemical extraction protocol (Dionex ASE 350) 
(Graphics credit: Hasnain Yaqoob). 
Traditional methods such as soxhlet and sonication are time consuming, difficult, labor 
intensive and require large amount of solvents. Dionex ASE 350 uses less solvent as compared to 
other extraction methods and allows simultaneous extraction of multiple samples. The concept 
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behind this technique is based on the use of elevated temperature to increase the extraction 
efficiency of analyte of interest from their matrix. Elevated nitrogen pressure is used to keep the 
solvents in a liquid state, the solubility of analyte is increased, and viscosity of the solvent is 
reduced, thereby increasing extraction efficiency and reducing extraction time (De Monte et al., 
2014). 
Using the Speed Dionex method, samples were initially placed in filter cell (thimble) and 
first extracted with 80% ethanol so that any low molecular weight compounds can be obtained. 
Samples were sequentially extracted with 50% methanol (for low molecular weight compounds) 
and then with water (for water-soluble polysaccharides). The 5% NaOH extraction step was then 
performed manually using a hotplate to extract water-insoluble polysaccharides. Several 
extraction parameters (temperature, time, cycle, nitrogen pressure) were considered, which can 
affect the stability and yield of the extracts (Liu et al., 2010). 
2.2.1 Rotary evaporation, pH neutralization, snake skin dialysis, and lyophilization 
of the extracts 
After successful extraction, the mushroom extracts were further processed for volume 
reduction to eliminate the excess amount of solvent. The process of evaporation was hastened 
with the help of rotary evaporator. Once the volume of the extracts was reduced to a required 
limit (if 90% solvent is removed), the extracts were subjected to pH neutralization. The pH range 
used as reference to neutralize the mushroom extracts was 6.90 to 7.10. For pH neutralization, 
either 2 M NaOH or 2 M HCl was used. To remove salts, the extracts were dialyzed using 
Thermo Scientific SnakeSkin Dialysis Tubing (3.5K MWCO) for 12 hours. The last step 
involved in the processing of extract was lyophilization. Extracts were first frozen in -80 ºC 
freezer and then lyophilized using Labconco Freeze dryer (0.008 bar vacuum pressure and -80 
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ºC). The amount of dried extracts was then determined so that the yield can be estimated and 
then used for biological assays. 
 
Figure 2. 2 Flowchart showing the scheme adopted to obtain dried extracts prior to cell 
treatment. 
2.2.2 Stock solution and filter sterilization 
Stock solution concentrations were made in consideration of the solubility of the extracts.  
Before making stock solutions, extracts were analyzed for their maximum solubility in an 
appropriate solvent. For extracts that were soluble in water, the stock solutions were prepared at 
20 mg/mL. For extracts that were not soluble in water but soluble in methanol, the final 
concentration of stock solutions was prepared at 40 mg/mL. For example, E1 and E2 of A. flettii 
and S. scabripes were insoluble in water and were prepared in this manner.  
After making the stock solution of the extracts, the next step was to filter-sterilize the 
solution. The process of filter-sterilization was carried out using 0.2 μm filter (Sarstedt, 
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Nümbrecht, Germany) to remove any precipitate or biological impurities (which can interfere 
with the results). 
2.3 Assessment of Anti-proliferative and Immuno-Modulatory Activities 
(Immuno-stimulatory and Anti-inflammatory) of Mushroom Crude Extracts 
 
2.3.1 Dose- and time-dependent MTT assay to determine the anti-proliferative 
activity of mushroom extracts on HeLa cell  
The lyophilized mushroom extracts were reconstituted in their respective suitable 
solvents mentioned in Table 2.7. The stock concentration was 40 mg/mL for methanol-soluble 
extracts and 20 mg/mL for water-soluble extracts. For dose-dependent MTT assay, the stocks 
were further diluted using EMEM (Eagle’s minimum essential media) supplemented with 10% 
FBS to make different doses of extracts. HeLa cells were first subjected to treatment with 
different concentrations (from 0.1 mg/mL to 1 mg/mL) of the extracts for 48 hours and MTT 
assay was performed. Based on the results from dose-dependent MTT assay, the time-dependent 
MTT assay was then performed. HeLa cells were subjected to treatment with selected 
concentration of active extracts for a specific period (1 to 7 days). 
2.3.1.1 Dose-dependent MTT assay for assessment of growth-inhibitory activity of 
mushroom extracts 
MTT [3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide] assay is a 
colorimetric bioassay used to assess cell viability. The MTT assay can be used to determine the 
growth-inhibitory effect of mushroom extracts on human cancer cell lines. The mitochondrial 
NADPH-dependent reductase enzyme in viable cells reduces the water-soluble yellow tetrazole 
MTT dye to insoluble purple formazan crystals (Meerloo et al., 2011), which are accumulated in 
lipid droplets because of their lipophilic nature (Stockert et al., 2012). 
25 
 
 
Figure 2. 3 Mechanism involved in the reduction of MTT dye by mitochondrial reductase 
(indicator of cell redox activity)  
The MTT dye readily penetrates viable cells (Riss et al., 2016). The mitochondria in 
viable cells has the enzyme that converts MTT into formazan. The concentration of the purple 
formazan makes it possible to estimate the number of viable cells. Dimethyl sulfoxide (DMSO) 
was then used to solubilize formazan crystals. After that, the absorbance from the formazan 
solution was determined using Synergy 2 multi-plate reader (BioTek®, USA). It is important to 
point out here that the MTT assay has some limitations regarding certain type of reductive 
chemicals and because of that, it can give an underestimation of the anti-proliferative activity of 
some chemicals (Wang et al., 2010). 
2.3.2.2 Dose-dependent MTT assay protocol 
Dose-dependent MTT assay was based on percent viability of HeLa (Henrietta Lacks 
cervical cancer cells) (ATCC®, Maryland US) after treatment with different concentrations of 
mushroom extracts. HeLa cells were propagated in a T-25 flask using Lonza Eagle’s Minimum 
Essential Medium (EMEM by VWR ON, CA) supplemented with 10 v/v Fetal bovine serum 
(FBS). At 80% confluency, the growth media (EMEM+ 10% FBS) was removed from the flask. 
Cells were then washed with 3 mL of Dulbecco’s Phosphate Buffer Saline (DPBS) (Lonza, 
Maryland) followed by trypsinization. Removal of adherent cell culture from T-25 flask surface 
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was carried out using 1 mL of Trypsin EDTA (0.25%) for 3 min. Cells were then quantified 
using a haemocytometer and further diluted to achieve the concentration of 15,000 cells/mL.  
 
Figure 2. 4 Schematic representation of dose-dependent MTT assay protocol using HeLa 
Cells. (Graphics credit : Hasnain Yaqoob) 
The 96-well plate was used to culture cells for treatment with different doses of extracts. 
The plated cells (1500 cells/100 µL/well) were incubated for 24 hours at 37°C in 5% CO2. 
Twenty-four hours after plating, different doses (0.1, 0.25, 0.375, 0.5, 0.75 and 1 mg/mL) of 
mushroom extracts were made using EMEM with FBS and the respective solvents (Table 2.5). A 
stock of mushroom extracts was prepared based on their solubility in a suitable solvent. For 
extracts soluble in water, the stock concentration was 20 mg/mL. The stock concentration of 
methanol soluble extracts (E1 and E2 extracts of A. flettii and S. scabripes) was made at 40 
mg/mL to reduce the final volume of methanol in well. The stock solutions were then filter-
sterilized using 0.2 µm filter (Sarstedt, Nümbrecht, Germany) to remove any biological 
contamination or insoluble materials from the extracts or solvents. 
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Table 2.5: Representation of the different doses of mushroom extracts used for MTT assay.  
  For One Well For 6 Wells 
Final 
conc. 
(mg/mL) 
(in plate) 
Stock 
(mg/mL) 
(in tube) 
Diluted 
water in 
MEM 
(µL) 
Fraction 
at 4 
mg/mL 
MEM 
(µL) 
Diluted 
water in 
MEM 
(µL) 
Fraction 
at 4 
mg/mL 
MEM 
(µL) 
1 2 0 50 50 0 300 300 
0.75 1.5 12.5 37.5 50 75 225 300 
0.5 1 25 25 50 150 150 300 
0.375 0.75 31.2 18.75 50 187.5 112.5 300 
0.25 0.5 37.5 12.5 50 225 75 300 
0.1 0.2 45 5 50 270 30 300 
0 0 50 0 50 300 0 300 
  Total Volume of 100 µL Total Volume of 600 µL 
 
Figure 2. 5: Plate pattern (96-well) followed to screen different doses of extracts from 
selected mushroom samples, for their potential to exhibit anti-proliferative activity based 
on the MTT assay. 
  1 2 3 4 5 6 7 8 9 
A water water water water water water water water water 
B water 1 
mg/mL 
0.75 
mg/mL 
0.50 
mg/mL 
0.375 
mg/mL 
0.25 
mg/mL 
0.1 
mg/mL 
Control water 
C water 1 
mg/mL 
0.75 
mg/mL 
0.50 
mg/mL 
0.375 
mg/mL 
0.25 
mg/mL 
0.1 
mg/mL 
Control water 
D water 1 
mg/mL 
0.75 
mg/mL 
0.50 
mg/mL 
0.375 
mg/mL 
0.25 
mg/mL 
0.1 
mg/mL 
Control water 
E water 1 
mg/mL 
0.75 
mg/mL 
0.50 
mg/mL 
0.375 
mg/mL 
0.25 
mg/mL 
0.1 
mg/mL 
Control water 
F water 1 
mg/mL 
0.75 
mg/mL 
0.50 
mg/mL 
0.375 
mg/mL 
0.25 
mg/mL 
0.1 
mg/mL 
Control water 
G water water water water water water water water water 
 
Cells were treated with 100 µL of the mushroom extract, making final concentration as 
planned. After treatment with different doses of mushroom extract and controls (water and 
methanol), cells were further incubated for 48 hours. On day 4, 50 µL of diluted MTT solution (1 
mg/mL) was added to cells. Cells were further incubated for 3 hours allowing the live cells to 
take up the MTT dye and converting it to formazan crystals by mitochondrial reductase. To 
calculate cell viability, the supernatant was removed from each well and 150 µL of DMSO was 
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added to each well to dissolve the formazan crystals. The appearance of dark purple color was 
indication of cell high cell viability. The absorbance was read at 570 nm using Synergy 2 multi-
plate reader. 
2.3.2.3 Time-Dependent MTT assay for assessment of growth-inhibitory activity of 
mushroom extracts 
Time-dependent MTT assay was also based on percent viability of HeLa (Henrietta 
Lacks cervical cancer cells) (ATCC®, Maryland US) cells after treatment with selected 
concentrations of mushroom extracts. HeLa cells were propagated the same way as in the case of 
dose-dependent MTT assay. Cells (750 cells/100 µL/well) were incubated for 24 hours at 37°C 
in 5% CO2 allowing them to adhere to the surface of wells.  
            
Figure 2. 6: Schematic representation of time-dependent MTT assay protocol using HeLa 
Cells. (Graphics credit : Hasnain Yaqoob) 
Twenty-four hours after plating, mushroom extracts were added to the cells at selected 
concentrations for several days (24, 48, 72, 96, 120, 144, 168 hours). There was a total of eight 
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96-well plates used which include one for zero time period, where cells had no treatment. MTT 
assay was performed on a daily basis as described above for the dose-dependent MTT assay. The 
data obtained from Synergy 2 was further processed using Microsoft excel and Kaleidagraph. 
2.3.2 Assessing TNF- α production by RAW 264.7 cells as an indication of immuno-
stimulation 
The stimulation of TNF-α production was conducted using mouse macrophage RAW 
264.7 cells purchased from the American Type Culture Collection (ATCC® Maryland). 
Macrophages were cultured in 96-well plates using DMEM without 10% FBS and incubated at 
37°C with 5% CO2 for 18 hours. The number of cells plated per well were 100,000 cells/200 µL. 
After 18 hours of incubation, the medium (200 µL DMEM without FBS) was removed from the 
wells and cells were washed with 200 µL Dulbecco’s Phosphate Buffer Saline (DPBS) (Lonza, 
Walkersville, Maryland). Plated RAW 264.7 cells were supplemented with 100 L DMEM 
without FBS each well.  
The mushroom extracts at 1 mg/mL (in DMEM without FBS) final concentration (in the 
well) were introduced (100 µL). Lipopolysaccharide (500 ng/mL) was used as a positive control 
while DMEM (Gibco’s) without FBS and the solvents (used in the reconstitution of extract e.g., 
methanol, and water) were used as negative controls. The supernatant was collected (150 µL) 
after a 6-hour exposure period. The collected supernatant was stored at -80°C prior to performing 
ELISA for quantification of TNF-α production. 
2.3.2.1 Enzyme-Linked Immunosorbent Assay (ELISA) 
The collected supernatant was subjected to enzyme-linked immunosorbent assay 
(ELISA) for the quantification of TNF-α production by RAW 264.7 cells. The concentration of 
TNF-α in supernatant was determined using TNF-α ELISA kit as per manufacturer’s protocol 
(BD OptEIA™ Mouse TNF (Mono/Mono) ELISA Set BD Biosciences, USA). The resulting 
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ELISA plate was coated with a capture antibody, diluted (1:250) in a coating buffer (pH 6.5) for 
16 hours at 4°C. Next, the plate was washed using washing buffer (diluted 20 times) and blocked 
with assay diluent (200 µL) for 1 hour. Afterwards, plate was treated with a solution (100 µL of 
1:9 collected supernatants in assay diluent) for 2 hours at room temperature. TNF-α standard 
dilutions (1000, 500, 250, 125, 62.5, 31.25 and 15.625 pg/mL) were prepared and added in 
duplicate to the last two columns of plate (100 µL/well). 
The plate was washed (5 times) again then instilled with biotinylated mouse TNF-α 
monoclonal antibodies as well as the enzyme reagent for 1 hour. Subsequently, the substrate 
solution (100 µL) was added to the wells after washing the plate a total of 7 times and incubated 
in dark for 30 min before 50 µL of stop solution was added. The concentration of macrophage 
TNF-α was calculated through optical density readings using Synergy 2 multi-plate reader at 450  
and 570 nm.  The data obtained was further processed using Graph prism 6 and the standard 
curve of mouse recombinant TNF-α was used for quantification of TNF-α in samples. 
2.3.3 Assessing inhibition of TNF-α production in RAW 264.7 cells as an indication 
of anti-inflammatory activity 
The cell plating work for anti-inflammatory assay was performed in a similar manner as 
for the immuno-stimulatory assay but with slight modification in the cell treatment part: cells 
were treated with LPS first and later with mushroom extracts. As in immuno-stimulatory assay, 
the number of cells plated per well were 100,000 cells/200 µL. 
Macrophage cells (RAW 264.7) were plated in 96 well plates using Dulbecco’s Modified 
Eagle Medium by life technologies (DMEM without 10% FBS) and incubated at 37°C with 5% 
CO2 for 18 hours. After 18 hours of incubation, the medium (200 µL DMEM without FBS) was 
removed from the wells and cells were washed with 200 µL Dulbecco’s Phosphate Buffer Saline 
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(DPBS) (Lonza, Walkersville, Maryland). Each well of plated RAW 264.7 cell was 
supplemented with 100 L LPS (250 ng/mL) in DMEM without FBS. The mushroom extracts at 
1 mg/mL (in DMEM without FBS) final concentration (in the well) were introduced (100 µL). 
Polymyxin-B (200 units/well) was used as a positive control, while DMEM (Gibco’s) without 
FBS and the solvents (used in the reconstitution of extract e.g. methanol, and water) were used as 
negative controls. The supernatant was collected (around 150 µL) from wells after a 6-hour 
incubation period. The supernatant was stored at -80°C prior to performing ELISA for the 
quantification of TNF-α production. 
2.4 Results and Discussion 
2.4.1 Genetic Identification of mushroom specimens 143 and 151. 
Figure 2.7 represents the bands for the PCR products from mushroom # 143 and 151. The 
DNA bands of both samples are visible in between 500 and 600 base pair range of the ladder, 
which confirms the DNA of mushroom samples being pure. The DNA sequences obtained for 
the forward primer ITS3 and the reverse primer NLB4 were compared with sequences available 
in the National Center for Biotechnology Information (NCBI) internet database, GenBank, using 
the Basic Local Alignment Search Tool (BLAST) program. Specimens are considered tentatively 
identified (subject to confirmation of correct GenBank information) if BLAST results showed a 
greater than or equal to 97% similarity. 
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Table 2.6: The identification of mushroom species using BLAST searches, along with the 
percent of matching bases between the unknown sample and the closest match. 
Identity  Collected By 
Best GenBank Match 
(% similarity/ % coverage)  
Fomitopsis officinalis (115) Dr. Roy Rea 
EU854436.1 
(99% / 79%) 
Sarcodon scabripes (124) Dr. Chow Lee  
JN135191.1 
(99% / 78%) 
Tricholoma vaccinum (125) Dr. Chow Lee 
FJ845444.1 
(99% / 99%) 
Cerrena unicolor (127) Dr. Chow Lee 
KC176316.1 
(99% / 100%) 
Albatrellus flettii (128) Dr. Chow Lee 
JF899544.1 
(97% / 99%) 
Albatrellus flettii (151) Dr. Chow Lee 
JF899544.1 
(97% / 99%) 
Trametes versicolor (143)   
Drs. Keith Egger & 
Hugues Massicotte 
KC581354.1  
(93% / 97%)  
   
                                           
Mushroom #151 Mushroom #143
600 bp
500 bp
 
Figure 2. 7: Agarose gel (1%) consisting of PCR product of mushroom # 151 and 1 kb DNA 
ladder. ITS3 and NLB4 were used as the primers for amplification.  
 
The percent match of identification for A. flettii mushroom specimens (151) was 97 % 
and for mushroom 143 (T. versicolor), it was only 93 % . A match of less than 97% could be an 
indication that the isolate does not belong to any entry in the database and could possibly be an 
undiscovered species, as seen in the case of mushroom 143 (T.  versicolor) the percent similarity 
was only 93%. It could also be an indication that the sequence obtained needs further sequencing 
and editing to eliminate ambiguous or incorrect base calls. 
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2.4.2 Chemical extraction of Canadian wild mushrooms 
The collected mushrooms were extracted using Dionex ASE 350 speed extractor for 
extract E1, E2, and E3 only. The extraction for E4 was done manually using a hotplate. The 
summary of extraction results is provided in Table 2.7.  
The higher yields were obtained for Extract E4 of all mushroom samples. The lower 
yields were obtained mostly for E1 extracts. The highest yield (78.77%) among all extracts was 
exhibited by E4 of T. versicolor, while the lowest yield (0.79%) was exhibited by E1 of C. 
unicolor. The physical properties of these extracts were also quite distinctive from each other. 
All four extracts from S. scabripes and T. vaccinum were coarse in nature.  E2 and E3 extracts of 
mushroom sample 115, 127 and 143 were fluffy in nature. The extract E1 and E2 of S. scabripes 
and A. flettii were only soluble in methanol, indicative of the hydrophobic nature of bioactive 
compounds within them. 
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Table 2.7: Summary of the fungal extracts obtained through successive extraction process 
using Dionex ASE-350 speed extractor. 
Extraction 
sample  
(grams) 
Extract 
type  
Solvent 
System used 
for extraction 
Extract 
weight 
(gm) 
Extract 
Yield 
(%) 
Physical 
appearance  
Solvent used 
for 
reconstitution 
Fomitopsis officinalis (115) 
 
5.690 
E1 80% Ethanol 0.329 5.50 Coarse powder Water  
E2 50% Methanol 0.226 3.97 Fluffy (Cotton like) Water 
E3 Water  0.205 3.60 Fluffy (Cotton like)  Water 
E4 5% NaOH 4.219 74.15 Chunky powder  Water 
Sarcodon scabripes (124) 
 
8.820 
E1 80% Ethanol 0.120 1.36 Coarse powder Methanol 
E2 50% Methanol 0.514 5.82 Coarse powder Methanol 
E3 Water  0.866 9.82 Coarse powder  Water 
E4 5% NaOH 3.474 39.39 Coarse powder Water 
Tricholoma vaccinum (125) 
 
14.420 
E1 80% Ethanol 0.246 1.71 Coarse powder Water 
E2 50% Methanol 0.448 3.11 Coarse powder Water 
E3 Water  0.927 6.43 Coarse powder  Water 
E4 5% NaOH 2.813 19.51 Coarse powder Water 
Cerrena unicolor (127) 
 
10.552 
E1 80% Ethanol 0.083 0.79 Coarse powder Water 
E2 50% Methanol 0.127 1.21 Fluffy (Cotton like) Water 
E3 Water  0.194 1.84 Fluffy (Cotton like)  Water 
E4 5% NaoH 4.137 39.21 Chunky powder  Water 
Albatrellus flettii (128) 
 
9.820 
E1 80% Ethanol 0.236 2.40 Sticky paste Methanol 
E2 50% Methanol 0.392 3.99 Sticky paste Methanol 
E3 Water  0.489 4.98 Coarse powder  Water 
E4 5% NaOH 1.758 17.90 Coarse powder Water 
Trametes versicolor (143) 
 
7.506 
E1 80% Ethanol 0.061 0.82 Coarse Powder Water 
E2 50% Methanol 0.117 1.56 Fluffy (Cotton like) Water 
E3 Water  0.158 2.11 Fluffy (Cotton like) Water 
E4 5% NaOH 5.913 78.77 Chunky powder Water 
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2.4.3 Dose- and time-dependent anti-proliferative assessment of mushroom 
extracts using HeLa cells 
 
2.4.3.1 Fomitopsis officinalis 
The results obtained from dose-dependent MTT assay performed using four extracts (E1-
E4) from F. officinalis are shown in Figure 2.8. The dose-dependent MTT results show that 
extract E1 and E2 reduced the cell viability by more than 90% at as low as 0.375 mg/mL. On the 
other hand, E3 only showed 40% reduction when treated at 0.75 and 1 mg/mL. No anti-
proliferative activity was observed using E4 extract. Hence, HeLa cells were subjected to time-
dependent MTT assay using selected doses of E1 and E2 extract.  
 
Figure 2. 8: Dose-dependent assessment of anti-proliferative activity of the four crude 
extracts isolated from F. officinalis. Several concentrations of crude extracts E1 (80% ethanol), 
E2 (50% methanol), E3 (water) and E4 (5% NaOH) were added to HeLa for 48 hours followed 
by assessment of cell viability using MTT assay. The result shown is a representative from two 
biological replicates (n=2). Error bars are standard deviation. 
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Figure 2. 9: Time-dependent assessment of anti-proliferative activity of E1 and E2 extracts 
from F. officinalis. (A) The time-dependent MTT assay of E1 extract at 0.1  and 0.25 mg/mL. 
(B) Time-dependent assay of E2 at 0.25, 0.375  and 0.5 mg/mL. Error bars are standard 
deviation. 
Results in Fig 2.9 (left panel) show that cells treated with extract E1 at 0.25 mg/mL 
resulted in cell viability of less than 20% by Day 3 and this persisted until at least Day 7. At 0.1 
mg/mL, E1 had little effect on cell viability. At 0.5 mg/mL, E2 extract significantly reduced cell 
viability to 10% by Day 1 and the effect persisted up to Day 7 (Figure 2.9, right panel). The cell 
viability after treatment with 0.25 mg/mL of E2 was less than 30 percent after 7 days of 
incubation. The time-dependent anti-proliferative effect exhibited by extract E2 at 0.25 mg/mL 
was moderate resulting in cell viability of more than 50% after 7 days of treatment.  
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2.4.3.2 Trametes versicolor 
Figure 2.10 shows the result from the dose-dependent MTT assay of T. versicolor. The 
results show that Extract E1 (at 1 mg/mL) suppressed the cell viability down to only 50%. 
Extract E2 showed weak growth-inhibitory activity by suppressing cell viability only by 30%. 
Since the very weak anti-proliferative activity exhibited by other extracts (E3 and E4) was 
considered negligible (less than 20%), time-dependent MTT assay was not performed on any of 
the extracts from T. versicolor. 
 
 
Figure 2. 10: Dose-dependent assessment of anti-proliferative activity of the four crude 
extracts isolated from T. versicolor. The result shown is a representative from two different 
biological replicates (n=2). Error bars are standard deviation. 
 
2.4.3.3 Cerrena unicolor 
Dose-dependent MTT assay on extracts from C. unicolor revealed that only extract E4 
had moderate anti-proliferative activity, reducing cell viability down to 54%. In contrast, the 
anti-proliferative activity shown by Extract E2 and E3 was close to negligible even at high doses 
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i.e., 1 mg/mL. The extract E1 showed very weak anti-proliferative activity by reducing cell 
viability by only 18% as compared to the control. 
 
Figure 2. 11: Dose-dependent assessment of anti-proliferative activity of the four crude 
extracts isolated from C. unicolor. The result shown is a representative of two biological 
replicates (n=2). Error bars are standard deviation. 
 
2.4.3.4 Tricholoma vaccinum 
The dose-dependent MTT assay on T. vaccinum showed that only extract E4 exhibited 
moderate anti-proliferative activity by reducing cell viability down to 54%. The effects by 
extracts E1, E2 and E3 were very similar. All three extracts exhibited weak anti-proliferative 
activity by reducing cell viability only by 30% as compared to the control. 
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Figure 2. 12: Dose-dependent assessment of anti-proliferative activity of the four crude 
extracts isolated from T. vaccinum. The result shown is a representative from two biological 
replicates (n=2). Error bars are standard deviation. 
 
2.4.3.5 Sarcodon scabripes 
Results obtained from the dose-dependent MTT assay using four extracts (E1-E4) of S. 
scabripes are shown in Figure 2.13. The dose-dependent MTT results show that extract E1, E2 
and E3 reduced the cell viability by more than 75% at 1.0 mg/mL. Extracts E1 and E2 were the 
most potent because the cell viability was inhibited to less than 20% when cells were treated at 
0.375 mg/mL. 
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Figure 2. 13: Dose-dependent assessment of anti-proliferative activity of the four crude 
extracts isolated from S. scabripes. The result shown is a representative from two biological 
replicates (n=2). Error bars are standard deviation. 
The anti-proliferative activity exhibited by extract E4 was moderate, reducing HeLa cell 
viability only by 50% at 1 mg/mL. Given the high potency of E1 and E2 in inhibiting growth, I 
next tested their effect on time-dependent MTT assay. Figure 2.14 (A) shows that, at 0.1 mg/mL, 
extracts E1 significantly reduced cell viability by Day 1 and this activity persisted up to Day 3. 
Figure 2.14 (B) shows that, at 0.375 mg/mL, both extracts E1 and E2 significantly reduced cell 
viability by Day 1 and this persisted up to Day 7. The time-dependent MTT assay results 
revealed that extract E1 was slightly more potent than E2 at 0.1 mg/mL after Day 3. However, 
the anti-proliferative activity was the same for both extracts at 0.375 mg/mL. 
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Figure 2. 14: Time-dependent assessment of anti-proliferative activity of E1 and E2 
extracts isolated from S. scabripes. (A) At 0.1 mg/mL, E1 and E2 were added to HeLa cells for 
the duration shown on the graph. (B) At 0.375 mg/mL, E1 and E2 were added to HeLa cells. 
Results shown are representative from two biological replicates (n=2). Error bars are standard 
deviation. 
 
2.4.3.6 Albatrellus flettii 
The dose-dependent MTT assay results based on four crude extracts from A. flettii show 
that extracts E1 and E2 had strong anti-proliferative activity (Figure 2.15). It is interesting to 
note that there was a slight increase in cell viability as the concentrations of E1 and E2 increases. 
This had also been observed in Dr. Lee’s lab with a small number of crude extracts from other 
mushrooms. The most possible explanation is that compound(s) present in some crude extracts 
reacted with MTT to give rise to colored reagents and hence detected as false negative in the 
MTT assay.  Extracts E3 and E4 showed very weak anti-proliferative activity even at high doses 
1 mg/mL (Figure 2.15). The cell viability after treatment with 1 mg/mL of both E3 and E4 
extracts was more than 70%. Based on the results from dose-dependent MTT assay, HeLa cells 
were subjected to time-dependent MTT assay with selected concentrations of E1 and E2 extracts. 
The time-dependent MTT assay results shown in figure 2.16 revealed no difference between the 
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activity of extract E1 and E2 at two different concentrations: 0.1 and 0.5 mg/mL. These results 
confirmed the presence of highly potent growth-inhibitory compounds in E1 and E2 of A. flettii. 
 
Figure 2. 15: Dose-dependent assessment of anti-proliferative activity of the four crude 
extracts isolated from A. flettii. The result shown is a representative from two biological 
replicates (n=2). Error bars are standard deviation. 
   
Figure 2. 16: Time-dependent assessment of anti-proliferative activity of E1 and E2 
extracts isolated from A. flettii. (E1 and E2 extracts at 0.1 mg/mL (A) or 0.5 mg/mL (B) were 
added to HeLa cells for the duration shown on the graph. Results shown are representative from 
two biological replicates (n=2). Error bars are standard deviation. 
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2.4.4 Stimulation of TNF-alpha production in RAW 264.7 cells after treatment with 
mushroom extracts 
All twenty-four extracts from six fungal specimens were assessed for immuno-
stimulatory potential by measuring TNF-α production in RAW 264.7 cells. The standard dose of 
each extract used to determine immuno-stimulatory potential was 1 mg/mL. LPS was used as the 
positive control and DMEM (without 10% FBS), water and methanol were used as negative 
controls.  
   
Figure 2. 17: Assessing the immuno-stimulatory activity of the four crude extracts isolated 
from T. vaccinum (A) and T. versicolor (B). RAW 264.7 macrophage cells in 96-well plates 
were treated with reagents as described in the Materials and Methods. LPS (500 ng/mL) was 
used as a positive control. Media, water and methanol were used as negative controls. Cell were 
treated with 1 mg/mL of crude extracts from T. vaccinum (A) or T. versicolor (B). Results shown 
are representative of two biological replicates (n=2). Error bars are standard deviation. 
Figure 2.17 (A) shows that only extract E3 from T. vaccinum had moderate immuno-
stimulatory activity by inducing TNF-α levels to 8646.8 pg/mL. The immuno-stimulatory 
potential shown by E1 and E2 extracts was insignificant compared to the controls. Extracts E1, 
E2 and E4 induced TNF-α levels to 1306.0, 1116.1, 2702.1 pg/mL respectively.  TNF-α 
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production by the positive control LPS was 17197 pg/mL. The negative controls Media, water 
and methanol induced TNF-α level to only 503.91, 359.98 and 261.20 pg/mL respectively. 
Extracts E2 and E3 from T. versicolor showed strong immuno-stimulatory activity by 
inducing TNF-α production to 12773 and 14344 pg/mL respectively. On the other hand, extracts 
E1 and E4 showed no immuno-stimulatory activity as the TNF-α production was close to the 
ones treated with media only. Media, water and methanol serving as a negative control induced 
TNF-α to 503.91, 359.98 and 261.20 pg/mL respectively, suggesting that negative controls had 
no effect on RAW 264.7 cells.  
         
Figure 2. 18: Assessing immuno-stimulatory activity of the four crude extracts isolated 
from F. officinalis (A) and C. unicolor (B).  RAW 264.7 cells were treated with 1 mg/mL of 
crude extracts from F. officinalis (A) or C. unicolor (B). Results shown are representative of two 
biological replicates (n=2). Error bars are standard deviation. 
As seen the Figure 2.18(A), no immuno-stimulatory activity was seen with all four 
extracts from F. officinalis at a concentration of 1 mg/mL. The TNF-α production by E1, E2, E3 
and E4 extracts of F. officinalis was 382.58, 279.54, 636.09 and 636.80 pg/mL respectively, 
which was very close to the negative controls. TNF-α production by positive control (LPS) was 
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17840 pg/mL. Media, water and methanol serving as a negative control induced TNF-α to 
251.61, 304.16 and 570.00 respectively. 
As shown in Figure 2.18(B), all four extracts from C. unicolor exhibited immuno-
stimulatory activity. Extract E1 induced TNF-α level to approximately 2584.2 pg/mL making it 
the weakest of all the four extracts. On other hand, extract E2 exhibited a strong immuno-
stimulatory activity by inducing TNF-α levels over 12580 pg/mL.  Strongest immuno-
stimulatory activity was exhibited by extract E3 where the TNF-α level was induced to a level 
slightly higher than the positive control: 18499 pg/mL. Extract E4 had moderate effect on RAW 
264.7 cells with TNF-α level induced to 6615.0 pg/mL. 
          
Figure 2. 19: Assessing the immuno-stimulatory activity of the four crude extracts isolated 
from A. flettii (A) and S. scabripes (B).  RAW 264.7 cells were treated with 1 mg/mL of crude 
extracts from A. flettii (A) or S. scabripes (B). Results shown are representative of two biological 
replicates (n=2). Error bars are standard deviation. 
No immuno-stimulatory activity was shown by any of the four extracts from A. flettii and 
S. scabripes (Figure 2.19). TNF-α production by E1, E2, E3 and E4 extracts of A. flettii was 
178.15, 62.687, 85.967, and 144.97 pg/mL respectively, which were very close to negative 
controls. Extracts E1, E2, E3 and E4 from S. scabripes induced the TNF-α production to 47.565, 
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124.50, 125.02 and 357.99 pg/mL respectively, which were also close to negative controls. The 
dark color of the E1 and E2 extracts of both mushrooms hindered the microscopic observation of 
RAW 264.7 cells morphology.  
2.4.5 Inhibition of TNF-alpha production in LPS-induced RAW 264.7 cells 
Selective extracts that were not active for immuno-stimulation was further assessed for 
their ability to inhibit LPS-induced TNF-α production in RAW 264.7 cells. This is an in-vitro 
measure of anti-inflammation (Smith et al., 2017). The standard dose of each extract used to 
determine such anti-inflammatory potential was 1 mg/mL. Polymyxin-B (200 units/well) was 
used as the positive control and DMEM (without 10% FBS) and water served as negative 
controls.  
       
Figure 2. 20: Assessing the anti-inflammatory activity of crude extracts isolated from T. 
vaccinum (A) and T. versicolor (B).  RAW 264.7 cells in 96-well plates were treated with test 
reagents in the presence or absence of LPS as described in Materials and Methods. Polymyxin-B 
(200 units/well) was used as a positive control. Media and water were used as negative controls. 
One mg/mL of crude extracts from T. vaccinum (A) and T. versicolor (B) were used. Results 
shown are representative of two biological replicates (n=2). Error bars are standard deviation. 
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Extract E1, E2 and E4 from T.  vaccinum were assessed for their anti-inflammatory 
potential and the results are shown in Figure 2.20A. E1 extract has strong anti-inflammatory 
activity as compared to E2 and E4. The treatment with extract E1 resulted in very low level of 
TNF-α 1562.2 pg/mL. This is evident of anti-inflammatory compound(s) present in E1 extract. 
Extract E2 also exhibited strong anti-inflammatory activity by inhibiting the TNF-α production 
down to 2669.5 pg/mL. Extract E4 showed weak but significant anti-inflammatory activity by 
inhibiting TNF-α level to 11337 pg/mL. TNF-α levels, after 6 hours of treatment with Media and 
water, were 20485 and 20367 pg/mL respectively. Polymyxin-B (200 units/well), after six hours 
of treatment, inhibited the production of TNF-α levels down to 873 pg/mL. 
Only two extracts from T. versicolor were assessed for anti-inflammatory activity. 
Extract E1 exhibited the potent anti-inflammatory activity by inhibiting the TNF-α level 
production down to 236.74 pg/mL which is even lower than positive control (PMB) at 873 
pg/mL. This indicates the presence of potent anti-inflammatory compound(s) in this extract. 
Extract E4 exhibited very weak anti-inflammatory activity, which was close to negligible. TNF-α 
production after 6 hours treatment with 1 mg/mL concentration of E4 was 17122 pg/mL. 
All four extracts of F. officinalis (E1, E2, E3 and E4) were assessed for their ability to 
inhibit the TNF-α production in RAW 264.7 cells (Figure 2.21 A). Extracts E1 and E2 showed 
the strongest anti-inflammatory activity by reducing the TNF-α production down to 89.446 and 
183.62 pg/mL respectively, which were even lower than positive control Polymyxin-B i.e. 
873.00 pg/mL. No significant anti-inflammatory activity was seen in Extract E3 and E4. 
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Figure 2. 21: Assessing the anti-inflammatory activity of crude extracts isolated from F. 
officinalis (A) and C. unicolor (B).  Cells were treated with test reagents in the presence or 
absence of LPS. Polymyxin-B (200 units/well) was used as a positive control. Media, water and 
methanol were used as negative controls. One mg/mL of crude extracts from F. officinalis (A) 
and C. unicolor (B) were used. Results shown are representative of two biological replicates 
(n=2). Error bars are standard deviation. 
 
The only extract from C. unicolor tested for its anti-inflammatory potential was E1. TNF-
α levels after 6 hours of treatment were close to 9407.3 pg/mL, indicating a weak but significant 
anti-inflammatory activity. This could either be due to the presence of anti-inflammatory 
compound in very low quantity or very weak in nature. TNF-α levels after 6 hours of treatment 
with Media and water were 20485 and 20367 pg/mL respectively.  
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Figure 2. 22: Assessing the anti-inflammatory activity of crude extracts isolated from A. 
flettii (A) and S. scabripes (B) RAW 264.7 cells were treated with test reagents in the presence 
or absence of LPS. Polymyxin-B (200 units/well) was used as a positive control. Media, water 
and methanol were used as negative controls. One mg/mL of crude extracts from A. flettii (A) 
and S. scabripes (B) were used. Results shown are representative of two biological replicates 
(n=2). Error bars are standard deviation. 
 
Furthermore, very interesting anti-inflammatory results were observed upon treatment 
with A. flettii and S. scabripes. A point to note is that the dark colored E1 and E2 extracts from 
both mushrooms made it hard to observe the post-treatment morphology of RAW 264.7 cells. All 
four extracts from both mushrooms showed strong anti-inflammatory activity, suggesting the 
presence of potent small and large anti-inflammatory molecules in these extracts. TNF-α levels,  
after 6 hours of treatment with media (EMEM), water and methanol were 20485, 20367 and 
13442 pg/mL respectively. Polymyxin-B (200 units/well) after six hours of treatment inhibited 
the production of TNF-α levels down to 873 pg/mL. 
TNF-α levels, after 6 hours of treatment with E1, E2, E3 and E4 extracts of A. flettii, 
were 77, 72, 281 and 1583 pg/mL respectively. Similar trend was observed after treatment with 
S. scabripes, The TNF-α levels, after 6 hours of treatment with E1, E2, E3 and E4 extracts of S. 
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scabripes, were 126.74, 106.18, 1772.5 and 3187.0 pg/mL respectively. These results suggested 
that both A. flettii and S. scabripes contain strong anti-inflammatory compounds. 
2.5 Discussion  
 In the study described in this chapter, I chemically extracted 4 crude extracts 
representing small molecules (Extracts 1 and 2) and large molecules (Extracts 3 and 4), from 6 
mushroom species. These crude extracts were screened for growth-inhibitory, immuno-
stimulatory and anti-inflammatory activities. I provide below, for each fungus, a critical 
assessment of the current knowledge as it pertains to the 3 biological activities.  
Fomitopsis officinalis, also known as quinine conk due to its extremely bitter taste, 
causes a brown heart rot on conifers (Ginns, 2017). In the current study, none of the extracts 
from F. officinalis showed immuno-stimulatory activity, while only Extract E1 and E2 showed 
potent anti-inflammatory activity. Fomitopsis officinalis polysaccharides (FOPS), at doses of 20, 
40, and 80 mg/kg, have the ability to potentiate the humoral immune response (Wuliya & Li, 
2003). Likewise, Hu et al. (2013) observed the effects of F. officinalis polysaccharides (FOPS), a 
hot water extract of F. officinalis, on S180 tumor bearing mice model and found remarkable 
growth-inhibitory and immuno-stimulatory effects. These in vivo findings do not seem to 
correlate with our in vitro study. It is possible that immune cells other than macrophage were 
responsive to F. officinalis as demonstrated in the two animal studies. Another possible reason 
could be due to the low content of FOPS present in E3 and E4 extracts in BC’s F. officinalis 
sample # 115. 
In this study, the E1 and E2 extracts of F. officinalis showed potent growth-inhibitory and 
anti-inflammatory activity, which is supported by previously reported studies. The investigation 
of chemical constituents of F. officinalis led to isolation of eight small molecules including (1) 
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4,6,8(14),22(23)-tetraen-3-one-ergos-tane, (2) ergosta-7,22,dien-3β-ol, (3) 3-
ketodehydrosulfurenic acid, (4) dehydroeburiconic acid, (5) 4,6,8(14),22(23)-tetraen-3-one-
ergostane, (6) fomefficinic acid A, (7) fomefficinic acid B and (8) fomefficinic acid C. Due to 
their higher abundance, compounds 3, 4, 6 and 8 were further screened for their growth-
inhibitory potential against human cancer cells. Compound 3, 6 and 8 were found to be active 
against MCF-7 cell line, while only two compounds (6 and 8) were able to inhibit proliferation in 
SMMC-7721 cells (Chi & Bao 2014).  
Han et al. (2016) isolated eight lanostane triterpenes named officimalonic acids A to H 
from the methanolic extracts of F. officinalis. Screening of these compounds for their ability to 
inhibit nitric oxide production in LPS-induced RAW 264.7 cells revealed that only officimalonic 
acids D, E, G, H, and fomitopsin A were potent for their anti-inflammatory activity. Lanostane 
triterpenes from F. officinalis have also been evaluated for their trypanocidal activity against 
Trypanosoma congolense. Five out of eight purified lanostane terpenoids exhibited trypanocidal 
activity with IC50 less than 27.1µM (Naranmandakh et al., 2018). 
In the current study, only extract E4 (5% NaOH) of C. unicolor (also known as the mossy 
maze polypore) exhibited the moderate growth-inhibitory activity in HeLa cells. Extract E2, E3 
and E4 showed immuno-stimulatory activity in RAW 264.7 macrophages. All these findings are 
in good agreement with the existing literature. A copper-containing enzyme laccase (molecular 
weight 57 kDa) responsible to degrade lignin has been isolated from C. unicolor (Kim et al., 
2002). Crude endopolysaccharide, extracellular laccase and a subfraction of low molecular-
weight secondary metabolites, isolated from C. unicolor, have shown antioxidant and 
antibacterial properties (Jaszek et al., 2013). These three compounds have cytotoxic activity 
against mouse melanoma B16-F10 cells. The crude endopolysaccharide also has the ability to 
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modulate the immune system (Statkiewicz et al., 2017). Two of these compounds (extracellular 
laccase 250 μg/ml and low molecular-weight secondary metabolites 10 μg/ml) have been studied 
further for their growth-inhibitory potential in cervical carcinoma. Laccase have also been found 
to have antiviral activity against different strains of viruses, specific to life cycle stages 
(Mizerska-Dudka et al., 2015). Chemical modifications to introduce both hydrophobic and 
hydrophilic characteristics in laccase resulted in more pH and thermostability as well as activity 
(Kucharzyk et al., 2012).  
In this study, E2 and E3 extracts of T. versicolor resulted in strong stimulation of TNF-α 
in RAW 264.7 macrophages, thus supporting the previous findings. Trametes versicolor, also 
known as Coriolus versicolor because of its morphological characteristics, is also referred to as 
Turkey tail. T. versicolor is a well-known mushroom for its two proteoglycans Krestin (PSK) 
and PSP (Kidd, 2002). Krestin (PSK) is a complex of proteoglycan molecules with molecular 
weights ranging from 94,000 to 100,000 kDa and is active if administered orally; it has the 
ability to activate T-cells based immune response and the overexpression of cytokines IL-1, IL-2, 
IL-6 and IL-8 TNF-α, and IFN-γ (Enshasy & Hatti-Kaul, 2014 ). Studies based on toxicological 
profile assessment have indicated that Krestin (PSK) has low toxicity, with no indications of 
abnormalities during clinical trials (Standish et al., 2008). Japan is the pioneer to study clinical 
trials based on T. versicolor. Based on the vast clinical research data available, Krestin (PSK) has 
been successfully used as an adjuvant for chemotherapy for cancer treatments, particularly in 
gastrointestinal types of cancer (Kobayashi et al., 1995). Studies based on the in vitro data, 
clinical and animal models have endorsed the idea that these two proteoglycans can be used as 
adjuvants in cancer therapy or may serve as a comprehensive cancer treatment (Fisher & Yang, 
2002).  
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In our study, extracts E1 and E2 of A. flettii showed strong growth-inhibitory and anti-
inflammatory activities. There has been no report on the bioactive compounds from A. flettii 
responsible for these activities. A. flettii is found in British Columbia, mainly in Haida Gwaii and 
Hazelton/Smithers area. The mushroom has a characteristic blue color which is mainly due to the 
presence of albatrellin and its 16‐hydroxy and 16‐oxo derivatives. In addition to these pigments, 
A. flettii also contains two colorless cytotoxic compounds, grifolin and neogrifolin (Koch & 
Steglich 2007). Liu et al. (2010) studied the anti-bacterial profile (against B. cereus and E. 
faecalis) of the bioactive compounds isolated from A. flettii and documented the presence of a 
third antibacterial compound (confluentin) along with grifolin and neogrifolin. 
The current study has also revealed the novel growth-inhibitory and anti-inflammatory 
activities of S. scabripes. All four extracts of S. scabripes possess anti-inflammatory activity 
while growth-inhibitory activity was only exhibited by extracts E1 and E2. Although many small 
molecules have been isolated from other Sarcodon species, there has been no study on 
bioactivities from S. scabripes. No study has been reported on anti-inflammatory activity of E1 
and E2 extracts of T. vaccinum which makes it a potential candidate for exploration of novel 
anti-inflammatory compound(s). Due to the limited sample of T. vaccinum and no genetic 
identification of S. scabripes (at that time), it was deemed logical to first proceed with further 
studies on A. flettii, as described in Chapter 3. 
2.6 Conclusion 
The primary screening highlighted very interesting results in regard to the therapeutic 
potentials of extracts from the six Canadian wild mushrooms studied here. These mushrooms 
could be developed into a future drug with potential therapeutic benefits. The main challenge is 
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the purification and structural elucidation of the bioactive compounds from a selected 
mushroom. Chapter 3 of this thesis will describe in detail the purification, characterization and 
structural elucidation of the anti-proliferative small molecules from E1 extract of A. flettii. The 
rationale for selecting  A. flettii for further studies is because no prior studies have been reported 
on its anti-cancer activity.  The summary of the primary screening of the six Canadian wild 
mushrooms used in the current study (growth-inhibitory, immuno-stimulatory and anti-
inflammatory potential) are presented in Table 2.8 and 2.9.   
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Table 2.8: Summary of bio-activity of Canadian wild mushrooms 
Mushroom 
specimen  
Extract 
Immuno-
stimulatory activity1 
(% stimulation of 
TNF-α w.r.t 
control) at 1 mg/mL  
Anti-inflammatory 
activity2 
(% inhibition of 
TNF-α w.r.t 
control) at 1 
mg/mL 
Anti-proliferative 
activity 
(% viability at 1 
mg/mL) 
Fomitopsis 
officinalis (115) 
E1 (80% ethanol) 2.10 99.5 6.74 
E2 (50% methanol)  1.56 99.10 9.31 
E3 (water) 3.50 6.0 59.80 
E4 (5% NaoH) 3.50 11.0 106.5 
Sarcodon 
scabripes (124) 
E1 (80% ethanol) 0.16 99.38 21.33 
E2 (50% methanol)  0.42 99.48 16.85 
E3 (water) 0.43 91.35 26.65 
E4 (5% NaoH) 1.22 84.44 53.61 
Tricholoma 
vaccinum (125) 
E1 (80% ethanol) 50.28 92 48.85 
E2 (50% methanol)  7.50 87 71.11 
E3 (water) 6.49 - 83.13 
E4 (5% NaoH) 15.71 44.0 80.19 
Cerrena 
unicolor (127)  
E1 (80% ethanol) 14.48 54.0 82.22 
E2 (50% methanol)  70.50 - 94.02 
E3 (water) 103 - 92.63 
E4 (5% NaoH) 37.0 - 56.54 
Albatrellus 
flettii (128) 
E1 (80% ethanol) 0.60 99.60 30.96 
E2 (50% methanol)  0.20 99.65 36.05 
E3 (water) 0.29 98.0 70.80 
E4 (5% NaoH) 0.49 92.27 69.60 
Trametes 
versicolor (143) 
E1 (80% ethanol) 2.90 98.8 70.19 
E2 (50% methanol)  74.27 - 69.33 
E3 (water) 83.41 - 72.07 
E4 (5% NaoH) 3.10 16.41 54.58 
 
1Percent stimulation of TNF-α relative to LPS. 
2Percent inhibition of LPS induced TNF-α relative to DMEM. 
3Percent viability of HeLa cells as compared to control. 
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Table 2.9: Summary of bioactivity of Canadian wild mushrooms and their known activities. 
Mushroom 
sample  
Immuno-
stimulatory 
activity1  
Anti-
inflammator
y activity2 
Growth- 
inhibitory 
activity3  
Known activity  Reference 
Fomitopsis 
officinalis (115) 
+ (E1, E2, 
E3, E4) 
+++ (E1, E2) 
+ (E3, E4) 
+++ (E1, 
E2) 
++ (E3) 
+ (E4) 
Anti-inflammatory 
and growth-
inhibitory 
(Han et al., 
2016) 
(Chi & Bao, 
2014) 
Sarcodon 
scabripes (124) 
+ (E1, E2, 
E3, E4) 
+++ (E1, E2, 
E3, E4) 
+++ (E1, 
E2) 
++ (E3, E4) 
No activity  - 
Tricholoma 
vaccinum (125) 
++ (E1) 
+ (E2, E3, 
E4) 
+++ (E1, E2) 
++ (E4) 
++ (E1) 
+ (E2, E3, 
E4) 
No-activity - 
Cerrena 
unicolor (127)  
+++ (E3) 
++ (E2) 
+ (E1, E4) 
++ (E1) ++ (E4) 
+ (E1, E2, 
E3) 
Immuno-
stimulatory, 
growth-inhibitory 
Mizerska-
Dudka et al., 
2015 
Albatrellus 
flettii (128) 
+ (E1, E2, 
E3, E4) 
+++ (E1, E2, 
E3, E4) 
+++ (E1, 
E2) 
+ (E3, E4) 
Antibacterial Only. Liu et al., 
2010 
Trametes 
versicolor (143) 
+++ (E3) 
++ (E2) 
+ (E1, E4) 
+++ (E1) 
+ (E4) 
++ (E4) 
+(E1, E2, 
E3) 
Immunomodulatory 
and growth-
inhibitory 
Fisher & 
yang, 2002. 
 
 
(+++); Greater than 80% of TnF-α stimulation1 in RAW 264.7 cells; greater than 80% of TnF-α 
inhibition in RAW 264.7 cells; greater than 80% growth-inhibition in HeLa cells3 or complete 
inhibition2,3 
(++); 40-80% stimulation1 of TnF-α stimulation1 in RAW 264.7 cells; 40-80% of TnF-α 
inhibition2; 40-80% growth-inhibition in HeLa cells3 
(+); 10-40% stimulation1 of TnF-α stimulation1 in RAW 264.7 cells or no stimulation; 10-40% of 
TnF-α inhibition2 or no inhibition; 10-40% growth-inhibition in HeLa cells3 or no inhibition. 
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Chapter 3: Purification, Identification and Characterization of Growth-
inhibitory Compounds from Albatrellus flettii 
This chapter focuses on the purification, characterization and structural elucidation of 
growth-inhibitory compounds from the E1 (80% ethanol) extract of A. flettii. 
3.1 Introduction 
3.1.1 Purification and characterization strategies 
Mushrooms are popular folk medicines, owing to their nutritional and medicinal values. 
Recently, mushrooms have attracted considerable attention because of their demonstrated 
efficient antitumor and immunomodulatory activities. Modern research also endorses the idea of 
therapeutic effects of traditionally used species. Mushrooms are rich in a wide range of 
therapeutic compounds, which could be small or large molecules. The isolation and purification 
strategies for bio-active compounds is dependent on the nature of the compound; the liquid -
liquid extraction, based on the polarity of compounds, is a first adequate step for compounds 
isolation. Using two immiscible liquids, liquid-liquid extraction can be carried out efficiently. 
Once the chemical nature of the compounds of interest is determined, it becomes easy to decide 
the subsequent steps of purification. Extensive studies along with advances in purification 
approaches have made analytical chemistry much easier in recent years. Purification techniques 
like size-exclusion chromatography (e.g., Sephadex-LH20), ion-exchange chromatography (e.g., 
DEAE), and high-pressure liquid chromatography (HPLC) are usually employed.  The structure 
of compounds is then characterized using analytical tools such as LC-MS (Liquid 
chromatography-Mass Spectrometry), GC-MS (Gas chromatography-Mass Spectrometry), 
Fourier transform infrared spectroscopy (FTIR) and NMR (Nuclear Magnetic Resonance).  
One of the best initial step approaches to separate the compounds based on the molecular 
masses is Sephadex™ LH-20. The compounds with the higher molecular masses elute early due 
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to less interaction with the resin, while the smaller molecular mass compounds elute later, due to 
higher interaction with the resin. After the size-exclusion chromatography, compounds can be 
further purified using high-resolution HPLC. 
The HPLC method could be either normal phase (NP-HPLC) or reverse phase (RP-
HPLC). The optimal separation of compounds is dependent on the nature of the compounds, the 
choice of stationary phase (column) and mobile phase (solvent system). HPLC method becomes 
very approachable, if the nature of the compounds of interest has been determined by Liquid-
Liquid extraction. If compounds are hydrophobic in nature, the C-18 column could be a good 
choice to proceed. The weakly polar end capped silica column can be used if the compound has 
both polar and non-polar components. HILIC (hydrophilic interaction) columns could be a good 
starting point if compounds are highly polar or have Zwitter ions. The solvent system could 
either be isocratic or gradient; this also depends on sample mixture as well as interaction of the 
compounds with column-packing material. To get a good separation, solvent system can be 
manipulated to obtain good peak shape and optimal separation of peaks as observed on HPLC 
spectra. By doing this, the collection of compounds also become feasible. The method 
development can be initiated on analytical columns.  
To increase the productivity, separation method can be scaled up to semi-preparative or 
preparative column. Combination of mass spectroscopy (MS) with HPLC provides the 
information about the molecular mass of the compounds of interest. Mass spectrophotometer 
works by ionizing the compounds and by sorting them based on their mass to charge (m/z) ratios. 
Quadrupole mass detectors use oscillating electrical fields to detect the ionized compounds. Only 
the ions within a selected scan range of mass to charge (m/z) ratio are detected through the 
quadrupole system.  
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Nuclear magnetic resonance (NMR), also known as magnetic resonance spectroscopy 
(MRS), is a technique that provides the detailed structural information of compounds. 
Combination of 1D and 2D spectrum provides in depth information on linkages and neighboring 
atoms. Only deprotonated solvents can be used for NMR analysis. Combination of one 
dimensional 13C and 1H spectra with two-dimensional spectra (HSQC and COSY) reveals the 
resonance for different functional groups and their positions in the structure. 
3.1.2 Albatrellus flettii 
In western North America, A. flettii (blue knight) is more common than A. confluens. 
Growing on the ground in coniferous forests (Arora 1986), it was first described by Elizabeth 
Eaton Morse as Polyporus flettii (Morse, 1941). Later, Zdeněk and Pouzar re-named it to the 
genus Albatrellus (Pouzar, 1973). Since no study has been reported on the growth-inhibitory 
activity of this mushroom, extract E1 (80% ethanol), which exhibited potent growth-inhibitory 
activity as described in Chapter 2, was selected for purification and characterization studies. 
3.1.3 Compounds already reported in Albatrellus flettii  
The fleshy polypore has a characteristic blue color which is mainly due to presence of a 
pigment named albatrellin and its 16-hydroxy and 16-oxo derivatives. Along with these 
pigments, A. flettii is also known to contain two colorless cytotoxic compounds, grifolin and 
neogrifolin (Koch & Steglich 2007). Liu et al. (2010) studied the anti-bacterial activity (against 
Bacillus cereus and Enterococcus faecalis) of the bio-active compounds isolated from A. flettii 
and claimed the presence of a third antibacterial compound confluentin along with grifolin and 
neogrifolin. To date, there has been no report on growth-inhibitory activity of A. flettii on 
mammalian cells. Grifolin and neogrifolin, in synthetic form or purified from the species A. 
confluens, had been studied in detail for their anti-proliferative biochemical pathways in 
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mammalian cells. In contrast, the mechanism for growth-inhibition by confluentin has not been 
studied 
3.1.3.1 Grifolin  
Grifolin was first screened in 2005 for its anti-cancer properties after more than 50 years 
of its discovery from A. confluens (Ye et al., 2005). The ability of grifolin to inhibit tumor 
growth in cell lines (CNE1, HeLa, MCF7, SW480, K562, Raji and B95‐8) is by induction of 
apoptosis through the pathway involving Bcl-2 family members and cytochrome c (Ye et al., 
2005). Monitoring the health of the mitochondrial membrane is one way to detect apoptosis. In 
general, the loss of mitochondrial membrane potential indicates cell apoptosis (Perry et al., 
2011). Cytochrome c also has an intermediate role in apoptosis, in response to damage to DNA. 
In a study by Yang et al. (2016), the release of cytochrome c from mitochondria to cytosol was 
investigated in two gastric cancer cell lines after treatment with grifolin. 
Grifolin downregulates the expression of mitogen activated protein kinases related genes 
and thus could induce apoptosis in many types of cancer cell lines (Jin et al., 2007). The cell-
cycle regulator, cyclin-dependent kinase 4 inhibitor2D (CDKN2D), was significantly upregulat-
ed, which suggests that grifolin might affect the cell-cycle by upregulating the expression of 
CDKN2D (Yang et al., 2016). Western blot analysis revealed another underlying mechanism 
involved in the arrest of tumor cells at G1 phase, mainly due to inhibition of cyclin D, Cyclin E 
and CDK 4 of the ERK1/2 or the ERK5 pathway (Ye et al., 2007). 
Researchers have found that the inhibition of Akt/mTOR/S6K pathway is associated with 
autophagy in human melanoma cells (Zhao et al., 2016). Grifolin could also induce autophagic 
cell death in ovarian cancer cell lines (A2780 and SKOV3), by inhibiting the activity of 
Akt/mTOR/S6K pathway (Che et al., 2016). Grifolin treatment resulted in reduced 
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phosphorylation of Akt, FOXO transcription factor and GSK3, which contributed to suppressed 
proliferation of osteosarcoma (Jin et al., 2007). Grifolin also induced apoptosis in osteosarcoma 
cells by down-regulating the expression of the IAP (inhibitor of apoptosis protein) and induction 
of caspases (Jin et al., 2007).  
Grifolin may serve as a promising anticancer compound because of its ability to directly 
target ERK1/2-Elk1-DNMT1 signaling pathway to suppress cancer cell metastasis, migration 
and invasion (Luo et al., 2015). Luo et al. (2016) studied the suppression of underlying 
mechanism responsible for adhesion and migration of highly metastatic 5-8F and MGC803 cells, 
using wound healing assay. It has been concluded that grifolin has the ability to cause reduction 
of reactive oxidative species by 40% and it also interferes with the interplay between PGC1α and 
Fra-1/LSF-MMP2/CD44 axes. Other important mechanism of grifolin to induce apoptotic effect 
on nasopharyngeal carcinoma cell CNE1 involved upregulation of DAPK1 via the p53–DAPK1 
pathway (Luo et al., 2011).  
3.1.3.2 Neogrifolin 
Neogrifolin is an isomer of grifolin, with the same molecular formula and mass, but with 
a slightly different structural conformation of the aromatic ring. Like grifolin, neogrifolin has 
also proven ability to inhibit tyrosinase (Dembitsky & Kilimnik, 2016). Neogrifolin, isolated 
from A. confluens, induced apoptosis in the aggressive cancerous neoplasm (osteosarcoma) 
(Chen et al., 2015). The underlying mechanism involved was found to be based on the induction 
of cytochrome c release, activation of caspases and cleavage of PARP (Chen et al., 2015). 
Furthermore, neogrifolin affected the AKT signaling pathway through the same mechanism as 
grifolin. Phosphorylated AKT level, FOXO transcription factor, and glycogen synthase kinase 3 
(GSK3) levels were found to be downregulated. Neogrifolin has the ability to induce apoptosis in 
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osteosarcoma cells by down-regulating the expression of the IAP (inhibitor of apoptosis protein) 
and induction of caspases (Chen et al., 2015). 
3.2 Materials and methods 
3.2.1 Large scale chemical extraction & confirmation of growth-inhibitory activity 
            Two fresh collections of A. flettii sporocarps were gathered on September 3, 2016 (70 
grams of sample 128) and September 20, 2017 (35 grams of sample 151) from the Twin Falls 
trail, in Smithers B.C. The samples were morphologically and genetically identified (see Chapter 
2). Subsequently, mushroom sample (128) was finely powdered using a blender, and large-scale 
extraction of extract E1 (80% ethanol) and E2 (50% methanol) was performed using the Dionex 
speed extractor ASE 350. Only the first two extractions (i.e. 80% ethanol and 50% methanol) 
were performed and the residue after two extractions was saved. The extracts were lyophilized 
using a Labconco freeze dryer and stored at -80°C. 
The E1 (80% ethanol) extract was then utilized for further biological cell assays and 
purification. E1 (80% ethanol) extract from new batch (151) of A. flettii was also tested on HeLa 
cells for growth-inhibitory activity.  
3.2.2 Liquid-liquid extraction (phase separation) 
Liquid–liquid extraction or phase separation is a method to separate compounds based on 
their chemical nature using two different immiscible liquids. To separate the compounds based 
on their solubility, water (polar) and chloroform (non-polar) were used.  To carry out liquid-
liquid extraction, a glass test tube was used. 
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Figure 3. 1 Illustration of the Liquid-Liquid extraction technique. (Graphics credit : 
Hasnain Yaqoob) 
First, a solution (4mL) of 20 mg/mL of E1 extract (80% ethanol) was prepared using 
chloroform as a primary solvent. Later, water was added in the equal volume (4mL) to make sure 
that separation of compounds between two layers was maximum. After adding the secondary 
solvent (water), the solution was vortexed for 2-3 minutes.  Solution was chocolate brown in 
color after vortexed. The last step involved separation of the immiscible layers by centrifugation. 
The process of centrifugation was performed using Allegra X-15R benchtop centrifuge 
(Beckman coulter) at the speed of 100 RCF for 5 min.  
After centrifugation, three layers were observed in the test tube (Figure 3.1). All three 
layers were collected into different clean test tubes using Pasteur pipettes. The lower layer 
(chloroform layer) was dried using a hot-plate at 65 °C. The top and middle layers were 
lyophilized using Labconco Freeze dryer (0.008 bar vacuum pressure and -80 ºC). Yield was 
calculated, based on the portions of E1 extract (80% ethanol) recovered from each layer. All 
three layers were further screened for their ability to exhibit growth-inhibitory activity using 
MTT assay. 
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3.2.3 Sephadex™ LH-20 (molecular sieve chromatography) 
Sephadex™ LH-20 column separates the compounds based on their molecular masses. 
Any larger size bioactive compound should be eluted in earlier fractions. In contrast, smaller 
molecules should be eluted in later fractions. Based on this separation technique, small and large 
molecules should be easily separated. 
 
Figure 3. 2 Photograph of the Sephadex™ LH-20 size exclusion technique using a large 
C26/100 column (GE Healthcare) and the mobile phase (degassed methanol) 
For all molecular sieve (size exclusion) chromatographic runs, the mobile phase used was 
100% methanol. The stationary phase utilized for this type of chromatographic technique was 
Sephadex™ LH-20 (swelled in methanol). Initial trial of compounds separation was done using a 
small 22 mL column (gravity drip) of Sephadex™ LH-20. This size-based elution technique was 
further scaled up to 100 mL column using a C16/70 glass column (GE Healthcare). The mobile 
phase (degassed methanol) flow rate was set at 1 mL/min using an automated pump (Pharmacia). 
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Fractions were collected using an automated fraction collector and the final volume of each 
fraction was 3 mL. This chromatographic technique was further scaled up to 400 mL (Figure 
3.2), using a larger C26/100 column (GE Healthcare) and the mobile phase (degassed methanol) 
flow rate was set at 2 mL/min. The final volume of each fraction collected from C26/100 column 
was 12 mL. 
3.2.3.1 Sephadex™ LH-20 resin swelling and column Packing 
The Sephadex™ LH-20 resin was first swelled in methanol which was used as mobile 
phase. The mobile phase (methanol) was chosen based on the nature of active compounds 
(chloroform layer). Methanol was degassed for 4-5 hours to make sure that the mobile phase was 
free from any dissolved gases. The swelling ratio of Sephadex™ LH-20 resin to methanol was 
1:4; for each gram of dry Sephadex™ LH-20 resin, 4 mL degassed methanol was required. The 
Sephadex™ LH-20 resin was swelled overnight in excess volume of degassed methanol. After 
the resin was completely swelled, the excessive volume of methanol was discarded from the 
slurry. 
To pack a small gravity drip 22 mL sized column, a 25 mL serological pipette (Sarstedt, 
Germany) was utilized. A cotton plug was used to support the resin at the opening of the pipette. 
To ensure that cotton plug has allowed the right flow of mobile phase (methanol), the column 
was first packed with only 2 mL of the resin. Next, full column (22 mL) was packed slowly 
under the influence of gravity (no external pressure or flow rate was applied), carefully to avoid 
air entrapment. To pack, 100 mL (C16/70) and 400 mL (C26/100) (GE Healthcare) glass 
columns were utilized. The top and lower adapters were used to support the resin in the glass 
column.  The column was packed and washed at a flow rate of 2 mL/min. The column was 
equilibrated with degassed methanol for at least two column volumes between every run. 
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3.2.3.2 Sample loading and fractions collection 
Sample was prepared using the dried material from the lower layer (chloroform layer) of 
liquid-liquid extraction. Methanol (100%) was used to reconstitute the sample because of its 
complete solubility. The final concentration of loading sample was 80 mg/mL. The sample was 
filtered using a 0.2 μm filter (Sarstedt, Germany) before loading onto the column. Because of 
100% solubility of sample in methanol, percent loss due to filtration was negligible. For a 22 mL 
column, the sample was loaded onto the column with the help of a micropipette (Thermo Fisher 
Scientific, USA). Final volume of the sample (organic layer) loaded was 2% (440 µL) of the 
packed column volume. Fraction collection was based solely on gravity. The final volume of 
each collected fraction was 1 mL.  The sample (2% of column volume) was introduced into the 
large (100 mL and 400 mL) (GE Healthcare) columns with the help of a syringe and three-way 
switch. The mobile phase flow rate for C16/70 (100 mL) and C26/100 columns was at 1 mL/min 
and 2 mL/min respectively. The volume of the collected fractions was 3 mL and 12 mL 
respectively. Fractions were collected using an automated fraction collector. After collection, the 
fractions were stored in a cold room (4°C) before assessment of their growth-inhibitory activity. 
3.2.3.3 Sephadex™ LH-20 Column clean-up, unpacking and storage 
After each run or between two runs, columns were washed with degassed mobile phase 
(100% methanol) at 1.5 times of the actual flow rate, and with mobile phase volume twice the 
column bed volume. This was to ensure the long shelf life and reusability of resin. After the 
column was washed, the resin was removed from the column in a way that there is minimal 
contact with air. The recovered resin was then stored at 4°C in degassed 100% methanol to 
prevent any microbial contamination of the resin.  
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3.2.4 Nanodrop analysis  
A nanodrop spectrophotometer (Thermo Fisher Scientific, SA) was utilized to determine 
the λmax of bioactive fractions 20 and 21 from Sephadex LH20 (22 mL column). After calibration 
with water, the spectrophotometer was blanked with HPLC grade methanol. Sample peddle was 
rinsed with the autoclaved milliQ water before analyzing the sample. A sample of 2 µL was used 
to determine λmax of fractions 20 and 21. The λmax for both fractions (20 and 21) was read at 279 
nm, which was later used in HPLC analysis of the active fractions. 
3.2.5 High performance liquid chromatography (HPLC-UV) analysis 
To efficiently and accurately separate bioactive compounds collected from Sephadex-
LH20 fractions, high performance liquid chromatography (HPLC) technique was utilized. The 
separation of each components of the mixture depends on three factors:(1) chemical nature of 
compounds, (2) stationary phase (column) and (3) mobile phase composition. Based on the 
results from liquid-liquid extraction experiments, bioactive compounds were found to be 
hydrophobic because of their presence in chloroform layer. Therefore, it was decided that the 
best option was a Phenomenex Aqua® 5 µm C18 125 Å (250 x 4.6 mm) column, for better 
resolution of hydrophobic small compounds and biomolecules.  
The wavelength (nm) used to visualize UV signal of bioactive compounds was 279 nm 
(based on reading from nanodrop spectrophotometer). All HPLC-MS analyses were performed 
using Agilent 1260 Infinity Systems (HPLC) and Agilent 6120 quadrupole mass 
spectrophotometer.  
The reverse phase (RP-HPLC) separation method was first developed using the non-polar 
analytical column Phenomenex Aqua® 5 µm C18 125 Å (250 x 4.6 mm). Mobile phase was 
based on two solvents, water and acetonitrile. To separate small molecules efficiently and 
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accurately, a gradient solvent system was used, starting with 40/60% water to acetonitrile at time 
zero and acetonitrile being increased constantly during run. The mobile phase after 15 min was 
not changed, i.e., isocratic with 10:90% water to acetonitrile. HPLC grade solvents were used for 
the separation of bioactive compounds. The solvents were automatically degassed through the 
degasser part of HPLC before entering the quaternary pump. The quaternary pump controls the 
flow rate as well as the gradient of the solvent system. The flow rate for gradient mobile phase 
was set at 1.0 mL/min.  
Samples were filtered using a 0.2 μm filter (Sarstedt, Germany) before injecting into the 
column using  auto-sampler. The needle of the auto-sampler was programmed to wash every 
time before sample injection to prevent any cross contamination. Before injecting the sample into 
the column, the column was washed with solvent system for at-least 10 column volumes. The 
sample volume loaded onto the column was 5 µL (20 mg/mL). It took 30 min in total to better 
separate and elute all the peaks out of the column. The fraction collection was done based on the 
HPLC-UV. The wavelength value used to operate variable wavelength recorder (Agilent infinity 
Lab 1260) was the same as obtained from nanodrop spectrophotometer, i.e., at 279 nm. The 
fractions were collected using a fraction collector (Agilent infinity Lab 1260). The vials used for 
fraction collection were 1.5 mL size. The fractions were collected based on the retention times of 
the compounds in UV spectra. 
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Figure 3. 3 Illustration of the gradient solvent system (Solvent A: water, solvent B: 
acetonitrile) adopted using the non-polar analytical column Phenomenex Aqua® 5 µm C18 
125 Å (250 x 4.6 mm).  
 
3.2.5.1 Semi-preparative HPLC  
To purify enough quantity of compounds for chemical and biological analyses, HPLC 
purification was scaled up using a semi-preparative column. The hydrophobic semi-preparative 
column used for this purpose was an Agilent Zorbax Eclipse XBD-C18 5 µm (9.4 mm x 250 
mm). The Solvent system used in semi-preparative HPLC was isocratic, consisting of 90% 
acetonitrile and 10% water. HPLC grade acetonitrile (VWR USA) and milliQ water were 
degassed before entering the quaternary pump and semi-preparative column. The isocratic 
mobile phase flow rate was set at 2 mL/min. Due to an increase in column size, the sample 
loading capacity was also increased, so the final volume of sample loaded on semi-preparative 
column was 20 µL. The sample was filtered using a 0.2 μm filter (Sarstedt, Germany) before 
loading it into auto-sampler and column. The compounds were collected by fraction collector 
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based on their retention times on UV signal. The wavelength value used was the same (279 nm) 
for the semi-preparative column as used previously for the analytical column. It took 25 min in 
total to elute all the compounds with best possible separation. Fractions were collected in 8 mL 
collection vials. The percent purity of the collected peaks/compounds was determined by re-
running the sample on the same column under same analytical conditions. 
3.2.5.2 HPLC-MS analysis 
A hydrophobic analytical column (Agilent Zorbax Eclipse XBD-C18, 4.6 mm x150 mm) 
was used to perform MS analysis of the purified compounds. Due to poor ionization of the 
bioactive compounds, the active splitter was removed from the assembly line and all the output 
of column was injected directly into the mass spectrophotometer. By doing this, the mass 
spectrophotometer signal shape was improved, and the abundance of the ions was also increased. 
The analysis condition for HPLC-MS was based on isocratic mobile phase (75% acetonitrile and 
25% water). The flow rate for isocratic mobile phase was set at 0.700 mL/min. The maximum 
limit for column pressure was set at 150 bar, considering the limitation for the guard column 
cartridge.  
3.2.6 Nuclear magnetic resonance (NMR) analysis 
After the successful purification, the compounds were subjected to nuclear magnetic 
resonance (NMR) analysis. The structural elucidation of the compounds was done using a Bruker 
300 MHz NMR spectrophotometer. 1D and 2D NMR spectra were recorded on a Bruker 300 
spectrometer with a 5 mm Fourier easy probe.  
To reduce the chances of the errors, the magnets of the Bruker 300 MHz NMR 
spectrophotometer were shimmed properly before analysis of each sample. Topspin 2.1 software 
was used to shim the magnets and operate the Bruker 300 MHz NMR spectrophotometer for 
sample analysis. Approximately 30 mg of the sample was solubilized using deuterated 
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chloroform CDCl3 (99.96 % chloroform-d and 0.3% TMS) (Sigma Aldrich) and transferred 
directly into 5 mm NMR tube (Kimble, USA). The final volume of the sample in NMR tube was 
approximately 1 mL.  
One-dimensional 13C spectrum was obtained using C13CPD mode of Topspin 2.1 
software. The number of scans performed for P5 (grifolin) was 1024, enough to get adequate 
information for C13CPD spectra. The number of scans performed to obtain HSQC2D spectra was 
also 1024. Heteronuclear Single-Quantum Correlation (HSQC) is a 2D spectrum that provided 
information about the directly-bonded protons to the carbons at different shifts. HSQC2D spectra 
offers the high sensitivity and detailed information of the structure as compared to conventional 
13C spectrum. 1H-NMR Spectrum provided clear information for each proton, even at 64 scans. 
Further, COSY scan was performed on samples to get the information related to neighboring 
protons. COSY is a homonuclear correlation spectroscopy, which provides information about 
spin-spin coupling of the protons. The tip angle used for COSY was 90 degrees. After getting 
good resolution, the 1D spectra were further integrated to calculate the exact number of carbons 
and protons. The 2D spectra provided more detailed information about the relationships between 
carbons and protons. Together, 1D and 2D spectrum integration provided clear information about 
the structure of compounds. Same methodology was followed for sample P6 (neogrifolin) and P8 
(confluentin) to obtain spectra for structural elucidation. The numbers of scans used for 
confluentin (P8) to get 13C spectrum were 4096. 
3.2.7 Fluorescent polarization  
We used a fluorescent polarization method to study the physical interaction between an 
RNA-binding protein called IMP-1 and KRas RNA (Wang C, 2016). The method employs a 
recombinant IMP-1 protein and a fluorescently-labeled KRas RNA. The fluorescent polarization 
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experiments described in this thesis were performed by Mr. Victor Liu. Recombinant full-length 
wild-type IMP-1 protein and truncated IMP-1 protein KH34 (containing only KH3 and KH4 
domains) were used. The following were mixed in a Thermo Scientific micro-Fluor 384-well 
microplate: 8 µL protein, 3 µL Thermo Scientific 45 nt fluorescein labeled K-Ras Probe 
(5’AUGGAGAAACCUGUCUCUUGGAUAUUCUCGACACAGCAGGUCAU-6-FL-3’) and 4 
µL binding buffer (50 mM Tris-Cl pH 7.4, 12.5 mM EDTA pH 8, 25% glycerol, 0.01% Triton-X 
and ddH2O). The final concentration of protein (IMP-1) and probe (KRas) was 300 nM and 10 
nM respectively. To each well, 4 µL of inhibitor was added for a final concentration of 10 µM, 
20 µM, 40 µM, 80 µM or 100 µM. DMSO (5%) was used as a control. The plate was incubated 
at 37ºC for 30 min prior to analysis on the Bio-Tek Synergy 2 plate reader. 
3.2.8 Western blot analysis 
3.2.8.1 Cell plating and lysate collection. 
Around 0.6 million (6 x 105) HT-29 cells/2 mL/well were plated into 6-well culture plate. 
Twenty-four hours after plating, cells were treated with different concentration of purified 
compounds as well as the control (2% DMSO). The cells were incubated further for 48 hours 
with purified compounds. On day 4, the cells were observed microscopically and washed with 1 
mL DPBS (Lonza) twice. Lysates were collected using ice cold lysis buffer (300 µL/well). To 
get lysates completely, scrapers were used to scrape off the cells from the bottom of the wells. 
Cell lysates were mixed in Eppendorf tube with acetone to cause complete precipitation of 
proteins (1:4 ratio). The cell lysates were stored at -80 0C to avoid any degradation of proteins. 
Next day, cell lysates in Eppendorf tube were spun at 16000 rpm at 40C for 10 min. 
Supernatant was removed and the pellet was air dried. Twenty µL of autoclaved MilliQ water 
was used to resuspend the pellet and solubilize the proteins. The protein solution in Eppendorf 
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tube was centrifuged again at same conditions and supernatant containing proteins was collected 
in a separate Eppendorf and saved at -80oC for western blot. 
3.2.8.2 Protein quantification 
The amount of protein in cell lysates were quantified using Pierce BCA protein assay kit 
(Thermo Fisher Scientific). Plate (96-well) was read using Synergy 2 spectrophotometer at 652 
nm wavelength. 
3.2.8.3 Gel preparation and sample introduction  
 Polyacrylamide gel (12%) was prepared for Western blot analysis. The upper layer 
(stacking layer) had a slightly different composition than the lower layer (resolving layer). 
Table 3. 1 Recipe of the upper (stacking) gel mix and lower (resolving) gel mix. 
Recipe Upper Gel mix Lower Gel mix 
30% polyacrylamide 3.33 mL 0.48 mL 
Gel Buffer (upper or lower) 2 mL 0.75 mL 
Water 2.67 mL 1.77 mL 
20% APS 4.8 µL 3 µL 
TEMED 16 µL 7.5 µL 
Approximately 30 µg of proteins in cell lysates were loaded onto sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE), along with 3 µL of the 5x dye containing 5% β-
mercaptoethanol. MilliQ water was used to make the final volume (15 µL). Before loading onto 
the membrane, the proteins were boiled at 95oC for 5 min.  BLUelf pre-stained protein ladder (7 
µL) was used as a reference. Gel was resolved at 120 volts until fully resolved. SDS (1 x) 
running buffer was used to run the gel. 
3.2.8.4 Bands transfer to nitrocellulose  
Transfer buffer (1x) containing 20% methanol was used to transfer the proteins from the 
gel to nitrocellulose membrane. The voltage during the transfer was kept to the lowest possible 
point (100 amp) to make sure the transfer was good as well as proteins are intact. A cold pack 
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was used in the transfer assembly to keep the temperature constant during the transfer of 
proteins. 
3.2.8.5 Blocking, antibodies treatment and developing 
Once transferred, the membrane was blocked overnight with 5% skimmed milk in 1 x 
TBST at 4oC. The membrane was further incubated with primary antibody for KRas (EMD 
Millipore, Germany) (1:500 in 1% skimmed milk in 1 x TBST) for one hour at room 
temperature. The membrane was washed three times with 1 x TBST (10 min each) on a rocker. 
Subsequently, the membrane was incubated with secondary antibody (anti-mouse antibody) for 
KRas (diluted 1: 4000 in 1% skimmed milk in 1 x TBST). The membrane was developed using a 
West pico chemiluminescent solution (Thermo Fisher Scientific) and chemiluminescence on the 
blot was imaged using a Flourchem Imager. GAPDH was used as the housekeeping gene. The 
same technique was applied for GAPDH except the dilution ratio for primary antibody was 
(1:10000). 
3.2.9 Flow Cytometry 
Around 0.6 million (6 x 105) SW480 cells/2 mL/well were plated into 6-well culture 
plate. Twenty-four hours after plating, cells were treated with 50 µM of confluentin as well as 
the negative control (2% DMSO). The cells were incubated further for 48 hours after treatment 
with confluentin. On day 4, the cells were observed microscopically and washed with 1 mL 
DPBS (Lonza) twice. Cells were trypsinized and counted using a haemocytometer. After 
counting, cells were centrifuged in an Eppendorf tube for 5 min at 400 x g. Cells were washed 
twice with cold PBS and then resuspended in 1 x binding buffer at a concentration of 1x 106 cells 
/mL. One hundred µL of cells (1x 105 cells) were filtered into a 5 mL polystyrene round bottom 
culture tube with a strainer cap. For assessing apoptosis, BD PharmingenTM PE annexin V 
Apoptosis Detection Kit-I (Cat # 559763) was used.  BD FACSMelodyTM flow cytometer was 
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used to perform the apoptosis assay. For cell cycle analysis, BD cycletest plus DNA reagent kit 
(ref # 340242) was utilized.  
3.3 Results 
3.3.1 Large scale chemical extraction and confirmation of growth-inhibitory activity 
Large scale chemical extraction to isolate extracts E1 and E2 was performed on both 
collections (samples 128 & 151) of A. flettii. The extract yield from both collections was very 
similar. For sample # 128, the yield for Extract E1 (80% ethanol) was 10.212% and the yield for 
Extract E2 (80% ethanol) was 9.074%. The yield for E1 and E2 extracts from sample # 151 was 
9.77% and 9.362% respectively. After large scale extraction, solubility of the extracts was re-
confirmed. 
Table 3. 2 Yield of two extracts (E1 and E2) from two different samples of A. flettii. 
Sample no. Mass of 
sample (g) 
Mass of 
extract E1 (g) 
Yield (%) Mass of 
Extract E2 (g) 
Yield (%) 
Sample 128  70  7.1489  10.212 6.3522  9.074 
Sample 151 35  3.4213  9.77 3.2767  9.362 
 
As shown in Figure 3.4, both E1 and E2 extracts (from sample 151) exhibited dose-
dependent growth-inhibitory activity against HeLa cells, consistent with earlier results (Chapter 
2). It is important to point out that the increase in cell viability, due to increase in colored 
solution, by E2 at above 0.5 mg/mL, was most likely due to the interaction between compounds 
in E2 and MTT. This is because complete cell killing by E2 was microscopically observed at 
concentrations above 0.5 mg/mL. 
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Figure 3. 4 Dose-dependent assessment of anti-proliferative activity of E1 and E2 extracts 
from A. flettii (#151). 
3.3.2 Phase separation (liquid-liquid extraction) 
Liquid-liquid extraction performed on Extract E1 (7.1489 grams) of A. flettii resulted in 
three distinct layers. The lower layer was chloroform and the top layer was water. The color of 
the lower chloroform layer was dark brown, and it had 44-50% yield (Table 3.3). Compounds 
present in the chloroform were most likely to be non-polar in nature. Interphase (middle-layer) 
was white in color and it contained the lowest yield, i.e., only 22% of the total mass (Table 3.3). 
Polar compounds were recovered from top water layer which was cream in color. The yield from 
the top water layer was 33.50% (Table 3.3). Furthermore, solubility of the compounds in both 
layers was determined in order to perform growth-inhibitory assay. Compounds from top-layer 
(water layer) were soluble in water. Compounds from interphase (middle layer) and lower layer 
(chloroform layer) were soluble in methanol. After determining the solubility, the layers were 
further screened for their growth-inhibitory potential. 
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Table 3. 3 Yield of three layers based on liquid-liquid extraction (Phase separation) of E1 
(80% ethanol) extract of A. flettii. 
 
3.3.3 Growth-inhibitory activity of the liquid-liquid extracted layers 
Dose-dependent MTT assay was performed on lyophilized samples from all three layers 
of the liquid-liquid extraction; HeLa cells plating, and doses used were as described in Chapter 2. 
The final concentration of the methanol was less than 2% in each well.  The range of the doses 
tested on HeLa cells was from 0.1 to 1 mg/mL. 
  
Figure 3. 5 Dose-dependent assessment of anti-proliferative activity of three layers from 
liquid-liquid extraction of E1 (80% ethanol) extract. 
As shown in Figure 3.5, strong growth-inhibitory activity was observed from the lower 
chloroform layer. The cell viability was less than 20% at each dose and results were consistent 
Layer of Liquid-Liquid 
extraction 
Color of 
the layer 
Mass 
(mg) out 
of 20mg 
Mass 
% 
Growth 
inhibitory 
Activity 
Solubility 
Top Layer (Aqueous Phase) Cream 6.70  33.50% No Water 
Interphase (middle layer) White 4.40  22.00% No Methanol 
Lower Layer (Chloroform phase) Dark Brown 8.90  44.50% Yes Methanol 
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with all doses. However, no growth-inhibitory activity was observed from the middle or lower 
layer. Based on the MTT results, it was decided to proceed with purification of bioactive 
compounds from the lower chloroform layer. 
3.3.4 Assessment of bio-activity of post-Sephadex™ LH-20 fractions collected from a 22 mL 
column 
Fractions from a 22 mL Sephadex LH-20 column were collected in 1.5 mL Eppendorf 
tubes and the final volume of each fraction was 1 mL. Fractions 1-11 & 22-30 were colorless 
while fractions 12-21 were pale yellow in color, suggesting presence of most compounds in the 
latter fractions.  
Results from the MTT assay (1500 cells/well), performed using the post-Sephadex™ LH-
20 (22 mL) fractions are shown in Figure 3.6. Fractions (1 mL each) were collected by running 
8.8 mg of the E1 (80% ethanol extract) chloroform layer of A. flettii. 
 
Figure 3. 6 Assessing anti-proliferative activity of fractions collected from 22-ml size 
Sephadex™ LH-20 column. 
Results showed that fractions 20 and 21 reduced the HeLa cell viability to even less than 
20% as compared to the control. Weak growth-inhibitory activity was observed for Fractions 19 
and 22, suggesting the presence of bioactive compounds in these fractions as well, which could 
be either low in quantity or different in nature. The cell viability after treatment with these 
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fractions was close to 50%. MTT assay was based on HeLa cells (1500 cells/well) after 24 hours 
of incubation and cells were treated with 2 µL of the fraction volume + 98 µL of EMEM with 
10% FBS. The final concentration of methanol in well was only 1% which was non-toxic to 
cells. MTT assay was performed on treated cells after 48 hours of incubation. Given that the 
inhibitory activity was observed in later eluting fractions, it is likely that the bioactive 
compounds are small. 
3.3.5 Assessment of growth-inhibitory activity of post-Sephadex™ LH-20 fractions 
from a 100 mL column  
After bioactivity was detected in specific fractions collected from the small Sephadex 
column (22 mL), the technique was scaled up to a 100 mL using a C16/70 (GE Healthcare, 
Quebec) column. MTT assay (1500 cells/well) was performed on fractions (3 mL each) obtained 
by running a total 40 mg of the E1 (80% ethanol extract) chloroform layer of A. flettii. The 
results of the MTT assay of the fractions are shown in Figure 3.7. 
 
 Figure 3. 7 Assessing anti-proliferative activity of fractions collected from a 100-ml size 
Sephadex™ LH-20 column. 
Results showed that fractions 30, 34, 35 and 36 reduced the HeLa cell viability to less 
than 20% as compared to the control. Weak growth-inhibitory activity was exhibited by 
Fractions 29 and 37, suggesting the presence of bioactive compounds in these fractions, but 
possibly in low quantity. Although the cell viability after treatment with fractions 31 and 32 was 
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close to 50%, the microscopic observation of the wells treated with fractions 31 and 32 revealed 
90% killing of HeLa cells. Based on microscopic observation of the cells treated with fractions 
31 and 32, the intrinsic reduction potential of these active compounds at high doses was 
discovered. In summary, results from 100 mL Sephadex LH20 column were consistent with the 
results from 22 mL columns. The active fractions from the 100 mL column were further 
analyzed using analytical HPLC. 
3.3.6 Assessing methanol for growth-inhibitory effect 
To assess the effects of methanol concentration on two different batches of HeLa cell 
cultures, dose-dependent MTT assay was performed (Figure 3.8). New cells were the ones which 
had not been split or propagated, while the cells which had propagated more than 15 times were 
labelled as old cells.  
 
Figure 3. 8 Effects of methanol on the growth of HeLa cells 
Final concentrations of methanol in wells were 0.1%, 0.25%, 0.50%, 1%, 2.5%, 5%, 
7.5%, & 10%. The safe limit of methanol concentration was determined to be 1%. Above 1% of 
methanol, cytotoxicity was observed in both HeLa cell types. The response of both HeLa cells 
cultures was quite similar towards each concentration of methanol. 
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3.3.7 Assessing fractions collected from Sephadex LH-20 for anti-inflammatory 
activity  
Anti-inflammatory assay was performed using the post-Sephadex™ LH-20 (100 mL) 
fractions. Anti-inflammatory assay was based on RAW 264.7 cells (100,000 Cells/well) and after 
16 hours of incubation, cells were treated with LPS (250 ng/mL) and 2 µL of the fraction volume 
+ 98 µL of DMEM without 10% FBS for 6 hours. The final concentration of methanol in well 
was only 1% (within safe limits). 
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Figure 3. 9 Assessing anti-inflammatory activity of fractions collected from a 100-ml size 
Sephadex™ LH-20 column. 
Only odd numbered fractions were assessed for their anti-inflammatory activity. Results 
in Figure 3.9 show that fractions 29 to 37 inhibited the LPS-induced TNF-α production at ≥ 95% 
in RAW 264.7 cells. The compounds present in these fractions were found to be cytotoxic, based 
on microscopic observation of the cells. The cell morphology after treatment with these fractions 
was different than normal macrophages. Given that the ‘anti-inflammatory activity’ could be the 
result of growth-inhibition by the fractions, the anti-inflammatory activity was not pursued 
further. 
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3.3.8 HPLC results 
3.3.8.1 Analytical  
 
Figure 3. 10 Flow chart diagram representing the method of compounds purification from 
E1 (80% ethanol) extract of A. flettii. 
 
The resolution based on analytical HPLC conditions was excellent: each peak was 
distinct and very well separated. It took 30 min for all the compounds to be eluted. The retention 
times for peak 5 (later confirmed to be grifolin), peak 6 (later confirmed to be neogrifolin) and 
peak 8 (later confirmed to be confluentin) were 14.324 min, 16.669 min and 20.077 min 
respectively (Figure 3.11). The retention time of the last peak was 28.720 minutes. The percent 
abundance based on UV spectra for peak 5 (later confirmed as grifolin), peak 6 (later confirmed 
as neogrifolin) and peak 8 (later confirmed as confluentin) were 32.62%, 51.97% and 8.12% 
respectively. The highest abundance was peak 6.  
Fractions 30 to 36 of the Sephadex LH-20 column were analyzed for the presence of the 
bioactive compounds. All six spectra were analyzed further by laying over to make a final 
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spectrum (Fig 3.11). Peaks 5, 6 and 8 were found to be most abundant in all of the spectra.  
Based on the spectra, 10 most abundant peaks were collected and further analyzed for growth-
inhibitory activity. 
 
Figure 3. 11 Illustration of HPLC-UV (Phenomenex aqua C-18 column) chromatogram at 
279 nm. Ten different peaks were collected at different retention times.  
The chromatograms from all six active Sephadex fractions (30-36) were overlayed. This 
was done to compare the pattern of similar peaks that were most abundant based on UV 
spectrum of all six fractions. Peaks 5, 6 and 8 were found to be most abundant in all of the UV 
spectra (Figure 3.12). 
 
Figure 3. 12 Illustration of layover UV spectrum representing Sephadex LH-20 fractions 
30-36. 
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3.3.8.2 Growth-inhibitory assessment of the peaks collected from analytical HPLC column. 
The sample (5 µL each) from Sephadex LH-20 active fraction was run ten times on the 
analytical HPLC column, and the ten distinct peaks were collected. The collected peaks volume 
was dried (no mass determination was done) and reconstituted in methanol (100µL) . To 
determine the growth-inhibitory activity of the different peaks, MTT assay was performed as 
before. The final concentration was 1% v/v (2 µL of peak solution+ 98 µL of EMEM 
supplemented with 10% FBS). The final concentration of methanol was also in the range where 
it had no toxic effects on cells.  
 
Figure 3. 13 Effect of HPLC-based collected peaks of E1 extract from A. flettii on HeLa cell 
viability: Cells were treated with Peak solution for 48 hours; 2% methanol in EMEM was used 
as the negative control. Error bars represent standard deviation for four biological replicates. 
As shown in Figure 3.13, compound(s) present in peak 5 and peak 6 showed growth 
inhibition. Due to insufficient samples, quantification of the compound(s) present in the peaks 
could not be done. So, it was decided to collect all three major peaks using a semi-preparative 
HPLC column (Peaks 5, 6 and 8). 
3.3.8.3 Anti-inflammatory assessment of the peaks collected from HPLC analytical column 
(Phenomenex aqua C-18) 
The peaks collected using analytical column (Phenomenex aqua C-18) were assessed for 
potential anti-inflammatory activity using RAW 264.7 cells as described in Chapter 2. The 
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volume of each peak used was 2 µL.  DMEM with LPS was used as the negative control, while 
the crude extract, at 1 mg/mL, was used as a positive control in LPS-activated RAW 264.7 cells. 
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Figure 3. 14  Assessing HPLC based collected peaks of E1 extract from A. flettii for anti-
inflammatory activity: Cells were treated with Peak solution for 6 hours; 2% methanol in 
EMEM was used as the negative control. Error bars represent standard deviation for four 
biological replicates. 
The cell morphology after treatment with Peaks 5 and 6 was found to be abnormal, 
suggesting cytotoxicity of these compounds toward RAW 264.7 cells. Given that there was no 
quantification of Peak 5 and 6 compound(s), it was proposed that toxicity could be due to high 
doses of the compounds. In contrast, no marked difference in anti-inflammatory activity was 
observed with Peaks 2-4 and 7-10 and the negative control (Figure 3.14).  
86 
 
 
Figure 3. 15 Results of Anti-inflammatory assay of HPLC based collected peaks of E1 
extract of A. flettii. Cells were treated with Peak solution for 6 hours; 2% methanol in EMEM 
was used as the negative control. Error bars represent standard deviation for four biological 
replicates. 
After determining the cytotoxicity of the two peaks in the macrophage cells, dilutions 
were made on the peak solutions. The dilutions were made 1 in 10, 1 in 25 and 1 in 50. The 
bioactive Fraction 19 collected from Sephadex LH-20 was also diluted in the similar manner 
using methanol. Anti-inflammatory assay was performed using each dilution. The purpose of 
making dilution was to see if there was any anti-inflammatory activity without toxicity being 
observed. The microscopic observation indicated toxicity of RAW 264.7 cells at each dilution 
except for 1:50 dilution (Figure 3.15). At this point, it was still inconclusive to decide whether 
compounds are cytotoxic or anti-inflammatory in nature. A proper quantification of compounds 
and a detailed anti-inflammatory analysis based on the quantified dose should be able to address 
this issue. 
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3.3.8.4 Assessing the three compounds purified from HPLC semi-preparative column for 
anti-inflammatory activity 
 
 
Figure 3. 16 Assessing HPLC based collected peaks of E1 extract from A. flettii for anti-
inflammatory activity: Cells were treated with Peak solution for 6 hours. 2% methanol in 
EMEM was used as the negative control. Error bars represent standard deviation. 
The potential anti-inflammatory activity of peak 5 (later confirmed as grifolin), 6 (later 
confirmed as neogrifolin) and 8 (later confirmed as confluentin) was performed as described 
previously. The lowest possible concentrations made were 0.005 mg/mL (15 µM) and 0.0025 
mg/mL (7.5 µM). The compounds were resuspended in methanol. DMEM w/o FBS and 1% 
methanol were used as negative controls while polymyxin-B (PMB) was used as a positive 
control. 
As shown in Figure 3.16, no anti-inflammatory activity was observed at these doses. 
Microscopic observation revealed the fact that these compounds are cytotoxic in nature rather 
than anti-inflammatory. Therefore, it is concluded that the reduced levels of TNF-α after 
treatment with these compounds described previously were due to cell killing and not because of 
anti-inflammatory activity. 
3.3.8.5 Semi-preparative HPLC 
To obtain a larger quantity of compound(s) in Peaks 5, 6 and 8, a semi-preparative HPLC 
column was used. A chromatogram obtained using the semi-preparative column is shown in 
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Figure 3.17.  The peak separation pattern was similar to the pattern obtained using the analytical 
column. Three major peaks holding around 92% of the total mass of the bioactive Sephadex LH-
20 fractions, were observed in the UV signal.  
The retention time for peak 5 was at 10.821 min on UV visible chromatogram and 
percent abundance was like the analytical column. The UV visible retention time for P6 was at 
14.582 min and the percent abundance was the highest, at around 52%.  Like the results of 
analytical HPLC, P8 was among the later eluting peak that was visible at 21.438 min with 
abundance at around 8.12%. It took 29.981 min for the last peaks to elute out of the column.  So, 
the total run time was set at 32 min. 
Many less abundant hydrophobic small molecule peaks were also observed in the UV 
spectra (Figure 3.17). The collection and further processing of these hydrophobic compounds 
was practically impossible due to limited quantity of sample and lower yields. 
 
Figure 3. 17 UV spectrum representing the relative abundance and retention time of the 
three major peaks using λmax 279 nm (using semi-preparative column and Sephadex LH-20 
fraction sample). 
It took more than 500 runs in total to purify the required amount of peak 5, peak 6 and 
peak 8; enough to perform biochemical studies. 
The purity of the collected compounds was further confirmed by running the collected 
“pure peaks” again under the same HPLC conditions. The retention time for all three purified 
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compounds was the same as the peaks observed using semi-crude sample. The percent purity for 
all three compounds was 100% (Figure 3.18-3.20). The structures of purified compounds were 
determined by NMR Spectroscopy. 
 
Figure 3. 18 UV signal confirming the 100% purity of the compound in peak 5 (later 
confirmed as grifolin). 
 
 
Figure 3. 19 UV signal confirming the 100% purity of the compound in peak 6 (later 
confirmed as neogrifolin). 
 
 
 Figure 3. 20 UV signal confirming the 100% purity of the compound in peak 8 (later 
confirmed as confluentin). 
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3.3.8.6 Yield of purified compounds from A. flettii 
 The final yield of P5 (later confirmed as grifolin), P6 (later confirmed as neogrifolin) and 
P8 (later confirmed as confluentin) from 70 g of A. flettii # 128 was 0.26, 0.16 and 0.025% 
respectively.  Table 3.4 shows the yield at each step of the purification.  
Table 3. 4 Techniques followed and yield of compounds from E1 (80% ethanol) extract of 
A. flettii  
Technique  Yield (in mass) 
% yield based on 
technique 
Powdered fungi sample # 128 70 g - 
E1 (80% Ethanol) Fraction weight  7.1489 g 10.21  
Liquid-liquid extraction yield. 3.1813 g 4.54 
Loaded on Sephadex™ LH-20 (400 mL)  
(Total 5 columns) 
= 640 mg/run 
(8 ml of 80 mg/mL 
each). 
- 
Active fractions obtained from 
Sephadex™ LH-20 (400 mL)  
~178 mg/run. (Total 
around 800 mg from 
5 columns) 
1.14 
Sample purified by HPLC-UV  
~400 mg (active 
fractions Post LH-
20 Sephadex®) 
- 
Purified compounds from HPLC-UV   ~350 mg 
- 
P5 (Later confirmed as grifolin) 182.5 mg 0.26 
P6 (Later confirmed as neogrifolin) 114.2 mg 0.16  
P8 (Later confirmed as confluentin) 17.5 mg 0.025  
3.3.8.7 Mass spectroscopy (MS) analysis 
The purified compounds were protonated with the aid of 0.1% formic acid isocratic 
solution. Figure 3.21 represents the UV spectrum showing three abundant peaks with their 
respective retention times.  
The molar mass of the protonated purified Peaks 5 and 6 was the same (m/z = 329.3) 
(Figure 3.24 and 3.27), suggesting that they may be isomers. Spectra shown in Figure 3.22 and 
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3.23 represent the SIM and scan signal of peak 5 respectively, while Figure 3.25 and 3.26 
represent the SIM and scan spectra of peak 6 respectively.  
However, the molar mass of the purified compound (peak 8) was determined to be 
ESIMS = 327.3 m/z (Figure 3.30). Spectra shown in Figure 3.28 and 3.29 represent the SIM and 
scan signal of peak 8 respectively. 
 
Figure 3. 21 UV spectrum representing the relative abundance and retention time of peaks 
at λmax 279nm (using analytical column and Sephadex LH20 active fraction sample). 
 
3.3.8.7.1 Peak 5 (Later confirmed as grifolin) 
 
Figure 3. 22 UV spectrum confirming the purity of the compound [M+H]+ m/z 329.3 
detected at 10.226 min through ESI (Electrospray ionization) chamber. The type of column 
utilized was Agilent C-18 analytical column and the sample was 5 μL of purified compound 
from Peak 5. 
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Figure 3. 23 MS Scan spectrum representing the relative abundance and retention time of 
the compound with [M+H]+ m/z 329.3 detected at 10.226 min through ESI (Electrospray 
ionization) chamber. The type of column utilized was Agilent C-18 analytical column and 
the sample was 5 μL of purified compound from Peak 5. 
 
 
  
Figure 3. 24 Integration of MS Scan spectrum indicating the presence and abundance of 
compound Peak 5 with [M+H]+ m/z 329.3 visible at 10.266 min. 
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3.3.8.7.2 Peak 6 (later confirmed as neogrifolin) 
 
Figure 3. 25 UV spectrum confirming the purity of the compound with [M+H]+ m/z 329.3 
detected at 13.987 min through ESI (Electrospray ionization) chamber. The type of column 
utilized was Agilent C-18 analytical column and the sample was 5 μL of purified compound 
from Peak 6. 
 
 
 
Figure 3. 26 MS scan spectrum representing the relative abundance and retention time of 
the compound with [M+H]+ m/z 329.3 detected at 13.987 min through ESI (Electrospray 
ionization) chamber. The type of column utilized was Agilent C-18 analytical column and 
the sample was 5 μL of purified compound from Peak 6. 
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Figure 3. 27 Integration of MS Scan spectrum indicating the presence and abundance of 
compound Peak 6 with [M+H]+ m/z 329.3 visible at 13.952 min. 
 
 
3.3.8.7.3 Peak 8 (later confirmed as confluentin) 
 
 
Figure 3. 28 UV spectrum confirming the purity of the compound [M+H]+ m/z 327.3 
detected at 23.555min through ESI (Electrospray ionization) chamber. The type of column 
utilized was Agilent C-18 analytical column and the sample was 5 μL of purified compound 
from Peak 8. 
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Figure 3. 29 MS scan spectrum representing the relative abundance and retention time of 
the compound with [M+H]+ m/z 327.3 detected at 23.555min through ESI (Electrospray 
ionization) chamber. The type of column utilized was Agilent C-18 analytical column and 
the sample was 5 μL of purified compound from Peak 8. 
 
 
Figure 3. 30 Integration of MS Scan spectrum indicating the presence and abundance of 
compound Peak 8 with [M+H]+ m/z 327.3 visible at 23.708 min. 
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3.3.9 Nuclear Magnetic Resonance (NMR) analysis 
In the course of investigation on growth-inhibitory constituents of the A. flettii, three 
previously reported compounds (grifolin, neogrifolin and confluentin) were isolated and 
structurally elucidated by comparing their NMR spectra (Table 3.5-3.6) with already published 
NMR data (Ishii et al., 19881 : Iwata et al., 20042: Liu & Woggon, 20103). Compounds in peaks 
5, 6 and 8 of HPLC UV spectra were identified as grifolin, neogrifolin and confluentin 
respectively.  
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Table 3. 5  13C NMR spectral data of purified compounds (grifolin, neogrifolin and 
confluentin) obtained using Bruker Fourier A-300 NMR. 
Carbon  Grifolin   Grifolin1  Neogrifolin  Neogrifolin1  Confluentin  Confluentin2  
C-1 109.1 109.3 (d) 109.7 109.9 (d)   
C-2 137.5 137.2 (s) 154.1 154.1 (s) 78.2 78.2 (s) 
C-3 109.1  109.3 (d) 101.1 101.2 (s) 127.2 127.2 (d) 
C-4 154.8  154.6 (s) 155.4 155.2 (s) 116.7 116.7 (d) 
C-4a     106.7 106.8 (s) 
C-5 110.4  111 (s) 117.9 118.4 (s) 151.0 151.0 (s) 
C-6 154.8  154.6 (s) 138.5 138.7 (s) 108.4 108.3 (d) 
C-7     139.5 139.5 (s) 
C-8 21.0  21 (q) 20.2 20.2 (q) 109.8 109.3 (d) 
C-8a     154.1 154.1 (s) 
C-1’ 22.2  22.3 (t) 25.1 25.2 (t) 41.0 41.0 (t) 
C-2’ 121.6  122 (d) 122 122.3 (d) 22.6 22.6 (t) 
C-3’ 139.1  138.4 (s) 137.7 137.3 (s) 124.0 124.0 (d) 
C-4’ 39.7  39.7 (t) 39.7 39.8 (t) 135.3 135.3 (s) 
C-5’ 26.7  26.7 (t) 26.4 26.6 (t) 39.7 39.7 (t) 
C-6’ 123.6  123.7 (d) 123.8 123.9 (d) 26.7 26.7 (t) 
C-7’ 135.6  135.4 (s) 135.5 135.4 (s) 124.4 124.4 (d) 
C-8’ 39.7 39.7 (t) 39.7 39.8 (t) 131.3 131.3 (s) 
C-9’ 26.7 26.7 (t) 26.7 26.8 (t) 25.7  25.7 (q) 
C-10’ 124.4 124.5 (d) 124.4 124.5 (d) 17.7  17.7 (q) 
C-11’ 131.3  131 (s) 131.4 131.4 (s) 15.9 16.0 (q) 
C-12’ 25.7 25.7 (q) 25.7 25.8 (q) 26.3 26.3 (q) 
C-13’ 17.7 17.7 (q)  17.7 17.8 (q) 21.5 21.5 (q) 
C-14’ 16.2 16.1 (q) 16.3  16.4 (q)    
C-15’ 16.0 16  (q) 16.2  16.2 (q)   
 
98 
 
Table 3. 6  1H NMR spectral data of purified compounds (grifolin, neogrifolin and 
confluentin) obtained using Bruker Fourier A-300 MHz NMR. 
Hydr
ogen  
Grifolin   Grifolin1  Neogrifolin  Neogrifolin1  Confluentin  Confluentin3  
H-1 6.23 (s) 6.20 (s) 6.25 (d, 3.0 Hz) 6.23 (d, 3.0 Hz)   
H-2       
H-3 6.23 (s) 6.20 (s) 6.21 (d, 3.0 Hz) 6.18 (d, 3.0 Hz) 5.48 (d, 10 Hz) 5.49 (d, 10 Hz) 
H-4     6.59 (d, 10 Hz) 6.60 (d, 10 Hz) 
H-6     6.11 (s) 6.11 (s) 
H-8 2.21 (s) 2.21 (s) 2.22 (s) 2.21 (s) 6.24 (s) 6.24 (s) 
H-1’ 3.37 (d, 7.0 Hz) 3.37 (d, 7.0 Hz) 3.27 (d, 7.0 Hz) 3.27 (d, 7.0 Hz) 1.67 – 1.78 (m) 1.65-1.78 (m) 
H-2’ 5.23 (t, 7.0 Hz) 5.26 (t, 7.0 Hz) 5.11 (t, 7.0) 5.11 (t, 7.0) 2.03-2.12 (m) 2.01-2.13 (m) 
H-3’     5.08 (m) 5.06 (m) 
H-4’ 1.96-2.12 (m) 1.9-2.10 (m) 1.84-2.04 (m) 1.84-2.04 (m)   
H-5’ 1.96-2.12 (m) 1.9-2.10 (m) 1.84-2.04 (m) 1.84-2.04 (m) 1.95 (m) 1.95 (m) 
H-6’ 5.05 (m) 5.06 (m) 5.04 (m) 5.04 (m) 2.03-2.12 (m) 2.01-2.13 (m) 
H-7’     5.11 (m) 5.11 (m) 
H-8’ 1.96-2.12 (m) 1.9-2.10 (m) 1.84-2.04 (m) 1.84-2.04 (m)   
H-9’ 1.96-2.12 (m) 1.9-2.10 (m) 1.84-2.04 (m) 1.84-2.04 (m) 1.67 (s) 1.67 (s) 
H-10’ 5.05 (m) 5.06  (m) 5.04 (m) 5.04 (m) 1.59 (s) 1.59 (s) 
H-11’     1.57 (s) 1.57 (s) 
H-12’ 1.67 (s) 1.66 (s) 1.67 (s) 1.66 (s) 1.37 (s) 1.37 (s) 
H-13’ 1.59 (s) 1.57 (s) 1.58 (s) 1.58 (s) 2.20 (s) 2.20 (s) 
H-14’ 1.58 (s) 1.57 (s) 1.58 (s) 1.58 (s)   
H-15’ 1.81 (s) 1.80 (s) 1.79 (s) 1.80 (s)   
 
3.3.9.1 Grifolin 
The signals observed for 13C NMR spectra of grifolin indicated the presence of twenty-
two carbons in the structure. The signals for non-proton bearing carbons of grifolin (C-3’, C-7’ 
and C-11’) were observed with shifts in the range 131.33-139.50 ppm. The downfield signal at 
154.81 ppm in the 13C NMR spectrum of grifolin was observed for aromatic carbons (C-4 & C-
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6) having hydroxyl groups attached to them. The 13C shifts at 25.74, 17.72, 16.23, 16.06 ppm 
were observed for side chain methyl carbons at positions C-12’, C-13’, C-14’ and C-15’ 
respectively. Side chain carbons C-4’ and C-8’ were observed as overlapping signal at 39.70 
ppm. This overlap is due to C-4’ and C-8’ existing in similar chemical environment. The signals 
at 121.62, 123.62 and 124.43 ppm correspond to the methine carbons at positions C-2’, C-6’ and 
C-10’ respectively. The signals for aromatic carbons (C-1 and C-3) were observed at 109.3 ppm, 
because C-1 and C-3 exist in identical chemical environment. The signal at 21.0 ppm is due to an 
aromatic methyl group (C-8). Grifolin structure is terpenoid in nature having an isoprene 
skeleton side chain. 
 
Figure 3. 31 Chemical structure of grifolin. 
 
The 1H NMR spectrum of grifolin (Table 3.6) exhibited four singlets for methyl groups at 
1.584 (3H,  H-14’), 1.594 (3H,  H-13’), 1.672 (3H,  H-12’), 1.812 ppm (3H,  H-15’). A singlet at  
2.205 ppm (3H, H-8) corresponds to an aromatic methyl group at C-8. A multiplet at 5.046 ppm 
corresponds to two hydroxyls (H-4 and H-6) and two methines (H6’ and H-10’). 
The signals for H-1 and H-3 appeared as singlet at 6.234 ppm. The multiplet at 1.962-
2.120 ppm was integrated to eight protons containing the signals for methylene groups at H-4’, 
H-5’ H-8’ and H-9’. The signal for (-CH2-) methylene group at H-1’ was observed as a doublet 
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at 3.376 (J = 7.0 Hz). The signals for methine protons (H-6’ and H-10’) were observed in the 
range of 5.046 - 5.23 ppm.  
On comparison using the 1H-NMR spectra of grifolin and neogrifolin, a prominent shift 
difference was observed for protons attached to carbon C-1 and C-3. The chemical environment 
for protons (H-1 & H-3) is equal in grifolin, due to symmetry of the neighbor substituents 
attached to aromatic ring. The singlet having two protons (H-1 & H-3) was observed for grifolin 
at 6.234 (s) ppm. A signal at 6.214 (d, 3.0 Hz) ppm was observed for neogrifolin aromatic 
protons (H-1 & H-3), indicating meta coupling of these protons. This indicates that the protons 
(H-1 and H-3) in grifolin structure are equally de-shielded, while in neogrifolin  H-3 is more de-
shielded than H-1. 
1H-1H COSY is a 2D method used for determining the signals arising from neighboring 
protons. The peaks that do not show up across diagonal are termed as cross peaks, which tell 
about coupled signals of neighboring protons. A cross peak was observed at 6.234 and 2.205 
ppm for aromatic protons at carbon (C-1 and C-3) and methyl group protons (H-8’) attached to 
aromatic ring, indicating them being neighbors. The presence of two aromatic hydroxyl group 
(H-4 and H-6) was confirmed by a cross peak at 5.046 and 2.205 ppm, indicating two hydroxyl 
group in close environment of the aromatic methyl group. The proton pair (H-1’) at carbon (C-
1’) displayed a cross-peak with H-15’ protons at 3.376 and 1.812 ppm. 
Heteronuclear single quantum correlation (HSQC), is used in NMR spectroscopy of 
organic molecules. HSQC is a two-dimensional spectrum having two axis, one axis for proton 
(1H NMR) and other for 13C spectrum. HSQC provides in detail information about protons and 
heteronuclear atoms (C or N), to which those protons are linked. The HQSC spectrum of grifolin 
revealed resonances for four methyl groups [1.584 (H-14’), 1.594 (H-13’), 1.672 (H-12’), and 
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1.812 ppm (H-15’)] and one aromatic methyl group at 2.205 ppm (H-8), three methines [ 5.046 
(H-6’), 5.046 (H-10’), 5.230 (H-2’) ], and five methylenes (-CH2-) groups at 3.376 ppm (j=7.0 
Hz, H-1’),  1.962-2.120 ppm (H-4’, H-5’, H-8’ and H-9’). The carbons at position C-3’, C-7’ and 
C-11, displayed no resonance signals with 1H signal indicating quaternary carbons. 
3.3.9.2 Neogrifolin 
 The signals observed for 13C NMR spectra of neogrifolin indicated the presence of 
twenty-two carbons in the structure. The signals for non-proton bearing carbons of neogrifolin 
(C-3’, C-7’ and C-11’) were observed downfield at 137.72 , 135.47 and 131.36 ppm respectively. 
Two distinct upfield signals were observed for aromatic carbons (C-1 and C-3) at 109.69 and 
101.05ppm respectively, making neogrifolin distinct from grifolin. The carbon signal trend for 
neogrifolin side chain primary carbons (C-12’, C-13’, C-14’ and C-15’) was the same as 
observed in grifolin spectra. The signals for C-12’, C-13’, C-14’ and C-15’ were observed at 
25.74, 17.72, 16.27 and 16.21 ppm respectively. Side chain carbons C-4’ and C-8’ exhibited 
signal at 39.68 ppm. The carbons C-4’ and C-8’ exist in similar chemical environment. The two 
downfield signals at 154.15 and 155.39 ppm on 13C NMR spectra was observed for aromatic 
carbons (C-2 & C-4) having hydroxyl groups attached to them. Neogrifolin structure is terpenoid 
in nature having an isoprene skeleton side chain. 
 
Figure 3. 32 Chemical structure of neogrifolin. 
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The 1H NMR spectrum of  neogrifolin (Table 3.6) exhibited four singlets for methyl 
protons attached to side chain primary carbons at 1.580 (3H,  H-14’), 1.580 (3H,  H-13’), 1.67 
(3H,  H-12’), 1.790 (3H,  H-15’) . A singlet at 2.226 ppm (3H, H-8) is characteristic of an 
aromatic methyl group. A multiplet signal at 5.049- 5.11 ppm represents five protons, mainly two 
from aromatic hydroxyl groups (H-2 and H-4) showed overlapping signals with side chain 
hydrogens attached to methines at positions H2, H6’ and H-10’. The signals for eight protons 
from four (-CH2-) methylene groups at H-4’, H-5’ H-8’ and H-9’ were observed as a multiplet at 
1.84-2.04 ppm. A doublet at 3.273 ppm (J=7.0 Hz) is due to the presence of two protons (H-1’) 
on (-CH2-) methylene carbon (C-1’). 
A cross peak indicating a hydroxyl group (C-2) close to the methyl group (C-8) of 
aromatic structure was observed at 5.049 and 2.226 ppm in neogrifolin 1H-1H COSY spectrum. 
Methylene (-CH2-) protons at position H-1’ displayed a cross peak at 3.273 and 5.11 ppm with 
protons at position H-2’, indicating them being neighbors. A cross peak was observed at 5.049 
and 1.84-2.04 ppm due to coupling of protons H-6’ and H-5’.  
The HQSC spectrum of neogrifolin revealed resonances for four methyl groups [1.580 ( 
H-13’& H-14’), 1.67 (H-12’), 1.790 ppm (H-15’)] and one aromatic methyl group 2.226 (H-8) 
ppm,  three methines [ 5.049 ( H-6’), 5.049  (H-10’), 5.11 ppm (H-2’) ], and five methylenes (-
CH2-) groups 3.273 ( j=7.0 Hz, H-1’),  1.84-2.04 ppm (H-4’, H-5’,H-8’and H-9’). The carbons at 
position C-3’, C-7’ and C-11, displayed no resonance signals with the 1H spectrum indicating 
quaternary carbons. 
3.3.9.3 Confluentin   
The signals observed for 13C NMR spectra of confluentin indicated the presence of 
twenty-two carbons in the structure. The structure of confluentin contains an oxygen containing 
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hetero cycle. The signals for the cyclic carbons bounded directly to the oxygen of the heterocycle 
(C-2 & C-8a) were observed  at 78.21 and 154.10 ppm. 13C NMR spectrum corresponded the 
presence of five non-proton-bearing cyclic carbons (C-2, C-5, C-7,C-4a and C-8a) exhibiting 
their signals at 78.21, 151.02, 139.55, 106.74 and 154.1 ppm respectively. The signals for non-
proton bearing side chain quaternary carbons (C-4’ and C-8’) were observed at 135.27 & 131.36 
ppm respectively. 
 
Figure 3. 33 Chemical structure of confluentin 
 
The chemical shift at 151.02 ppm, is representative of aromatic carbon (C-5) having a 
hydroxyl group substitution. The signals for methine carbon C-3’ and C-7’ were very close to 
each other (124.06 & 124.38 ppm). The signals for side chain (-CH2-) methylene groups (C-1’, 
C-2’, C-5’ and C-6’) were visible at 41.06, 22.61, 39.68 and 26.68 ppm respectively. Confluentin 
structure is terpenoid in nature having an isoprene skeleton side chain. 
For 1H-NMR spectrum, two doublets were observed at 5.478 (j= 10 Hz) and 6.593 (j= 10 
Hz) ppm representing H-3 and H-4 respectively. Two singlets visible at 6.116 and 6.241 ppm 
represents the protons H-6 and H-8 respectively. A multiplet at 5.082 ppm (j= 7.0 Hz) ppm 
indicates the presence of two protons attached to methine carbons (H-3’ and H-7’). A singlet at 
2.201 ppm was corresponds to protons of methyl group (H-13’) attached to the aromatic ring. 
The signal for the methyl protons (H-9’, H-10’, H-11’ and H-12’) attached to the side chain 
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primary carbons were observed as singlets at 1.670, 1.587 and 1.575 and 1.374 ppm respectively. 
The signals for the protons bound to the methylene (-CH2-) carbons (C-1’, C-2’, C-5’ and C-6’) 
were visible as multiplets from 1.740 to 2.120 ppm.  
In COSY spectrum, cross peak at 5.478 ( j= 10 Hz) and 6.593 ppm ( j= 10 Hz) are due to  
two neighboring aromatic protons (H-3 and H-4). Cross peaks were observed for the H-5’ and H-
6’ at 1.949 ppm and 2.031 ppm. Protons at H-1’ and H-2’ showed a cross peak at 1.670 and 
2.031 ppm.  The HQSC spectrum of the confluentin revealed resonances for three methyl groups 
at 1.670 ppm (H-9’), 1.587 ppm (H-10’), 1.575 ppm (H-11’) and two aromatic methyl group at 
1.374 ppm (H-12’) and 2.201ppm (H-13’). The carbons at position C-2, C-4’ and C-8’, displayed 
no resonance signals with 1H signal indicating quaternary carbons. Due to the unavailability of a 
chiral column (HPLC), it was not possible confirm the stereochemistry of the purified 
compound. 
Grifolin and confluentin are structurally relatable to each other. Either grifolin can be a 
precursor in confluentin formation or vice versa. Confluentin has a pyran ring in its structure, 
which could possibly be formed due to the bonding between aromatic hydroxyl (at C-4) and 
carbon (C-3’) of the side chain of grifolin. Or, it is also possible that grifolin could have been 
formed by the breakage of bond between oxygen and carbon-2 of pyran ring of confluentin. 
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3.3.10 NMR Spectrum of the compounds purified from A. flettii 
3.3.10.1 Grifolin (C22H32O2) 
 
 
Figure 3. 34  13C-NMR spectrum of grifolin in CDCl3 containing 0.3% TMS. 
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Figure 3. 35  1H-NMR spectrum of grifolin in CDCl3 containing 0.3% TMS. 
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Figure 3. 36  1H- 1H NMR correlation spectroscopy (COSY) 2D spectrum of grifolin in 
CDCl3 containing 0.3% TMS. 
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Figure 3. 37 1H- 1H NMR correlation spectroscopy (COSY) 2D spectrum of grifolin 
(expanded). 
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Figure 3. 38 HSQC-NMR-2D (13C-1H-NMR) spectrum of grifolin in CDCl3 containing 
0.3% TMS. 
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3.3.10.2 Neogrifolin (C22H32O2) 
 
Figure 3. 39  13C-NMR spectrum of neogrifolin in CDCl3 containing 0.3% TMS. 
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Figure 3. 40 1H-NMR spectrum of neogrifolin in CDCl3 containing 0.3% TMS. 
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Figure 3. 41  1H- 1H NMR correlation spectroscopy (COSY) 2D spectrum of neogrifolin in 
CDCl3 containing 0.3% TMS. 
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Figure 3. 42 1H- 1H NMR correlation spectroscopy (COSY) 2D spectrum of neogrifolin 
(expanded). 
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Figure 3. 43 HSQC-NMR-2D (13C-1H-NMR) spectrum of neogrifolin in CDCl3 containing 
0.3% TMS. 
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Figure 3. 44 HSQC-NMR-2D (13C-1H-NMR) spectrum of neogrifolin (expanded). 
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Figure 3. 45 HSQC-NMR-2D (13C-1H-NMR) spectrum of neogrifolin (expanded). 
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3.3.10.3 Confluentin (C22H30O2) 
 
 
Figure 3. 46  13C-NMR spectrum of confluentin in CDCl3 containing 0.3% TMS. 
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Figure 3. 47 1H-NMR spectrum of confluentin in CDCl3 containing 0.3% TMS. 
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Figure 3. 48 1H- 1H NMR correlation spectroscopy (COSY) 2D spectrum of confluentin in 
CDCl3 containing 0.3% TMS. 
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Figure 3. 49 1H- 1H NMR correlation spectroscopy (COSY) 2D spectrum of confluentin 
(expanded). 
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Figure 3. 50 HSQC-NMR-2D (13C-1H-NMR) spectrum of confluentin in CDCl3 containing 
0.3% TMS. 
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Figure 3. 51 HSQC-NMR-2D (13C-1H-NMR) spectrum of confluentin (expanded). 
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Figure 3. 52 HSQC-NMR-2D (13C-1H-NMR) spectrum of confluentin (expanded). 
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3.3.10.4 Physical properties of the purified compounds from A. flettii 
The three major compounds (Peak 5, Peak 6 and Peak 8), purified using HPLC, were 
lyophilized. All three compounds had very distinctive physical characteristics. Compound Peak 5 
(grifolin) was cream color fluffy (needle shaped) powder, while compound Peak 6 (neogrifolin) 
was oily in nature and yellowish brown in color. The physical appearance of compound Peak 8 
(confluentin) was completely different from the previous two pure compounds (grifolin and 
neogrifolin): it was light brown sticky paste (Figure 3.53). 
 
       
Figure 3. 53 Photographs of three purified compounds from A. flettii. 
 (A) Grifolin: Cream color (needle) powder: (B) Neogrifolin: Brownish colored oil: (C) 
Confluentin: Brownish colored sticky compound 
 
3.3.11 Intrinsic reductive potential of purified compounds in cell-based and cell-free 
environment 
Anti-oxidant compounds can directly reduce the MTT dye (yellow) to formazan crystals 
(purple). Because of this intrinsic reduction potential of plant extracts, phytoestrogens and anti-
oxidants, MTT tetrazolium assay may lead to false negative growth-inhibitory results 
(Bruggisser et al., 2002). Grifolin has been shown to possess antioxidant properties (Jing et al., 
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2017). Therefore, grifolin has an intrinsic reduction potential toward MTT dye. Neogrifolin 
could also be anti-oxidant in nature, because of its structural similarity with grifolin and 
interaction with MTT dye. 
 
Figure 3. 54 Illustration of proposed mechanism of MTT dye reduction by grifolin. 
Treatment of HeLa cells with higher doses of the purified compounds resulted in false 
negative growth-inhibitory results. Although HeLa cell numbers were decreased (observed 
microscopically), interestingly formation of formazan (purple color) also increased, suggesting a 
direct interaction of these purified bioactive compounds with the MTT reagent.  
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Figure 3. 55a Reductive potential of A. flettii crude extract (top left); P5 (grifolin: top 
right), P6 (neogrifolin: lower left) and P8 (confluentin: Lower right) at different doses. 
(Plate columns from left to right represent were Negative control, 0.25 mg/mL, 0.1 mg/mL, 
0.075 mg/mL, 0.05 mg/mL, 0.035 mg/mL, 0.025 mg/mL, 0.010 mg/mL, 0.005 mg/mL and 
Negative control) 
 
The interaction of purified compounds with MTT solution can clearly be seen in Figure 
3.55a. Plates 1, 2, 3 and 4 are representative of crude extract, grifolin, neogrifolin and 
confluentin respectively. Grifolin exhibited the strongest interaction (at 0.25 and 0.1 mg/mL) 
with MTT solution as compared to the crude extract and neogrifolin. Confluentin showed no 
interaction with MTT tetrazolium dye. This interesting observation indicates the possibility of 
false negative growth-inhibitory results using natural compounds with intrinsic reduction 
potential towards MTT tetrazolium bromide reagent. Neogrifolin and crude extract showed 
interaction at 0.25 mg/mL only. 
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The reduction potential of grifolin and neogrifolin towards MTT dye was reconfirmed in 
a cell-free environment. Figure 3.55b represents the reduction of MTT (5 mg/mL) into formazan 
after incubation with equal volume of grifolin and neogrifolin solution (1 mg/mL). Figure 3.47 
illustrates the proposed mechanism behind reduction of MTT dye by grifolin. 
 
Figure 3.55b Intrinsic reductive potential of grifolin (left) and neogrifolin (right) in a cell 
free system. MTT tetrazolium bromide (5 mg/mL) and Purified compounds (1 mg/mL) were 
mixed in equal quantity (300 µL each) in an Eppendorf and incubated for 3 hours at 37 °C. 
 
3.3.12 IC50 determination of purified compounds on HeLa cells 
Dose-dependent MTT assays of grifolin, neogrifolin and confluentin on HeLa cells were 
performed. The concentration range tested was from 7.6 to 228 μM. As shown in Figure 3.56, 
grifolin and neogrifolin were the most potent growth inhibitors in HeLa cells.  The IC50 of 
grifolin and neogrifolin on HeLa cells was 29.85 and 23.22 μM respectively. On the other hand, 
the IC50 of confluentin on HeLa cells was determined to be 50.47 μM, making it the least potent. 
The cell viability (% of control) of HeLa cells treated with 76.10 μM concentration of grifolin, 
neogrifolin and confluentin was 11.44, 10.50 and 12.76 respectively.  No cytotoxicity was 
observed in HeLa cells with confluentin at the lowest dose 7.6 μM. 
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Figure 3. 56 Dose-dependent growth-inhibitory effect of grifolin, neogrifolin and 
confluentin on HeLa cells. The graph is representative of results from two biological replicates 
(n=2). Error bars are standard deviation. 
 
3.3.13 IC50 determination of purified compounds on human colon cancer cells lines 
Similar dose-dependent MTT assay experiment was performed on human colon cancer 
cell lines SW480 and HT29 cells. Different wells containing 1500 cells each were treated with 
different final concentrations of grifolin and neogrifolin. The control used was 2% DMSO 
because the compounds were dissolved in DMSO.  
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Figure 3. 57 Dose-dependent growth-inhibitory effect of grifolin and neogrifolin human 
colon cancer cell lines, SW-480 (left) and HT-29 (right) 
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As shown in Figure 3.57, both compounds appear to have similar effect on SW480 and 
HT29 cells. The IC50 of grifolin on HT-29 cells was 30.62 µM and 33.48 µM on SW-480 cells. 
However, neogrifolin was slightly more potent than grifolin. The IC50 of neogrifolin on SW-480 
and HT-29 was 31.023 and 28.77 µM respectively. 
3.3.14 Assessing grifolin and neogrifolin on IMP1-KRas RNA interaction using 
fluorescent polarization method 
The fluorescent polarization experiments described here were performed by Mr. Victor 
Liu. Different concentrations were utilized to determine the potential inhibitory effects of the 
grifolin and neogrifolin on the interaction between and KRas RNA and IMP1. For IMP1 protein, 
both the full-length recombinant wild-type IMP1 protein and truncated IMP1 KH34 protein 
containing only the KH3 and KH4 domains were used.  
            
Figure 3. 58 Assessing grifolin and neogrifolin for their ability to disrupt IMP1 and KRas 
RNA interaction using fluorescent polarization. (A) Dose-dependent effect of grifolin and 
neogrifolin on the interaction between IMP1 KH34 (300 nM) and fluorescently labeled KRas 
RNA (10 nM). (B) Effect of grifolin and neogrifolin on the interaction between full-length IMP1 
(300 nM) and fluorescently labeled KRas RNA (10 nM) 
 
 
130 
 
As shown in Figure 3.58A, no inhibitory effect was observed at any concentrations of the 
grifolin and neogrifolin. In contrast, when the full-length IMP1 protein was used (Figure 3.58B), 
both grifolin and neogrifolin dose-dependently inhibited IMP1 and KRas RNA interaction.  
3.3.15 Assessing grifolin, neogrifolin and confluentin on KRas expression using 
Western blot analysis 
 Based on the results from fluorescent polarization experiments, it was deemed logical to 
assess the purified growth-inhibitory compounds (grifolin, neogrifolin and confluentin) from A. 
flettii on KRas expression in colon cancer cells. K-Ras4a and K-Ras4b are two splice variants of 
KRAS. Although both isoforms have a lot of similarities, there are also major differences. The 
major difference is based on their disordered C-terminal hypervariable region and four catalytic 
domain residues (G151R/D153E/K165Q/H166Y). They also differ based on the hypervariable 
region charge; K-Ras4b (+9e) has more charge hypervariable region than K-Ras4a (+6e). 
(Chakrabarti et al., 2016). 
Treatment with three purified compounds (grifolin, neogrifolin and confluentin) elicited 
growth-inhibitory effect in a concentration-dependent manner in SW480 and HT-29 human 
colon adenocarcinoma cells (Figure 3.57). To determine whether the purified compounds 
(grifolin, neogrifolin and confluentin) have any effects on KRas expression, SW480 and HT-29 
cell lines were treated with 20 µM of grifolin, neogrifolin and confluentin for 24 hours. The 
results are described below. 
3.3.15.1 HT-29 Cells 
HT-29 cells were treated with 20 µM concentration grifolin, neogrifolin and confluentin. 
After 48 hours of treatment, the KRas-4b levels were found to be down-regulated by grifolin, 
neogrifolin and confluentin to 48.25, 51.84 and 54.04% respectively (Figure 3.59). 
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Figure 3. 59 Effects of grifolin, neogrifolin and confluentin on Kras-4b expression in HT29 
Colon adenocarcinoma cells. (A) Cells were treated with 20 µM of drugs for 48 hours. Lysates 
from cells were isolated and subjected to Western blot analysis. (B) The Kras-4b band in (A) was 
normalized to the house-keeping gene GAPDH and expressed relative to the control, DMSO, 
taken as 1.0.      
Lysates from another biological replicates confirmed the results shown in Figure 3.59. 
The KRas-4b expression levels after treatment with different (20 and 50 µM) concentrations of 
positive controls (AcQ and VLA9) and purified compounds from A. flettii (grifolin, neogrifolin 
and confluentin) are shown in Fig 3.60. The KRas-4b levels were down-regulated to 71.26 and 
52.60% after treatment with 50 µM of grifolin and neogrifolin respectively. Treatment with the 
positive controls (20 µM) ACQ and VLA9 also down-regulated KRas-4b expression by 25.29% 
and 22.86% respectively. The KRas-4a levels were also down-regulated after treatment with 
different concentrations of these compounds.  
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Figure 3. 60 Effects of grifolin, neogrifolin and confluentin on Kras-4a and Kras-4b 
expression in HT29 Colon adenocarcinoma cells. (A) HT29 Cells were treated with 20 and 50 
µM of drugs for 48 hours. Lysates from cells were isolated and subjected to Western blot 
analysis. (B) The Kras-4a band in (A) was normalized to the house-keeping gene GAPDH and 
expressed relative to the control, DMSO, taken as 1.0. (C) The Kras-4b band in (A) was 
normalized to the house-keeping gene GAPDH and expressed relative to the control, DMSO, 
taken as 1.0. 
 
Another technical replicate of the above experiment showed similar results (Fig 3.61). 
This further confirmed the reproducibility of the results for KRas expression. The only dose 
tested for confluentin was 20 µM; however, it proved to have very little effect on down-
regulation of both forms of Kras. 
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Figure 3. 61 Effects of grifolin, neogrifolin and confluentin on Kras-4b expression in HT29 
Colon adenocarcinoma cells. (A) Cells were treated with 20 and 50 µM of drugs for 48 hours. 
Lysates from cells were isolated and subjected to Western blot analysis. (B) The Kras-4b band in 
(A) was normalized to the house-keeping gene GAPDH and expressed relative to the control, 
DMSO, taken as 1.0.  
 
3.3.15.2 SW480 Cells 
To determine whether Kras-4b expression in SW480 cells is also affected by the purified 
compounds, two experiments were performed using different doses of neogrifolin only. KRas-4b 
expression in SW480 cells, after treatment with 10 (Fig. 3.62B) and 50 µM (Fig. 3.62B) 
concentration of neogrifolin was downregulated to 85.72 and 34.10 % respectively. No effect on 
Kras-4b expression was observed after treatment with 5 µM of neogrifolin (Fig. 3.62B).  
KRAS-4a levels were also found downregulated to 87.20% after treatment with 50 µM 
(Fig. 3.63B)  concentration of neogrifolin. So, both KRas isoforms were also affected in SW480 
cells after treatment with neogrifolin treatment. 
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Figure 3. 62 Effects of neogrifolin treatment on Kras-4b expression in SW480 Colon 
adenocarcinoma cells. (A) Cells were treated with 5 and 10 µM of neogrifolin for 48 hours. 
Lysates from cells were isolated and subjected to Western blot analysis. (B) The Kras-4b band in 
(A) was normalized to the house-keeping gene GAPDH and expressed relative to the control, 
DMSO, taken as 1.0.  
                    
Figure 3. 63 Effects of neogrifolin treatment on Kras-4a and Kras-4b expression in SW480 
Colon adenocarcinoma cells. (A) Cells were treated with 50 µM of neogrifolin for 48 hours. 
Lysates from cells were isolated and subjected to Western blot analysis. (B) The Kras-4a and 
Kras-4b bands in (A) were normalized to the house-keeping gene GAPDH and expressed relative 
to the control, DMSO, taken as 1.0.  
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The Kras-4b expression was determined in SW480 cells based on the time of treatment. 
Figure 3.64B represents the normalized expression of Kras-4b using housekeeping gene 
(GAPDH). Treatment of SW480 cells after 24 hours of treatment (50µM) with grifolin, 
neogrifolin and confluentin resulted in downregulation of  Kras-4b to 72.59, 76.52 and 67.77% 
respectively (Figure 3.64B).  
            
Figure 3. 64 Effects of grifolin, neogrifolin and confluentin treatment (50µM) on Kras-4b 
expression in SW480 Colon adenocarcinoma cells. (A) Cells were treated with 50 µM of 
grifolin, neogrifolin and confluentin for 24 hours. Lysates from cells were isolated and subjected 
to Western blot analysis. (B) The Kras-4b bands in (A) were normalized to the house-keeping 
gene GAPDH and expressed relative to the control, DMSO, taken as 1.0. 
 
Figure 3.65A is the representative of Kras-4b expression after treatment (48hrs) with 50 
µM of grifolin, neogrifolin and confluentin. Figure 3.65B represents the normalized expression 
of Kras-4b using housekeeping gene (GAPDH). The Kras-4b expression was downregulated to 
72.03, 80.32 and 49.08 % after 48hrs treatment with grifolin , neogrifolin and confluentin 
respectively. 
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Figure 3. 65 Effects of grifolin, neogrifolin and confluentin treatment (50µM) on Kras-4b 
expression in SW480 Colon adenocarcinoma cells. (A) Cells were treated with 50 µM of 
grifolin, neogrifolin and confluentin for 48 hours. Lysates from cells were isolated and subjected 
to Western blot analysis. (B) The Kras-4b bands in (A) were normalized to the house-keeping 
gene GAPDH and expressed relative to the control, DMSO, taken as 1.0. 
 
3.3.16 Apoptosis induction in SW480 cells 
PE Annexin V was used to determine the percentage of cells undergoing apoptosis. To 
distinguish viable cells from non-viable cells a standard 7-AAd viability probe was used for flow 
cytometry. Only necrotic or dead cells are permeable to 7-AAd. Figure 3.66 (A) represents cells 
treated with the negative control 2% DMSO. While cells treated with 50 µM of confluentin are 
represented in Figure 3.66 (B). Figure 3.66 (A and B) bottom left panels Q4 (PE Annexin V and 
7-AAD negative) indicated that the cells were viable and not undergoing apoptosis. The total 
number of events (population of cells) recorded for negative control (2% DMSO) and 
confluentin (50µM) were 13197 and 12090 respectively. 
The population of cells undergoing apoptosis after confluentin treatment (3627 events) 
were higher than the control (1102 events). While there is also a huge population of cells (962 
events) in panel Q1, indicating a large number of cells being necrotic or dead after 24 hours 
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treatment with 50 µM confluentin. The population of cells undergoing necrosis after treatment 
with negative control was only 68 events. 
The percentage of the cells viable after treatment with 2% DMSO and confluentin 50 µM 
were 90.0% (11877 events) and 61.60% (7447 events) respectively. Panels Q3 and Q2 (PE 
Annexin V positive and 7-AAD negative) represent the early and late stage apoptosis 
respectively. The population of cells in Q3 and Q2 after treatment with the negative control was 
156 and 1102 events respectively. On the other hand, the population of cells in Q3 and Q2 after 
treatment for 24 hours with 50 µM confluentin was 56 and 3627 events respectively. The cells in 
panel Q1 are considered dead /necrotic (PE Annexin V and 7-AAD positive). The population of 
cells undergoing necrosis after 24 hours treatment with 2% DMSO and confluentin 50 µM were 
68 and 962 events respectively.  
      
Figure 3. 66   Flow cytometry analysis of SW480 cells using PE annexin V in a buffer 
containing 7-Amino-Actinomycin (7-AAD) staining. (A) Cells after treatment for 24 hours with 
2% DMSO. (B) Cells after treatment for 24 hours with 50 µM of confluentin. Bottom left panel 
Q4 (PE Annexin V and 7-AAD negative) in (A) and (B) indicated the cells were viable and not 
undergoing apoptosis. Cells undergoing apoptosis (PE Annexin V positive and 7-AAD negative) 
(Q3 Early stage apoptosis and Q2 Late apoptosis). Population of cells observed to be PE 
Annexin V and 7-AAD positive, indicating end stage apoptosis or already dead (Q1). 
138 
 
The flow cytometry assay on the effect of confluentin on apoptosis was done twice using 
different cell preparations. From this result it is clear, that confluentin induced apoptosis in 
SW480 cells. 
Another experiment (treatment time 14 hours) (Figure 3.67) using the same cell line 
(SW480) revealed confluentin as being more a potent inducer of apoptosis than grifolin. After 
plating, SW480 cells were incubated for 60 hours and treated with 50 µM concentration of 
grifolin (Figure 3.67B) and confluentin (Figure 3.67C) for 14 hours. For negative control (Figure 
3.67A), 13030 events (cell population) were recorded using FACSMelody. The population of 
cells in Q3 and Q2 after treatment with the negative control (2% DMSO) was 263 and 1915 
events respectively. The population of cells undergoing necrosis was 185 only. The major 
population (visible in panel Q4) containing viable cells (not undergoing apoptosis or necrosis) 
was 10658 events (81.80%). The number of events recorded for SW480 cells after treatment with 
grifolin and confluentin (50 µM) were 10917 and 10884 respectively. The population of viable 
cells (panel Q4) were 8133 (74.50%) and 6008 (55.20%) respectively.  
The population of cells undergoing necrosis or already dead were similar in grifolin- and 
confluentin-treated cells. The population of cells dead or necrotic after treatment with grifolin 
and confluentin (Panel Q1) were 608 (5.57%) and 1197 (11.0%) events respectively. A 
significant difference in cell population undergoing apoptosis can be seen after treatment with 
grifolin and confluentin. The population of SW480 cells in the late apoptosis stage was 1965 
(18.0%) and 3534 (32.50%) respectively after grifolin and confluentin treatment. 
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Figure 3. 67  Flow cytometry analysis of SW480 cells using PE annexin V in a buffer containing 
7-Amino-Actinomycin (7-AAD) staining. (A) Cells after treatment for 14 hours with 2% DMSO. 
(B) Cells after treatment for 14 hours with 50 µM of grifolin. (C) Cells after treatment for 14 
hours with 50 µM of confluentin.  Bottom left panel Q4 (PE Annexin V and 7-AAD negative) in 
all panels indicated the cells were viable and not undergoing apoptosis. Cells undergoing 
apoptosis (PE Annexin V positive and 7-AAD negative) (Q3 Early stage apoptosis and Q2 Late 
apoptosis). Population of cells observed to be PE Annexin V and 7-AAD positive, indicating end 
stage apoptosis or already dead (Q1). 
 
 Treatment of SW480 cells with same concentration of confluentin revealed that 
confluentin has ability to induce apoptosis even within 6 hours (Figure 3.68). 15000 events were 
recorded for both negative control and confluentin (50µM) treated cells. The population of viable 
cells (panel Q4) after treatment with negative control and confluentin were 86 % (12900 events) 
and 70.3 (10545 events) respectively. The population of SW480 cells going under apoptosis after 
treatment with negative control (DMSO) and confluentin is 1385 events (9.23%) and 2895 
events (19.3%) respectively. Population undergoing necrosis after treatment with 50 µM 
confluentin is 6.20% (Panel Q1). 
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Figure 3. 68 Flow cytometry analysis of SW480 cells using PE annexin V in a buffer containing 
7-Amino-Actinomycin (7-AAD) staining. (A) Cells after treatment for 6 hours with 2% DMSO. 
(B) Cells after treatment for 6 hours with 50 µM of confluentin. Bottom left panel Q4 (PE 
Annexin V and 7-AAD negative) in (A) and (B) indicated the cells were viable and not 
undergoing apoptosis. Cells undergoing apoptosis (PE Annexin V positive and 7-AAD negative) 
(Q3 Early stage apoptosis and Q2 Late apoptosis). Population of cells observed to be PE 
Annexin V and 7-AAD positive, indicating end stage apoptosis or already dead (Q1). 
 
3.3.17 Cell cycle arrest at G2/M phase 
G2 phase of the cell cycle is the second sub-phase of interphase and is crucial for cell 
growth and protein synthesis. Figure 3.69A represents cell population after treatment with the 
negative control 2% DMSO. Figure 3.69B represents cell population after treatment with 
confluentin (50 µM). As shown, confluentin (50 µM) exhibited cycle arrest at G2/M phase in 
SW480 cells. The percent population of cells at G2/M phase after treatment for 24 hours with 
confluentin 50 µM and negative control (2% DMSO) was 11.40% and 0.42% respectively. 
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Table 3. 7 Representing relative percentage of SW480 cells in different phases of cell cycle. 
                      
         
 
                 
Figure 3. 69 Flow cytometry analysis of SW480 cells using propidium iodide staining. (A) Cells 
after treatment for 24 hours with 2% DMSO. (B) Cells after treatment for 24 hours with 50 µM 
of confluentin. G1 phase is represented by blue color, S phase is represented by yellow and G2/M 
phase is represented by green color. 
3.4 Discussion 
This chapter describes the successful purification, characterization, structural elucidation 
and molecular mechanistic studies of the three growth-inhibitory compounds from A. flettii. E1 
(80% ethanol) and E2 (50% methanol) extracts of the A. flettii exhibited potent growth-inhibitory 
activity. HeLa cell viability after treatment with both extracts was less than 20%. For further 
studies, extract E1 was selected because of its potent growth-inhibitory activity. To obtain the 
bioactive compounds from A. flettii E1 extracts, a series of purification steps were developed 
(Figure 3.70). 
Treatment G1 phase (%)  S phase (%) G2/M phase (%) 
2% DMSO 79.4 17.6 0.42 
Confluentin (50 µM) 83.3 4.12 11.40 
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Figure 3. 70 Flow diagram representing the steps involved in the purification and 
structural elucidation of pure compounds from A. flettii.  
 The E1 extract was first subjected to phase separation of molecules based on the liquid-
liquid extraction technique. This approach was based on two immiscible solvents (due to 
differences in polarity index). Separation of compounds was possible based on their polarity. 
Non-polar compounds were expected to move into the chloroform layer, while polar compounds 
were expected to solubilize and move into the water layer. An interphase was also observed 
which could be the degraded proteins not soluble in any of the solvents. Further screening for 
growth-inhibitory activity confirmed the presence of bioactive molecules in chloroform layer 
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(non-polar in nature). The yield of compounds in chloroform layer after liquid-liquid extraction 
was 44.50%. 
 Compounds from the chloroform layer were then subjected to Sephadex LH-20 size 
exclusion chromatography. The fractions collected from Sephadex LH-20 columns were further 
assessed for growth-inhibitory potential. Even at 1 µL, the fractions were capable to reduce the 
cell viability down to 20% as compared to the negative control (methanol). Since bioactive 
compounds were eluting in later fractions, it was proposed that compounds are smaller in size. 
This technique was further scaled up to 400 mL Sephadex LH-20 column. Sample introduced 
onto the column was 80 mg/mL of chloroform layer. Yield of active fractions from Sephadex 
LH-20 column was 27.813%.   
The post Sephadex LH-20 bioactive fractions were subjected to a second purification step 
using high-resolution HPLC. Initially, a method was developed for optimal separation of 
compounds present in the bioactive post-Sephadex LH-20 fractions. The solvent system utilized 
for optimal separation of peaks was a gradient solvent system based on acetonitrile and water. 
Later, the HPLC technique was scaled up using Agilent Zorbax C-18 semi-preparative column 
and isocratic solvent system using 90% acetonitrile and 10% water. After multiple runs, three 
peaks were collected and lyophilized. After collection, the three major peaks were re-assessed 
for their purity as well as determination of the molar mass. The purity of all three peaks (Peak 5, 
6 and 8) were determined to be 100%. The m/z [M+H]+ of peak 5, 6 and 8 were determined to be 
329.3, 329.3 and 327.3 respectively. All these three compounds were further tested for their 
growth-inhibitory and anti-inflammatory activities. It was concluded that all three compounds 
are cytotoxic in nature towards RAW 264.7 macrophages instead of being anti-inflammatory.  
144 
 
The three peaks (Peak 5, 6 and 8) collected based on semi-preparative HPLC were further 
lyophilized. Purified compound form Peak 5 was cream color fluffy needle-like powder while 
the compound purified from peak 6 was oily in nature. The physical appearance of the purified 
compound from peak 8 was sticky brownish paste. The yield of purified compounds from Peak 
5, 6 and 8 based on semi-preparative HPLC was 52.14, 32.62 and 5.00 percent respectively. The 
overall yield of HPLC column was 89.77%. 
For structural elucidation, the purified sample were further analyzed using Bruker NMR 
300 MHz. Sample was prepared using deuterated chloroform CDCl3 (99.96 % chloroform-d and 
0.3% TMS) (Sigma Aldrich) directly in NMR sample tube. The information based on 1D (1H-
NMR and 13C-NMR) and 2D (COSY and HSQC) revealed the purified compounds in Peak 5, 6 
and 8 as grifolin, neogrifolin and confluentin respectively. The final yield of grifolin, neogrifolin 
and confluentin from 70 grams of A. flettii # 128 was 0.26, 0.16 and 0.025% respectively, 
showing that confluentin was the least abundant growth-inhibitory compound from A. flettii. 
Experiments aimed at determining the potency of grifolin, neogrifolin and confluentin on 
HeLa cells revealed their IC50 to be 29.85, 23.22 and 50.47 µM respectively.  
 The purified compounds, especially grifolin and neogrifolin, were found to downregulate 
KRas expression in human colon cancer cell lines (HT-29 and SW480). The IC50s of these 
compounds on HT29 and SW480 cells were also determined. To my knowledge, this is the first 
study reporting the growth-inhibitory compound(s) on mammalian cells isolated from A. flettii. 
This is also the first study to show the ability of grifolin and neogrifolin to down-regulated KRas 
expression in cancer cells. However, the mechanism of action of these purified compounds 
(grifolin, neogrifolin and confluentin) on KRas expression is yet to be investigated in detail 
(whether it is affecting mRNA levels or not). At the outset of this study, grifolin and neogrifolin 
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had been extensively studied for their effect on the apoptosis and cell cycle pathways. In 
contrast, confluentin has not been investigated for its growth-inhibitory molecular mechanism. 
This study shows for the first time that confluentin can induce apoptosis and arrest cell cycle at 
G2/M phase in SW480 human colon cancer cells. 
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Chapter 4: Purification and Characterization of Growth-Inhibitory 
Compounds from Sarcodon scabripes 
This chapter focuses on the purification and characterization of growth-inhibitory 
compound(s) from the E1 (80% ethanol) extract of Sarcodon scabripes. There has been no prior 
study on bioactivity from S. scabripes. Therefore, this species is an ideal candidate for searching  
for potential novel growth-inhibitory compounds.  
4.1 Materials and Methods  
4.1.1 Manual extraction  
Manual extraction was performed on 81 grams of pulverized mushroom sample. Only E1 
(80% ethanol) and E2 (50% methanol) extraction was performed, and the residue was saved. The 
manual extraction was done using a hotplate at 65oC for 6 hours. The extract was then filtered 
using Whatman filter paper on a Büchner funnel. The extracts were lyophilized using Labconco 
freeze dryer and stored in -80°C freezer. The E1 (80% ethanol) extract was then utilized for 
further biological cell assays and purification process. 
4.1.2 Two-step sequential liquid-liquid extraction 
The E1 (80% ethanol) extract of S. scabripes was first phase-separated using water 
(inorganic) and chloroform (organic). This technique was utilized to separate the compounds 
based on their polarity index. For that purpose, VWR glass culture tube was used. First, 20 
mg/mL solution of E1 (80% ethanol) extract of S. scabripes was prepared in a glass culture tube 
using chloroform. Later, water was added in the equal volume to make sure that separation of 
compounds between the two layers was optimum. The solution was vortexed for 2-3 min and 
centrifuged. The process of centrifugation was carried out using Allegra X-15R benchtop 
centrifuge (Beckman Coulter) at the speed of 100 RCF for 5 min. Once a clear separation of 
three layers has been achieved, all the layers were separated in clean culture tubes. The water 
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layer was further re-extracted with ethyl acetate to further separate the compounds (present in the 
water layer) based on the weak polar nature. The color of each layer was distinct, suggesting the 
presence of different types of compounds in each layer. The color of the chloroform layer was 
dark brown, while the ethyl acetate and water layers were dark orange and green respectively. 
All layers were dried using a hotplate at 65oC and stored at 4oC. 
4.1.3 Sephadex LH-20 
In general, the procedures used to separate compounds in Sephadex LH-20 columns are 
essentially the same as those described in chapter 3 section 3.2.3. Briefly, compounds were 
separated from the chloroform layer of E1 extract usingSephadex-LH20 resin as the stationary 
phase and degassed 100% methanol was utilized as the mobile phase. Initial trial of compounds 
separation was done using a small 25 mL column (gravity drip) of Sephadex™ LH-20. This size-
based elution technique was further scaled up to a 100 mL column using a C16/70 glass column 
(GE Healthcare). Fractions were collected using automated fraction collector and final volume of 
each fraction was 5 mL. Mobile phase (degassed 100% methanol) flow rate was set at 1 mL/min 
using an automated pump (Pharmacia). 
The Sephadex-LH20 column-based purification was performed only for chloroform 
layer. The sample concentration of 80 mg/mL was prepared and only 2% of column volume was 
loaded onto the column (500 µL containing 40 mg of chloroform layer). For gravity drip 25 mL 
column, sample (500 µL) was loaded into the column using a micropipette. Sample was loaded 
into C16/70 glass column (GE Healthcare) with syringe using 3-ways valve. Collected fractions 
were stored at 4oC. 
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4.1.4 Nanodrop Analysis  
A nanodrop spectrophotometer (Thermo Fisher scientific, USA) was used to determine 
the λmax of fraction 18 and 26 from Sephadex LH20 (gravity drip/small column). After 
calibration with water, the spectrophotometer was blanked with HPLC grade methanol. Sample 
peddle was rinsed with the autoclaved milliQ water before analyzing the sample. A sample of  2 
µL was used to determine λmax of fraction 18 and 26. The λmax for both fractions (18 and 26) was 
observed at 262 nm, which was further used as a function of UV spectrophotometer in HPLC 
analysis of the Sephadex LH-20 active fractions.  
4.1.6 HPLC-MS 
4.1.6.1 Chloroform layer  
The reverse phase (RP-HPLC) separation method was first developed using the non-polar 
analytical column (Zorbax eclipse, 5 µm C18, 150 x 4.6 mm) and gradient solvent system (Fig 
4.1). Solvent A is water, solvent B is acetonitrile and solvent C is methanol. Gradient mobile 
phase was developed for the optimal peak separation and better peak shape in UV spectra.  
Starting at (A: B: D) 60: 6: 34% at time zero, water was consistently reduced and organic 
content (acetonitrile and methanol) was increased. The solvent ratio after 8 min of HPLC sample 
run was (47: 8: 45%) and was kept consistent after 8 min until each compound elutes out of the 
column. HPLC grade solvents (VWR) were used for the separation of the bioactive compounds. 
The solvents were automatically degassed through the degasser part of the HPLC before entering 
the quaternary pump. The quaternary pump controls the flow rate as well as the gradient of the 
solvent system. Flow rate for gradient mobile phase was set at 0.7 mL/min. The amount of the 
sample injected into the HPLC analytical column was 2 µL. Fraction 24 of the Sephadex gravity 
drip column was analyzed using these conditions. 
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Figure 4. 1 Illustration of gradient solvent system utilized to resolve HPLC profile peaks 
generated from the chloroform layer. 
 Mass spectroscopy was performed using an active splitter. The active splitter ratio 
used was 1:66. Scan mode was performed first to determine the mass of ionized compounds in 
the peaks. Formic acid (0.1%) isocratic solution was utilized to ionize the compounds of sample. 
After determination of molecular masses, a second step confirmation was done using SIM mode. 
SIM mode only targets the masses for which the mass spectrophotometer has been programmed. 
It took 30 min in total to elute all the compounds out of the column. 
4.1.6.2 Ethyl acetate layer (TEA) 
 HPLC analysis of the ethyl acetate layer was performed using Phenomenex phenyl-
Hexyl column (4.6 x 250 mm) and isocratic solvent system (three solvent system). The 
Sephadex-LH-20 based size separation was not performed on this layer. The composition of 
isocratic mobile phase was based on water 50%, acetonitrile 40% and methanol 10%. Flow rate 
was set at 0.6 mL/min for optimal resolution of peaks. It took 15 min in total to elute all the 
compounds out of the column. Mass spectroscopy was performed using an active splitter. The 
active splitter ratio used was 1:66. Scan mode was performed first to determine the mass of 
ionized compounds in the peaks. Formic acid (0.1%) isocratic solution was utilized to ionize the 
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compounds of sample. After determination of molecular masses, a second step confirmation was 
done using SIM mode. SIM mode only targets the masses for which the mass spectrophotometer 
has been programmed.  
4.1.6.3 Water layer (TW) 
             The method to resolve the water (TW) layer compounds was based on Phenomenex 
Phenyl-Hexyl 4.6*250 mm analytical column. Optimal flow rate for mobile phase was 
determined to be 0.6 mL/min. Isocratic mobile phase was developed based on 80% water, 10% 
acetonitrile and 10% methanol. It took 10 min in total to elute all peaks out of the column. The 
nature of the compounds present in water layer was highly polar and the column type used for 
this analysis was weakly polar. Due to this limitation, it was impossible to clearly separate the 
peaks from each other. The best possible separation was achieved based on the manipulation of 
solvent system. 
4.1.7 Semi-preparative HPLC 
HPLC technique was scaled up to a semi-preparative column, Agilent Zorbax Eclipse 
XBD-C18 5um (9.4 mm * 250 mm) for bioactive fractions collected from Sephadex LH-20 that 
originally derived from the chloroform layer. The optimal peak shape and separation was 
attained using isocratic mobile phase (water 43%, acetonitrile 12% and methanol 45%). 
Degassing of the solvents was carried out by the degasser part of the HPLC (Agilent 
technologies 1200 series). The sample was filtered using 0.2 μm filter (Thermo Fisher Scientific, 
USA) before loading into the column. A sample volume of 10 μL was injected through an auto-
sampler. Based on these conditions, it took 50 min in total to elute all peaks out of the semi-
preparative column. The peaks were collected using a fraction collector based on their retention 
times on UV signal. Fractions were collected in 8 mL collection vials. 
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4.2 Results  
4.2.1 Yield from manual extraction 
The yield of both extracts (E1 and E2) using manual extraction was higher than that 
obtained using the Dionex speed extractor. The yield for E1 and E2 extracts was 6.19 and 5.839 
% respectively, when using manual extraction. The yield of E1 and E2 extracts using Dionex 
ASE speed extractor (as shown in Table 2.7) was 1.36 and 5.82% respectively. The color of both 
extracts was dark greenish brown. After a large-scale manual extraction, the solubility (Table 
4.1) and growth-inhibitory activity of the extracts was re-confirmed (as shown in Figure 4.2). 
After treatment with 1 mg/mL final concentration of extracts E1 and E2, HeLa cell viability was 
11.79 and 8.81 % respectively. 
 Table 4. 1 Representing the yield of two extracts (E1 and E2) from S. scabripes. 
Mushroom Mass of 
sample  
Mass of 
Extract E1  
Yield Mass of 
Extract E2 
Yield  
Sample 128  81 g 5.02 g 6.19%  4.730 g 5.839 % 
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Figure 4. 2 Growth-inhibitory activity of extracts E1 and E2 from S. scabripes. One mg/mL 
of E1 and E2 was added to HeLa cells for 48 hours, after which MTT assay was performed. 
Error bars represent standard deviation of four biological replicates. 
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4.2.2 Liquid-liquid extraction/phase separation 
Liquid-liquid extraction of E1 from S. scabripes resulted in three distinct layers. Non-
polar compounds were present in the chloroform layer (CL), while polar and weak polar 
compounds were present in water layer (TW) and top ethyl acetate (TEA) respectively.  
Table 4. 2 Yield of three layers, based on liquid-liquid extraction (phase separation) of E1 
(80% ethanol) extract of S. scabripes. 
 
The ethyl acetate layer (TEA) was dark orange in color containing the highest yield  
(35.55%). TEA was assumed to contain weak polar compounds due to nature of ethyl acetate. 
The water layer has the lowest yield (26%). Solvents from these layers were evaporated using a 
hotplate at 65oC. The dried mass from all three layers was solubilized and then assessed for 
growth-inhibitory activity. 
4.2.3 Assessing the three layers obtained from liquid-liquid extraction of E1 for 
growth-inhibitory activity  
 Dose-dependent MTT assay was performed on all three layers of the liquid-liquid 
extraction.  The final concentration of the methanol was less than 2% in each well.  The doses 
tested on HeLa cells were 0.5 and 1 mg/mL. At the high concentration of 1 mg/mL, both water 
(TW) and chloroform layer resulted in false negative results because colored solution was seen. 
This was presumably the results of chemical reaction between MTT and compounds present in 
the water and chloroform layers. 
Layer of liquid-liquid 
extraction 
Color of 
the layer 
Mass (mg) 
out of 20 
mg 
% Mass  Growth 
inhibitory 
Activity 
Solubility 
Top Layer (Aqueous 
Phase) (TW) 
Green 5.20  26.00 Yes Water 
Lower Layer 
(Chloroform phase) 
Dark 
Brown 
6.94  34.70 Yes Methanol 
Ethyl acetate (TEA) Dark 
orange 
7.11  35.55 No Methanol 
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Figure 4. 3 Growth-inhibitory potential of the liquid-liquid extraction layers. CL 
represents Chloroform layer. TEA and TW are Top Ethyl acetate layer and Top water 
Layer respectively. Error bars represent standard deviation of four biological replicates. 
However, as shown in Figure 4.3, strong growth-inhibitory activity was observed after 
treatment with 0.5 mg/mL of chloroform and 1 mg/mL of water layer. No growth-inhibitory 
activity was observed after treatment with the ethyl acetate (TEA) layer at 1 mg/mL. Based on 
the results, I decided to focus on the chloroform layer for the next step of purification using size-
exclusion chromatography. 
4.2.4 Assessing fractions collected from Sephadex LH-20 (25 mL) gravity drip 
column for growth-inhibitory activity. 
The final volume of each fraction collected from gravity drip column (25 mL) was 1 mL. 
All the fractions were collected using 1.5 mL Eppendorf tubes. The color of all the collected 
fractions was quite distinct from each other. 
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Figure 4. 4 Photograph of Sephadex LH-20 gravity drip column (25 mL). The final 
concentration of the sample (Chloroform Layer) loaded onto the column was 80 mg/mL. 
 The color of the fractions F14-F22 was pale yellow, while dark yellow color was 
observed for fraction 24. Dark grey color was observed for fractions F28-F30. No growth-
inhibitory activity was shown by fractions F36 and F46, having pale green and red color 
respectively. 
Table 4. 3 Representing the color and activity of Sephadex LH-20 (gravity drip, 25 mL) 
column fractions. 
Fraction number Color Growth-inhibitory 
activity 
F14-F22 Pale yellow Yes 
F24 Yellow Yes 
F28-F30 Dark grey Yes 
F36 Pale green No 
F46 Red No 
 
 The fractions collected from gravity drip Sephadex-LH20 column were assessed for their 
growth-inhibitory activity using HeLa cells. The final volume of fraction added into each well 
was 2 μL with 98 μL of EMEM + 10% FBS. No activity was observed in the first attempt. 
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Consequently, the fractions volume was reduced from 1 mL to 200 μL and re-assessed for 
growth-inhibitory activity. Only even number fractions were tested for growth-inhibitory 
activity. 
 
Figure 4. 5 Growth-inhibitory activity of fractions collected from 25-mL size Sephadex™ 
LH-20 column. HeLa cells were plated at 1500 cells/well. The final volume of fraction 
introduced in each well was 2 μL with 98 μL of EMEM + 10% FBS.  HeLa cells were 
treated with the fractions for 48 hours. Error bars represent standard deviation for four 
biological replicates. 
MTT assay results revealed that fractions 14-30 reduced HeLa cell viability to less than 
50% compared to control (Figure 4.5). Some fractions (16 and 22) exhibited weaker growth-
inhibitory activity, suggesting the presence of bioactive compounds in these fractions either in 
low quantity or different in nature. Due to the activity observed in later eluting fractions, it is 
likely that the bioactive compounds are small. 
4.2.5 Assessing the fractions collected from Sephadex LH-20 (100 mL column) for 
growth-inhibitory activity  
MTT assay results based on the fractions collected from Sephadex LH-20 (100 mL) 
column were more revealing than the 25 mL gravity drip column. Fractions 15 and 16 exhibited 
strong growth-inhibitory activity; the cell viability after treatment with these fractions was 26% 
and 31% respectively (Figure 4.6). Cell viability after treatment with fractions 17, 18 and 19 was 
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above 90%, indicating no growth-inhibitory potential of these fractions. Weaker growth-
inhibitory activity was exhibited by fractions 20, 21, 22 and 24 (Figure 4.6). The cell viability 
after treatment with fractions 20, 21, 22 and 24 was 59%, 40%, 70% and 61% respectively.  This 
weak activity of fractions could either be due to low abundance of cytotoxic compounds or less 
potent cytotoxic compounds in these fractions. Other than that, no fraction showed any growth-
inhibitory activity on HeLa cells. 
 
Figure 4. 6 Assessing fractions collected from 100-ml size Sephadex™ LH-20 column for 
growth-inhibitory activity. HeLa cells were plated 1500 cells/well. The final volume of 
fraction introduced in each well was 2 μL with 98 μL of EMEM + 10% FBS. HeLa cells 
were treated with the fractions for 48 48 hours. Error bars represent standard deviation 
for four biological replicates. 
4.2.6 HPLC-MS  
4.2.6.1 Chloroform layer (CL) 
The optimal resolution of the peaks in UV spectra upon analysis of the chloroform layer 
indicated the ideal conditions of mobile and stationary phase.  The most abundant peak on UV 
spectrum was observed at 16.672 min containing 58.66% of the sample mixture (Figure 4.7). The 
percent abundance of UV peak visible at 10.703 min was 12.9368%, making it the second most 
abundant peak on the spectrum. The percent abundance of the peaks at 8.610 and 3.080 min was 
3.087% and 6.476% respectively. The molar mass [M+H]+ of ionized compound present in the 
8.610 min peak was determined to be 428.1 m/z. The signal of UV major peak for MS scan 
signal was observed for peak at 16.672 min. The m/z of  ionized compounds present in the UV 
peaks at 16.672, 10.703 and 27.921 min were determined to be 484.1, 442.1, and 526.0 
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respectively. The MS signals are visible with slight delay time because of the travel time through 
the 24-inch line from UV spectrophotometer to the active splitter and then to the mass 
spectrophotometer. 
 
Figure 4. 7 UV spectrum representing the relative abundance and retention time of peaks 
at λmax 262 nm (using analytical column and Sephadex LH-20 active fraction of Chloroform 
layer sample). 
 
 
Figure 4. 8 MS Scan spectrum representing the relative abundance and retention time of 
the ionic compounds detected in ESI (Electrospray ionization) chamber. The type of 
column utilized was Agilent Zorbax analytical and sample was 1 μL of filtered Sephadex 
active fraction. 
 
Figure 4. 9 Integration of MS scan spectrum revealing the presence and abundance of 
compound with m/z 428.1 in the peak visible at 8.926 min; representing peak at 8.610 min 
in UV signal shown in Figure 4.7. 
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Figure 4. 10 Integration of MS scan spectrum revealing the presence and abundance of 
compound with m/z 442.1 in the peak visible at 11.149 min; representing peak at 10.703 
min in UV signal shown in Figure 4.7. 
 
Figure 4. 11 Integration of MS scan spectrum revealing the presence and abundance of 
compound with m/z 484.1 in the peak visible at 17.061 min. (represents peak at 16.672 min 
in UV signal shown in Figure 4.7).  
 
 
Figure 4. 12 Integration of MS scan spectrum revealing the presence and abundance of 
compound with m/z 526.0 in the peak visible at 28.095 min. (represents peak at 27.921 min 
in UV signal shown in Figure 4.7).  
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4.2.6.2 Second step confirmation using SIM mode and targeting the selected masses 
 A second step confirmation using SIM (selected ion mode) was performed on the 
same semi-crude sample. Molecular masses targeted are shown in Figure 4.15. The SIM mode 
signal (Fig 4.14) confirmed the presence of the target masses. The abundance of the targeted 
masses was also found to be higher in SIM mode than in the SCAN mode, confirming the 
presence of the compounds in the sample. The abundance of m/z = [M+H]+ 484.1 ions in SIM 
mode was found to be three time higher than in the SCAN mode. The abundance of m/z = 
[M+H]+ ions was also found to have increased for other SIM signals. Figure 4.13 shows the UV 
spectrum, the retention times and abundance for all the peaks that are quite similar to those seen 
in the UV spectrum in Figure 4.7. Figure 4.16 shows the integration of the peak visible at 8.902 
min (visible at 8.610 min of UV signal), therefore confirming the presence as well as the 
abundance of compound with [M+H]+ m/z = 428.0. Integration of MS SIM spectrum for ions 
with [M+H]+ m/z = 442.0, 484.0 and 526.0 are  illustrated in Figures 4.17, 4.18 and 4.19 
respectively.  
 
Figure 4. 13 UV spectrum representing the relative abundance and retention time of peaks 
at λmax 262 nm (using analytical column and Sephadex LH-20 active fraction sample of 
chloroform layer). 
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Figure 4. 14 MS SIM spectrum representing the relative abundance and retention time of 
the targeted masses, detected through ESI (Electrospray ionization) chamber. The type of 
column utilized was Agilent Zorbax analytical and the sample was 1 μL (20mg/mL) of 
filtered Sephadex active fraction. 
 
 
 
Figure 4. 15 Screen computer image showing the SIM mode targeted masses and the 
fragmented value as well as % relative dwell time for the targeted masses. 
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Figure 4. 16 Integration of MS SIM spectrum confirming the presence and abundance of 
compound with m/z 428.0 in the peak visible at 8.761 min. (represents peak at 8.610 min in 
UV signal shown in Figure 4.7). 
 
 
Figure 4. 17 Integration of MS SIM spectrum confirming the presence and abundance of 
compound with m/z 442.0 in the peak visible at 11.319 min. (Represents peak at 10.703 min 
in UV signal shown in Figure 4.7). 
 
 
Figure 4. 18 Integration of MS SIM spectrum confirming the presence and abundance of 
compound with m/z 484.0 in the peak visible at 17.503 min. (Represents peak at 16.672 min 
in UV signal shown in Figure 4.7). 
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Figure 4. 19 Integration of MS SIM spectrum confirming the presence and abundance of 
compound with m/z 526.0 in the peak visible at 28.479 min. (Represents peak at 27.921 min 
in UV signal shown in Figure 4.7). 
 
4.2.6.3 Top ethyl acetate layer (TEA) 
 The column used for the analysis of the top ethyl acetate layer was the weak polar 
Phenomenex Phenyl-Hexyl column (4.6 x 250 mm). The optimal resolution of the peaks in UV 
spectra indicated the ideal conditions of mobile and stationary phase. Two major peaks were 
observed at 4.963 and 7.738 min (Figure 4.20). The most abundant peak on UV spectrum was 
observed at 4.963 min, containing 48.38% of the sample mixture. The molar mass [M+H]+ of 
ionized compound present in the peak at 4.963 min was determined to be 339.1 m/z.  The percent 
abundance of UV peak visible at 7.738 min was 34.81%, making it the second most abundant 
peak on the spectrum. A small peak was observed at 6.646 min with an abundance of 8.27%. The 
molar mass m/z = [M+H]+ of ionized compound present in peaks at 6.464 and 7.738 min was 
444.1 and 442.1 respectively. Figure 4.21 represents the MS scan spectrum of TEA sample. 
while Figures 4.22, 4.23 and 4.24 show the presence and abundance of compound with m/z 
339.1, 44.1 and 442.1 respectively. 
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Figure 4. 20 UV spectrum representing the relative abundance and retention time of peaks 
at λmax 262 nm (using analytical column and TEA Top ethyl acetate layer sample). 
 
 
Figure 4. 21 MS Scan spectrum representing the relative abundance and retention time of 
the ionic compounds detected in ESI (Electrospray ionization) chamber. The type of 
column utilized was Phenomenex phenyl-hexyl column and the sample was 1 μL 
(20mg/mL) of top ethyl acetate layer. 
 
 
Figure 4. 22 Integration of MS Scan spectrum indicating the presence and abundance of 
compound with m/z 339.1 in the peak visible at 5.289 min. (Represents peak at 4.963 min in 
UV signal shown in Figure 4.20). 
164 
 
 
Figure 4. 23 Integration of MS scan spectrum indicating the presence and abundance of 
compound with m/z 444.1 in the peak visible at 6.647 min. (Represents peak at 6.646 min in 
UV signal shown in Figure 4.20). 
 
 
Figure 4. 24 Integration of MS scan spectrum indicating the presence and abundance of 
compound with m/z 442.1 in the peak visible at 8.018 min. (Represents peak at 7.738 min in 
UV signal shown in Figure 4.20). 
 
4.2.6.4 Second step confirmation using SIM mode by targeting the selected masses 
 A second step confirmation using SIM (selected ion mode) was performed on the 
same semi-purified sample. The SIM mode signal (Figure 4.25) confirmed the presence of the 
target masses. The abundance of the targeted masses was also found to be higher in the SIM 
mode than in the SCAN mode, confirming the presence of compounds in the sample. The 
abundance of all compounds ( m/z = [M+H]+ in SIM mode) was found to be three time higher 
than the SCAN mode. Since the ethyl acetate layer did not exhibit any growth-inhibitory activity, 
165 
 
it was considered of less priority for purification purposes. Figures 4.26, 4.27 and 4.28 confirm 
the presence and abundance of compound with m/z 338.9, 44.1 and 442.1 respectively. 
 
Figure 4. 25 MS SIM spectrum representing the relative abundance and retention time of 
the targeted masses, detected through ESI (Electrospray ionization) chamber. The type of 
column utilized was Phenomenex phenyl-hexyl column and sample was 1 μL (20mg/mL) of 
top ethyl acetate layer. 
 
Figure 4. 26 Integration of MS SIM spectrum confirming the presence and abundance of 
compound with m/z 338.9 in the peak visible at 5.199 min. (Represents peak at 4.963 min in 
UV signal Figure 4.20). 
 
Figure 4. 27 Integration of MS SIM spectrum confirming the presence and abundance of 
compound with m/z 440.1 in the peak visible at 6.613 min. (Represents peak at 6.464 min in 
UV signal Figure 4.20). 
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Figure 4. 28 Integration of MS SIM spectrum confirming the presence and abundance of 
compound with m/z 442.0 in the peak visible at 8.041 min. (Represents peak at 7.738 min in 
UV signal Figure 4.20). 
 
4.2.6.5 Top water layer (TW) 
 Due to the limited range of HPLC columns available for separating polar compounds, 
it was difficult to obtain optimal separation of compounds using the currently available columns. 
Also, the UV Spectrum (Figure 4.29) peaks obtained using phenyl-Hexyl column did not 
correlate with the mass spectrophotometer signals. The mass spectrophotometer signals had a 
totally different retention time than the UV signals. This suggests the presence of carbohydrates 
in the sample (which needs to be separated using Sephadex column) or the compounds were not 
quite visible at this UV wavelength. Since this water layer exhibited a strong growth-inhibitory 
activity (Figure 4.3), future studies by other lab members should focus on using an appropriate 
HPLC column to purify the bioactive compound(s).  
 MS scan mode (Figure 4.30) indicated the presence of two small molecules with m/z 
values of 360.2 and 258.1 at 4.89 and 4.727 min respectively. While there was no peak in UV 
signal visible with these retention times, SIM mode mass spectrometry (by targeting these two 
compounds) revealed the two distinct signals at 4.923 and 6.243 min. The SIM signal at 4.932 
min represents the compound with 360.2 m/z and 77992 abundance. Figures 4.31 and 4.32 are 
the integration of the scan spectrum showing the presence and abundance of compound with m/z 
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360.2 and 358.1 respectively.  Figure 4.34 shows integration of MS-SIM spectrum at 4.391 min 
to confirm the presence of the compound with m/z 360.0. 
 
Figure 4. 29 UV spectrum representing the relative abundance and retention time of peaks 
at λmax 262 nm (using analytical column and Top water layer). 
 
 
Figure 4. 30 MS scan spectrum representing the relative abundance and retention time of 
the compounds detected through ESI (Electrospray ionization) chamber. The type of 
column utilized was Phenomenex phenyl-hexyl column and sample was 1 μL of top water 
layer. 
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Figure 4. 31 Integration of MS Scan spectrum indicating the presence and abundance of 
compound with m/z 360.2 visible at 4.895 min.  
 
 
Figure 4. 32 Integration of MS Scan spectrum indicating the presence and abundance of 
compound with m/z 258.1 visible at 4.727 min. 
 
 
 
Figure 4. 33 MS SIM spectrum representing the relative abundance and retention time of 
the targeted masses, detected through ESI (Electrospray ionization) chamber. The type of 
column utilized was Phenomenex phenyl-hexyl column and sample was 1 μL of top water 
layer. 
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Figure 4. 34 Integration of MS SIM spectrum confirming the presence and abundance of 
compound with m/z 360.0 at 4.931 min. 
4.2.7 Possibility of isolating novel compounds from S. scabripes 
 HPLC-MS analyses of the liquid-liquid extraction layers had provided an insight to 
the possibility of isolating novel compounds from S. scabripes. Tables 4.4 and 4.5 provide a 
summary of the identified compounds with different m/z present in the different liquid-liquid 
extraction layers. By comparing these m/z with known small molecules already identified from 
mushrooms of the same or different genus, it is possible to speculate which compounds could 
potentially be novel. An additional advantage is that S. scabripes has never been explored for its 
chemical constituents.  
HPLC analysis revealed the compounds present in the bioactive Sephadex LH-20 
fractions being smaller in size (Table 4.4 and 4.5). The molecular masses of the compounds 
present in S. scabripes (E1 extract) fell in the range of 360 to 526 m/z.  The m/z [M+H]+ of the 
most abundant compound present in chloroform layer was 484.0, which could be either methyl 
antcinate-B or a novel compound. Methyl antcinate-B is a cytotoxic compound purified from 
Antrodia camphorata (Yue et al., 2010).  The m/z [M+H]+ value of the compound present in 
water layer was 360.0, which could possibly be sarcodonin E (purified from S. scabrosus) (Dong 
et al., 2009) or it could also be a novel compound.  
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Table 4. 4 HPLC-UV data representing the peaks, their retention time and abundance in Sephadex fractions of chloroform 
layer. 
Layer  HPLC 
column 
used  
Retention 
time in 
UV signal 
(min) 
Abundance 
based on 
UV signal 
Molecular 
mass 
Closest mass found in 
compounds isolated 
from other 
mushrooms 
Reported 
Bioactivity of the 
compounds  
Reference 
Chloroform 
layer 
 
 (exhibited 
cytotoxic 
activity on 
HeLa cells) 
 
 
Zorbax C-18 
analytical 
column 
8.610 3.0807% 428 9,11-dehydroergosterol 
peroxide 
have molecular mass 
426.63 found in  
Sarcodon aspratus. 
Inhibitor of HL60 
leukemia growth, 
apoptosis-inducer  
 
Kobori et al., 
2006. 
10.703 12.9368% 442 Scabronine H or 
Sarcodonin P both have 
molecular mass of 
440.58 found in S. 
scabrosus.  
Anti-bacterial and 
anti-fungal. 
Ma et al., 2010. 
16.672 58.6614% 484 
 
Methyl antcinate B 
have molecular mass  
482.65 found in  
Antrodia camphorata. 
Cytotoxic against 
several cancer cell 
lines. 
Yue et al., 
2012. 
27.921 6.4767% 526 Aurisin-K  
have molecular mass of 
524.6 found in  
Neonothopanus nambi
  
Antimalarial 
activity (P. 
falciparum); 
antimycobacterial 
(M. tuberculosis) 
Kanokmedhakul 
et al ., 2012. 
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Table 4. 5 HPLC-UV data representing the peaks, their retention time and abundances in top ethyl acetate and top water layer 
of the liquid-liquid extraction. 
Layer  HPLC 
column 
used  
Retention 
time in UV 
signal (min) 
Percentage 
abundance 
based on 
UV signal 
Molecular 
mass 
Closest mass 
found in 
compounds 
isolated from 
other mushrooms 
Reported 
Bioactivity of 
the 
compounds 
Reference 
 
Top layer 
ethyl 
acetate 
(did not 
show any 
activity on 
HeLa cells) 
 
 
 
 
Phenyl-
hexyl 
4.963 48.3859%. 339 None - - 
6.464 8.2706 %. 444 Inonotsudiol A and 
inotodiol both 
have molecular 
mass of 442.72 
found in  
Inonotus obliquus. 
Cytotoxic 
against several 
cancer cell 
lines. 
Handa et al., 
2010. 
7.738 34.8103%. 442 
(also found 
in 
chloroform 
layer) 
Maybe It’s a 
weak polar 
in nature  
Scabronine H or 
sarcodonin P both 
have molecular 
mass of 440.58 
found in S. 
scabrosus. 
Anti-bacterial 
and anti-fungal. 
Ma et al., 2010. 
Top water 
layer 
(exhibited 
cytotoxic 
activity on 
HeLa cells) 
 
 
Phenyl-
Hexyl 
column 
6.063 42.9028% 360 Sarcodonin E or 
19-O-
acetylsarcodonin G 
have molecular 
mass of 358.47 
found in S. 
scabrosus. 
- Dong et al., 
2009. 
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4.2.7 HPLC- semi-preparative (peaks collection) 
  The method developed and based on isocratic solvent system (water 43: acetonitrile 
12: and methanol 45) using Agilent Zorbax C-18 semi-preparative column resulted in optimal 
separation of peaks (as shown in Figure 4.35). The abundance of peaks varied with different 
samples from different Sephadex fractions. Fraction collector was programmed to collect 10 
fractions containing the different peaks. Once the compounds are purified in sufficient quantity, 
NMR analysis will be performed by other lab members to help elucidate the structure. 
 
Figure 4. 35 UV spectrum representing the relative abundance  and retention time of peaks 
at λmax 262 nm (using semi-preparative column and Sephadex LH-20 fraction sample). 
 
4.3 Discussion  
This chapter describes the successful development of methods to purify growth-inhibitory 
compounds from S. scabripes. Extracts E1 (80% ethanol) and E2 (50% methanol) of S. scabripes 
exhibited potent growth-inhibitory activity. HeLa cell viability after treatment with both extracts 
(1 mg/mL) was less than 20%. For detailed study of chemical constituents, extract E1 was 
selected because of its potent growth-inhibitory activity. To obtain the bioactive compounds 
from E1 extracts, a series of purification steps were developed (Figure 4.36). 
The E1 extract was first subjected to liquid-liquid extraction technique. This approach 
was based on two immiscible solvents (due to difference in polarity index). The first liquid-
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liquid extraction was based on chloroform and water. The second sequential liquid-liquid 
extraction was based on same water layer with acetonitrile. Non-polar compounds were expected 
to move into the chloroform layer, while polar compounds were expected to solubilize and move 
into the water layer. Weakly polar molecules present in water layer were re-extracted with 
acetonitrile during the second step of liquid-liquid extraction.  
 
Figure 4. 36 Flow diagram representing the steps involved in the purification of compounds 
from S. scabripes. 
 
Chloroform layer was then subjected to Sephadex LH-20 size exclusion chromatography. 
The volume of the fractions collected from Sephadex LH-20 columns were reduced by drying 
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(1/5th) and further assessed for growth-inhibitory potential. Even at 1 µL, the fractions were 
capable to reduce the cell viability down to 20% as compared to the negative control (Figure 
4.5). A Nanodrop spectrophotometer was used to determine the λmax=262nm of active Sephadex 
LH-20 fractions.  
The post Sephadex LH-20 bioactive fractions were subjected to a second purification step 
using a high-resolution HPLC. Initially, a method was developed for optimal separation of 
compounds present in the bioactive post-Sephadex LH-20 fractions. The solvent system utilized 
for optimal separation of peaks was a gradient solvent system based on acetonitrile, methanol 
and water. The reverse phase (RP-HPLC) separation method was first developed using the non-
polar analytical column (Zorbax eclipse, 5 µm C18, 150 x 4.6 mm) and a gradient solvent system 
(Figure 4.2). It was then scaled up to a semi-preparative column (Zorbax eclipse, 5 µm C18, 250 
x 9.2 mm) using an isocratic solvent system (water 43: Acetonitrile 12: and methanol 45). The 
UV spectrum obtained using the semi-preparative column is shown in Figure 4.35. Peaks at ten 
different points of the UV spectrum were targeted for further collection, purification and mass 
determination of the compounds present in active Sephadex LH-20 fractions of chloroform layer 
(CL). The m/z [M+H]+ of the compounds present in chloroform layer were 428.0, 442.0, 484.0 
and 526.0. 
No size-based separation using Sephadex LH-20 was performed on the water layer (TW) 
and top ethyl acetate layer (TEA). The HPLC method developed using analytical Phenyl-Hexyl 
column and isocratic solvent system (water 50%, acetonitrile 40% and methanol 10%) revealed 
the presence of three compounds present in the top ethyl acetate layer (TEA). The peaks obtained 
in the UV spectrum (Figure 4.29) of TW layer had different retention times than the peaks of TW 
in the MS Scan (Figure 4.30) and SIM spectrum (Figure 4.33).  
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4.4 Future directions 
 The E1 (80% ethanol) extract of S. scabripes could be a source to discover novel anti-
cancer compounds. The purification of compounds present in the chloroform layer based on a 
semi-preparative HPLC method is still in progress. Purification of compounds in larger quantity 
is required for structural elucidation and biochemical characterization studies. Therefore, it is the 
priority of this study.  
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Chapter 5: General Discussion & Future Directions 
5.1 General Discussion 
5.1.1 Screening BC wild mushrooms for immuno-modulatory and growth-inhibitory 
activities 
 Wild mushrooms in North America have largely been unexplored for their medicinal 
properties. Recent studies by the research team at UNBC on wild mushrooms native to northern 
British Columbia showed that many species have never been reported for their growth-
inhibitory, immuno-stimulatory or anti-inflammatory activities (Deo et al., in review; Smith et 
al., 2017). One of the major aims of this MSc thesis was to screen some of the wild mushrooms 
collected across Canadian forests for their immuno-modulatory and growth-inhibitory potential. 
To determine the growth-inhibitory and immuno-modulatory potential, HeLa human cervical 
cancer cells and Raw 264.7 mouse macrophage cells were used respectively. After successful 
screening of the growth-inhibitory and immuno-modulatory potential of extracts, I decided to 
focus on E1 extract (80% ethanol) of A. flettii because there has been no report of growth-
inhibitory and anti-inflammatory activities of extract from this species. In addition, the E1 
extract of S. scabripes was also explored for the same reason. 
One of the objectives of this thesis was to reveal the immuno-modulatory potential of six 
genetically identified wild mushrooms collected from the forests in Canada: F. officinalis, T. 
vaccinum, T. versicolor, A. flettii, S. scabripes and C. unicolor. All twenty-four mushroom 
extracts were first screened for immuno-stimulatory activity. Eighteen extracts that showed weak 
or no immuno-stimulatory activity were further screened for anti-inflammatory activity.  
Results from the screening of 24 crude mushroom extracts revealed that Canadian wild 
mushrooms have great potential for the discovery of novel immuno-modulatory and growth-
inhibitory compounds. Out of the twenty-four extracts tested, five showed at least moderate (≥ 
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40% stimulation) immuno-stimulatory activity. Among these, two extracts, E3 from C. unicolor 
and T. versicolor exhibited very strong (≥ 90%) immuno-stimulatory activity.  
Out of 18 crude extracts tested, fifteen extracts showed at least moderate (≥ 40% 
inhibition) anti-inflammatory activity. Among these, twelve extracts from five species, A. flettii 
(E2, E3 and E4 only because E1 was cytotoxic), F. officinalis  (E1 and E2), S. scabripes (E1, E2, 
E3 and E4), T. vaccinum (E1 and E2), and T. versicolor (E1), demonstrated very strong (≥ 90%) 
anti-inflammatory activity.  The fact that there were more extracts with anti-inflammatory rather 
than with immuno-stimulatory activity is consistent with the earlier findings (Deo et al., in 
review; Smith et al., 2017). This suggests that in general, mushrooms have good anti-
inflammatory activity. 
In the case of growth-inhibitory activity screening, dose-dependent MTT assay was first 
performed on all twenty-four extracts. The extracts with potent growth-inhibitory activity (E1 
and E2) from F. officinalis, A. flettii and S. scabripes were further studied for time-dependent 
MTT assay. Out of twenty-four extracts tested for dose-dependent MTT assay, twelve extracts 
demonstrated at least moderate (≥ 40% inhibition) growth-inhibitory activity. Among these, six 
extracts from three different mushrooms, A. flettii (E1 and E2), F. officinalis (E1 and E2), S. 
scabripes (E1 and E2), demonstrated very strong (≥ 90%) growth-inhibitory activity. These 6 
extracts also showed potent growth-inhibitory activity in the time-dependent MTT assay. This 
study has further added to the list of wild mushrooms (Deo et al., in review; Smith et al., 2017) 
that should be explored for potential novel anti-cancer compounds. Taken together, it can be 
concluded that Canadian wild mushrooms are indeed good sources for the discovery of potential 
novel immuno-modulatory and growth-inhibitory compounds. 
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5.1.2 Purification, identification and characterization of growth-inhibitory 
compounds from Albatrellus flettii 
This is the first study from Dr. Lee’s lab describing purification, identification and 
characterization of small molecules from natural products, which in this case are mushrooms. I 
have carefully developed a purification strategy to isolate three growth-inhibitory compounds 
(grifolin, neogrifolin and confluentin) from A. flettii that can be generally adopted for the 
isolation of small molecules from any mushrooms (Figure 3.57). The first  purification step 
involved liquid-liquid extraction that will provide clues as to the nature of the bioactive 
compounds. Presence of growth-inhibitory compounds (grifolin, neogrifolin and confluentin) in 
the chloroform layer suggested that they are more hydrophobic. Further purification based on 
Sephadex LH-20 size exclusion chromatography provided general information about the size of 
the bioactive molecules; smaller molecules will elute at later fractions. The last purification step 
using HPLC revealed the presence of three major growth-inhibitory small molecules present in 
bioactive fractions from Sephadex LH-20. Collection of the three bioactive small molecules from 
HPLC followed by 1-D and 2-D NMR analyses confirmed their identity as grifolin, neogrifolin 
and confluentin. The final yield of grifolin, neogrifolin and confluentin was 0.26, 0.16 and 
0.025% respectively. These compounds possessing antibacterial property against Bacillus cereus 
and Enterococcus faecalis had been previously identified from A. flettii collected from 
California, USA, in January 2007 (Liu et al., 2010).   
Grifolin and neogrifolin, both the synthetic form and naturally isolated from other 
Albatrellus species, had been extensively studied for their anti-cancer properties and most of the 
underlying mechanisms (as discussed in headings 3.1.3.1 and 3.1.3.2).  
The underlying mechanisms of grifolin for the apoptosis induction in nasopharyngeal 
carcinoma cell CNE1 was found to be based on upregulation of DAPK1 via the p53–DAPK1 
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pathway (Luo et al., 2011) as well as by involvement of Bcl-2 family members and cytochrome c 
(Ye et al., 2005). Another mechanism involved in apoptosis induction in osteosarcoma cells was 
found out to be based on down-regulating the expression of the IAP (inhibitor of apoptosis 
protein) and induction of caspases (Jin et al., 2007). The autophagic cell death in human 
melanoma cells after treatment with grifolin was found mainly due to inhibition of 
Akt/mTOR/S6K pathway (Zhao et al., 2016). Grifolin resulted in reduced proliferation of 
osteosarcoma cells by reducing phosphorylation of Akt, FOXO transcription factor and GSK3 
(Jin et al., 2007). The ability of grifolin to arrest tumor cells at G1 phase, was found mainly due 
to the inhibition of cyclin D, cyclin E and CDK 4 of the ERK1/2 or the ERK5 pathway (Ye et al., 
2007). 
Like grifolin, neogrifolin also has the ability to affect the AKT signaling pathway through 
the same mechanisms. Neogrifolin-treated osteosarcoma cells resulted in downregulation of 
phosphorylated AKT level, FOXO transcription factor, and glycogen synthase kinase 3 (GSK3) 
and IAP (inhibitor of apoptosis protein), while caspases were found upregulated (Chen et al., 
2015). 
Confluentin is a relatively new compound and it has not been explored for any of the 
anti-cancer properties nor underlying mechanisms (Hellwig et al., 2003).  
In this study, grifolin, neogrifolin and confluentin purified from A. flettii were found to 
possess novel biochemical activity as described below. 
5.1.2.1 Disrupting IMP1-KRas RNA interaction in vitro and inhibition of KRas expression 
in human colon cancer cells 
In this study, grifolin, neogrifolin and confluentin isolated from A. flettii were assessed 
for their ability to disrupt IMP-1-KRas RNA interaction using an established fluorescent 
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polarization method. Both grifolin and neogrifolin dose-dependently inhibited the interaction 
between full-length IMP1 and KRas RNA but not the interaction between KH34 IMP1 and KRas 
RNA. This suggested that the compounds may bind to sites other than the KH34 di-domains of 
IMP1 (Barnes et al., 2015). At the time of writing this thesis, confluentin has not been tested on 
the fluorescent polarization assay. 
Based on the results from the fluorescent polarization experiments, I hypothesized that 
the compounds could disrupt IMP1-KRas mRNA interaction in colon cancer cells leading to 
decrease in KRas expression (Mongroo et al., 2011). To test this hypothesis, the compounds 
were added to SW480 and HT-29 human colon cancer cells and KRas expression monitored 
using Western blot analysis. Interestingly, all three compounds were found to suppress KRas 
expression in both SW480 and HT-29 cells. To my knowledge, this is the first demonstration of 
the ability of grifolin, neogrifolin and confluentin in inhibiting KRas expression in cancer cells. 
Such inhibition on KRas expression could represent a mechanism whereby these compounds 
exert their growth-inhibitory effects on cells (Pagliuca et al., 2013). 
The least abundant bio-active compounds present in A. flettii, confluentin, was 
investigated for its ability to induce apoptosis and cell cycle analysis in SW480 cells. This study 
shows for the first time that confluentin is a potent inducer of apoptosis in SW480 colon 
adenocarcinoma cells as well causing cell cycle arrest at G2/M phase.  
5.1.3 Purification and identification of growth-inhibitory compounds from Sarcodon 
scabripes 
The techniques used in the purification of growth-inhibitory compounds from S. 
scabripes was based on the method developed earlier for A. flettii. However, the liquid-liquid 
extraction was done twice based on water/chloroform and water/ethyl acetate solvent system to 
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get a clearer separation of compounds based on polarity. Three layers were named as top ethyl 
acetate layer (TEA), top water layer (TW) and chloroform layer (CL). CL and TW were found to 
contain growth-inhibitory compounds. MTT assay results using Sephadex LH-20 fractions (of 
chloroform layer) suggested that the compounds were small in size (bioactive compounds 
present in later eluting fractions). Further analyses using HPLC confirmed that the compounds 
present in the bioactive Sephadex LH-20 fractions were small molecules (Table 4.4 and 4.5). The 
molecular masses of the compounds present in S. scabripes fell in the range of 360 to 526 m/z.  
The m/z of the most abundant compound present in chloroform layer was 484.0, which could be 
methyl antcinate-B or a novel compound. The molecular mass of methyl antcinate-B is 482.65 
g/mole, a cytotoxic compound purified from Antrodia camphorata (Yue et al., 2010). The 
compounds with m/z 442.0 could be either Scabronine H or Sarcodonin P (anti-bacterial) which 
was isolated from S. scabrosus (Ma et al., 2010). TEA layer based HPLC-MS results revealed 
the presence of an abundant compound with 442.0 m/z ratio. Scabronine H or sarcodonin P both 
purified S. scabrosus have molecular mass of 440.58 (Ma et al., 2010). So, it could be either of 
these two or it could be a novel compound.  
 The m/z value of the compound present in water layer was 360.0, which could possibly 
be Sarcodonin E (purified from S. scabrosus) (Dong et al., 2009) or it could also be a novel 
compound. It is important to point out that Sarcodonin E has not been studied for any biological 
activity. Taken together, it is reasonable to speculate that for the possibility of finding novel 
growth-inhibitory compounds from S. scabripes is high because this mushroom has not been 
previously explored for its chemical constituents nor bioactivity. 
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The HPLC based purification technique was further scaled-up to a semi-preparative 
column in an effort to obtain sufficient quantity for further chemical analyses and compound 
identification purposes. 
5.1.4 Conclusions 
At the outset of this research, it was hypothesized that wild Canadian mushrooms contain  
potent small bioactive compounds. The results from this study showed that indeed northern BC 
is home to a large variety of mushrooms containing potent growth-inhibitory small molecules. 
Overall, the results generated from this study have provided an important platform for future 
investigations into discovering potential novel bioactive small molecules from Canadian wild 
mushrooms. For example, the crude extracts from S. scabripes and T. vaccinum may serve as 
potential sources for future discovery of novel growth-inhibitory or immuno-modulatory 
compounds. With the successful purification of three growth-inhibitory compounds (grifolin, 
neogrifolin and confluentin) from A. flettii, future studies could focus on understanding their 
mechanism of action in inhibiting KRas expression, a cellular effect that has not been previously 
described nor studied for these compounds. 
There is a high possibility of isolating novel growth-inhibitory compounds from S. 
scabripes. This is based on the HPLC-MS analyses of the growth-inhibitory Sephadex LH-20 
fractions from the chloroform layer sample. Further scaling-up the HPLC technique using a 
semi-preparative column will make the process of collection faster, hopefully leading to 
identification and characterization of the compounds. 
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Appendix  
(i) Fomitopsis officinalis (115) 
NLB4 
NNNNNNNNNNGNNTCGTGCAGNNANGGTCCNGCGCGGANGCACTTCTCCAGACTAC
AACTCGGACGGCCAGAGACCGCCAGATTTTAAATTTGAGCTCTTCCCGCTTCACTCG
CAGTTACTAGGGGAATCCTTGTTAGTTTCTTTTCCTCCGCTTATTGATATGCTTAAGT
TCAGCGGGTAATCCTACCTGATTTGAGGTCAGAGGTCAAAAAAACAATTGTCCGAA
AGGACGATTGGAAGCCCAAACCCTCACAAAGTGTAAACCCTCCGGCGTAGACAAAA
CTATCACACCGGATTGAGCAAGATACACAGAGGTCCAAGCTAATGCATTCAAGAGG
AGCCGAACGTTTGACCGTCCGGCAGAAAACCTCCAAATCCAACCCCCCCCNNACCA
ACAAAGGNNNGGGGGGTGAAAANTTCCTNGNCNNTCAACCAGGCTNGTTCCTCGAA
ATACCAAGGACCNAAGGGGGCGTTCAAAANTCCAATAATTCCNNAANTTNTGCATT
NNNTTNACTTATNGNTTTNNNTNCNNTNNNANCCNNNNANNNNNNNN 
(ii) Sarcodon scabripes (124) 
ITS3 
NNNNNNNNNNATNATNNNTGCAGATTCANTGAATCATCGAATCTTTGAACGCACCT
TGCGCTCCTTGGTATTCCGAGGAGCATGCCTGTTTGAGTGTCATGAAATTCTCAACT
GCTTCAGCTTTGTTGAAGTGAAGTTGGACTTGGAGGATCTTTGCTGGCGTAAGTGTA
CACAATGTTGTAACATTTGCTTGTTGGCTCCTCTTAAAGATATGAAGCTTTTCTAGTA
GATCTTTGGCAGAAAAGTACCATTGATGTGATAATTATCTGCATCATTGAGAAAGCC
ATAGAGCAGAGTCCTACTTTATAAGGGCTCCTACAGAAAATGTTTATGATGTTCATT
GCCTTTCAACAATGATCACAATTGACCAAATTTGACCTCAAATCAGGTAGGACTACC
CGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACTAACAAGGATTCCCCT
AGTAACTGCGAGTGAAGCGGGAAAAGCTCAAATTTAAAATCTGGCGTGCCTTTGGC
CGTCCGAGTTGTAGTCTGGAGAAGTGTTTTCTGTGCTGGACCGTGTACAAGTCCCTT
GGAACAGGGCGTCATAGAGGGTGAGAATNNNN 
NLB4 
NNNNNNNNNNNNCNNNNNGNTCCNCTCNCATGATGCNCTTCTCCAGACTACAACTC
GGACGGCCAAAGGCACGCCAGATTTTAAATTTGAGCTTTTCCCGCTTCACTCGCAGT
TACTAGGGGAATCCTTGTTAGTTTCTTTTCCTCCGCTTATTGATATGCTTAAGTTCAG
CGGGTAGTCCTACCTGATTTGAGGTCAAATTTGGTCAATTGTGATCATTGTTGAAAG
GCAATGAACATCATAAACATTTTCTGTAGGAGCCCTTATAAAGTAGGACTCTGCTCT
ATGGCTTTCTCAATGATGCAGATAATTATCACATCAATGGTACTTTTCTGCCAAAGA
TCTACTAGAAAAGCTTCATATCTTTAAGAGGAGCCAACAAGCAAATGTTACAACATT
GTGTACACTTACGCCAGCAAAGATCCTCCAAGTCCAACTTCACTTCAACAAAGCTGA
AGCAGTTGAGAATTTCATGACACTCAAACAGGCATGCTCCTCGGAATACCAAGGAG
CGCAAGGTGCGTTCAAAGATTCGATGATTCACTGAATTCTGCAATTCACATTACTTA
TCGCATTTCGCTGCGTTCTTCNATCGATGCAN 
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(iii) Tricholoma vaccinum (125) 
ITS3 
GNNNNNNNNANNNGNNNNANNNNNNGAANNNNNTGAATNATTCCGAATTCCTTNT
GAACGCACCTTGCGCTTCCCTTGGTATTTCCGAAGGAGCATGCCTGTTTGAGTGTCA
TGAAATTCTCAACCATTTCAGCTTTTTCTAGTTGATTTAGGCTTGGATGTGGGAGTTT
GCGGGCTTCTCTGAAGTCGGCTCTCCTTAAATATATTAGTAGGGACCTCTGTTGCCTC
AGCTCTTGGTGTGATAGTTATCTACGCCATTCTGCGAAGCAGCTTTAAAATGGGGTT
ACTGCTTTCTAACCGTCTCTACCGAGACAGCTTCTGACAATTTGACCTCAAATCAGG
TAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACTAACAA
GGATTCCCCTAGTAACTGCGAGTGAAGCGGGAAAAGCTCAAATTTAAAATCTGAGG
GTCCTTGCGGCCTTCCGAGTTGTAATCTAGAGAAGTGCTATCCCCGCTGAACACCGA
GAACGCTCCGGGCACNCTGAGACTCAAAGAGTGACAGNNCACNTGCATCCATGAAC
AAAT 
 
NLB4 
NNNNNNNNNGNNNNNCGNTNCNCTCGCGGANGGNACTCTCTCTAGATTAANGCTCG
GAAGGCCGCAAGGACCCTCAGATTTTAAATTTGAGCTTTTCCCGCTTCACTCGCAGT
TACTAGGGGAATCCTTGTTAGTTTCTTTTCCTCCGCTTATTGATATGCTTAAGTTCAG
CGGGTAGTCCTACCTGATTTGAGGTCAAATTGTCAGAAGCTGTCTCGGTAGAGACGG
TTAGAAAGCAGTAACCCCATTTTAAAGCTGCTTCGCAGAATGGCGTAGATAACTATC
ACACCAAGAGCTGAGGCAACAGAGGTCCCTACTAATATATTTAAGGAGAGCCGACT
TCAGAGAAGCCCGCAAACTCCCACATCCAAGCCTAAATCAACTAGAAAAAGCTGAA
ATGGTTGAGAATTTCATGACACTCAAACAGGCATGCTCCTCGGAATACCAAGGAGC
GCAAGGTGCGTTCAAAGATTCGATGATTCACTGAATTCTGCAATTCACATTACTTAT
CGCATTTCNCTGCATTCTTGATCAATGCANCNTGNANGGNGANAANACAAAGGAGN 
(iv) Cerrena unicolor (127) 
ITS3 
NNNNNNNNNNANNGANNNNTTGCAGAATTCNGTGAATCATCGAATCTTTGAACAGC
ACCTTGCGCCCCTTGGTATTCCGAGGGGCATGCCTGTTTGAGTGTCATGGTATTCTCA
ATACCCTAAATCTTTGCGGATGAGGGTGTATTGGATTTGGAGGTTTTTGCAGGCAAT
ATTCATTGTCAGCTCCTCTTAAATACATTAGCAGAGATATTACTGCTACTCTCCAGTG
TGATAATTGTCTACACTGTTAGTAGTGCGGTATAATCAAAGTCTTTGCTTCTAATCGT
CTTCGGACAATTCTTTGACATCTGACCTCAAATCAGGTAGGACTACCCGCTGAACTT
AAGCATATCAATAAGCGGAGGAAAAGAAACTAACAAGGATTCCCCTAGTAACTGCG
AGTGAAGCGGGAAAAGCTCAAATTTAAAATCTGGCAGCCTTCGGTTGTCCGAGTTGT
AGTCTGGANAAGCGTTTTCCGCGCTGGACCGTGTATAACTCCCTTGGANNAGGGGTG
TCCCAAAATGNTAAGAATCCAAAANTGCTGCAAAGCACAACCCCTATAGAANTCCC
GTGAATTCCAGGCCAAAAAGAAGANNTNANCCCCAAATN 
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NLB4 
CNNNNNNNGGNNGNNNNNNNNNCCNCGNGGAAGCGCNCTNCNNGANNNNNNGNC
GGACAACCGAAGGCTGCCAGATTTTAAATTTGAGCTTTTCCCGCTTCACTCGCAGTT
ACTAGGGGAATCCTTCGTTAGTTTCTTTTCCTCCGCTTATTGATATGCTTAAGTTCAG
CGGGTAGTCCTACCTGATTTGAGGTCAGATGTCAAAGAATTGTCCGAAGACGATTAG
AAGCAAAGACTTTGATTATACCGCACTACTAACAGTGTAGACAATTATCACACTGGA
GAGTAGCAGTAATATCTCTGCTAATGTATTTAAGAGGAGCTGACAATGAATATTGCC
TGCAAAAACCTCCAAATCCAATACACCCTCATCCGCAAAGATTTAGGGTATTGAGAA
TACCATGACACTCAAACAGGCATGCCCCTCGGAATACCAAGGGGCGCAAGGTGCGT
TCAAAGATTCGATGATTCACTGAATTCTGCAATTCACATTACTTATCGCATTTCGCTG
CGTTCTTCATCGATGCNNGTTGGATTCTGCCCCTCNATGATGTGTTCTTCTTCNAAGC
ACCNNTTCTTTNAAAGAGGGGAGCTCCTATGGTCCACA 
 
(v) Albatrellus flettii (128) 
ITS3 
NNNNNNNNNNGNNGNNNNNNNAANNNGTGAATATCGAATCTCGAACGCACCNNGC
GCCNNNNGGTATTCCGAGGGGCACACCNGTTTGAGTANCGTGAAATCATCAACCCA
GAACCCTTNTTTGTNGGGGGGTTCGAGGGCTTGGACTTGGAGGTCGTTGCCGGGTCC
CCCCCTTACGTGGGGGGGGAATCCGCTCCTCTTGAATGGATTAATGGGAACCCTCTC
TCCCCCTGCTCTCTTTGCCTCTCGGCGTGATAATTCCTCTGCGCCGACGTTGTGAGAA
AAGGGGGGAAAAGGAAACCGCTTCCAACCGTCTCTCGTCTGAAACAATTTTATGAA
CCCTTCCATCTCAAATCAGGGGGGACTACCCGCTGAACTTAAGCATATCAATAAACG
GAAGAAAAAAAACTAACAAGGATTCCCCTAATAACTGCCAGTGAAGCGGGAAAAG
CTCAAATTTGAAATCTGGCGGTCTTTGGCCGTCCGAATTGTAATCTGGAAAANCGCT
TTCCNCGCCNGAACATGTACAANTCCTCTGGAACGGGGCGTCATAAAAGGTGAAAA
TCCAANNTN 
NLB4 
GCNNNNNNNNNNNGNNNNNNNCCGGNNGCTGGAAAGCGCTTTNTCCAGAACNACA
ACTCCGGACGGNNAAAGACCGCCAGATTNCNAATTCCGAGCTCCNTCCCGCTCTCA
CTCGCAGTTACTAGGGGAATCCNNGNTAGTTTCTTTTCCTCCGCTTATNGATATGCTT
AAGTTCAGCGGGTAGTCCCACCTGATTTGAGATCGAAGGGTTCATAAAATTGTCTCA
GACGAGAGACGGTTCGAAGCGGTCTCCTTTTCCCCCCTTTTCTCACAACGTCGGCGC
AGATGAATTATCACGCCGAGAGGCAAAGAGAGCAGGGTGAGAGAGGGCTCCCACT
AATGCATTCAAGAGGAGCCGATTCCCCCCCCCCCTAAGGGGGGGAACCGGGAACCA
CCTCCCAGTCCCAACCCTCCAACCCCCCAACAAAAAGGGTTCTGGGTTGAAGAATTC
CCNAAACTCCAACCGGGGTGCCCCTCCGAATACCCANAAGCCCNAGGGGGGTTCCA
ANAATCCATGAATCCCTGAATTCNGCNATTTNNNTTANTTATCNCATTTCCCTGCCTT
CTTNNNCCATGCAANGGAATCGGNANCCCCAGGGGGGNTTTTTAAAANTTNNANNN
NNCNCCCCCCNNNNCNCCGANNTNTTNNNNCN 
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(vi) Trametes versicolor (143) 
ITS3 
NNNNNNNNNNNNNNNNNNNNNAATTNNNTGATCATNNGAATNCTNTGAACGCACC
TTGCGCTCCTTGGTATTCCGAGGAGCATGCCTGTTTGAGTGTCATGGAATTCTCAACT
TATAAATCCTTGTGATCTATAAGCTNGGACTTGGAGGCTTGCTGGCCCTTGCTGGCC
GCTTCCCCTTGATGGCTTTACTTCATTCCCTAACGGTCCGCTCCTCATGGGGATATTT
GCCACCCCTGGGCCCGGGAATGGTTTTGCCAACTTTCTACCCTCCCATTAGACCAAT
TTTTTACNTTCGAACTTCAATCCAGGAAGAANTACCCCTTNACTTTAACCTAATCATT
AACCGAAGAAAAAAAACTAANNANGANTTCCCCTANAANNTGNAANGNANNCGGA
AAAACTCCAATTTTAAATCCGGNCGNCCTTTGNCCNNCCAATTTGNATCCGGAAAAA
CCTCCTTCNNCTTTGAACCTGGACCAATCNCCTTGAACCAAACCNCCTNNNAGGGGA
AAAATCCAA 
NLB4 
NNNCNNNNNNNNNGNNNNNNNCANGCGGAGACGCTTCTCCAGACTACAACTCGGA
CGGCCAAAGACCGCCAGATTTTAAATTTGAGCTTTTCCCGCTTCACTCGCAGTTACT
AGGGGAATCCTTGTTAGTTTCTTTTCCTCCGCTTATTGATATGCTTAAGTTCAGCGGG
TAGTCCTACCTGATTTGAGGTCAGATGTTAAAAATTTGTCCTAATGGACGGTTAGAA
GCTCGCCAAAACACTTCACGGTCACAGCGTAGACAATTATCACACTGAGAGCCGAT
CCGTACGGAATCGAGCTAATGCATTCAAGAGGAGCCGACCGCCAGGGGCCAGCAGG
CCCCCAGTCCCAANCTAATAAATCACAGGGATTTAAGGTTGAAAAATTCCTGGACCT
TCAAACGGGCTGGCCCCTCGAAAAACCAGGGAGCGCAGGGGGCGTTCAAAAATCCA
AGAATTCNNGGATTTCGGCATTTCNATTTANTTACCGAATTTCNTGGCNTTCTCCATC
AAGNNN 
 
(vii) Albatrellus flettii (151) 
ITS3 
NNNNNNANNTNGTGATNGNAGANTANNTGATCATCGAATCCTTTGAACGCACCTTG
CGCCTCTTGGTATTCCGAGGGGCACACCTGTTTGAGTATCGTGAAATCATCAACCCA
GAACCCTTTTTGTTGGGGGGTTCGAGGGCTTGGACTTGGAGGTCGTTGCCGGGTCCC
CCCCTTACGTGGGGGGGGAAACCGCTCCCCCTGGATGGCTTAATGGGAACCCTCCCC
CCCCCTGGTCTCCTTGGCTCCCGGCGTGGTAATTCCTCCGGCCCCAACTTGTGGAAA
AAGGGGGGAAAAGGGAAACCCTTCCAACCGTCTCTCCTCTGAAAAAATTTTATGAA
CCCTTCCATCCCCAATCCAGGGGGAATACCCGCTGAACTTAANCCTATCCATAAACG
GAAGAAAAAAAACTAACAANGGTTCCCCTAATAACTGGNAATGGAACGGGAAAAG
CTCCAATTTGAAATCTGGGGGTCTTTGGNCGTCCCAATTGNANTCTGGAAAAACCCT
TTCCNCGCCCGAACCTGGANNANNNCTCTGGAACGGGGCGTCNTTANNGGGGAAAA
TCCAA 
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NLB4 
NNNNNNNNNNNNANTGGTCCGGCGCGGAAGCGCTTCTCCAGACTACAACTCGGACG
GCCAAAGACCGCCAGATTTCAAATTTGAGCTTTTCCCGCTTCACTCGCAGTTACTAG
GGGAATCCTTGTTAGTTTCTTTTCCTCCGCTTATTGATATGCTTAAGTTCAGCGGGTA
GTCCCACCTGATTTGAGATCGAAGGGTTCATAAAATTGTCTCAGACGAGAGACGGTT
CGAAGCGGTCTCCTTTTCCCCCCTTTTCTCACAACGTCGGCGCAGATGAATTATCAC
GCCGAGAGGCAAAGAGAGCAGGGTGAGAGAGGGCTCCCACTAATGCATTCAAGAG
GAGCCGATTCCCCCCCCCCCGAAGGGGGGGAACCCGGCACCAACTCCCAGTCCCAA
CCCCCCAACCCCCCCACAAAAAGGGGTCCGGGGTGAAGAATTCCNNAAACTCCAAC
CGGGGGGGCCCCCCGAAAAACCANAAGGGCCAGGGGGGGTCCAAAAATCCAAGAA
TCCNTGGATTTCGGCATTTCNNTTANTTANCCCATTTCCCTGGCNTCTNNNNCCNAN
GCAN 
 
 
 
 
 
 
 
 
 
 
 
 
